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Abstract 
Interferon-inducible transmembrane (IFITM) proteins are host cell derived restriction 
factors. Mammalian IFITM proteins have been shown to confer antiviral resistance when 
challenged with a diverse range of both enveloped and non-enveloped viruses. Little 
characterisation has been undertaken to date with the specific aim of elucidating their 
function and the antiviral properties of the chicken IFITM (chIFITM) gene family. 
 
The chIFITM gene family contains four genes located within a 17kb region on Gallus gallus 
chromosome 5. Currently there is little information available about the sequence diversity 
of these genes, their expression profiles or the role that they may play in restricting avian 
viral pathogens. Data presented in this thesis outlines a novel DNA pull-down sequencing 
technique which has allowed for the generation of a high quality contiguous reference 
sequence, alongside targeted sequencing of chicken cell lines and ex vivo cell cultures. 
Studies in this thesis have established that the chIFITMs are interferon stimulated and have 
characterized their upregulation in response to viral challenge with influenza A virus (IAV) in 
ovo, in  vivo and in vitro, alongside other avian viruses. Stably-overexpressing DF-1 
(immortalized chick embryo fibroblast) cells that express chIFITM1, 2, 3 and 3MUT (C71/71A) 
have been generated. These cell lines have been challenged with avian viruses including 
diverse strains of IAV and infectious bronchitis virus (IBV) and this data demonstrates that 
the chIFITMs are able to restrict avian viruses in vitro. Moreover, novel interactions have 
been identified which may help to uncover a possible mechanism of action. 
 
Global food security and protection of livestock from infectious agents remains a key 
priority, both in the United Kingdom and Internationally. This study examines the role of 
chIFITM proteins during viral infections and highlights one potential method of 
safeguarding the poultry industry, ensuring continuity of global food security.   
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CIL – cytoplasmic intracellular loop 
CK Cells – chicken kidney cells 
CoV – coronavirus 
cRNA – complementary RNA 
CS – chicken serum  
CTD – C-terminal domain  
DAPI – 4’,6-diamidino-2-phenylindole 
DMEM – Dulbecco’s minimum essential medium 
DMSO – dimethyl sulfoxide 
dNTP – deoxyribosenucleotide triphosphate 
DNA - deoxyribonucleic acid 
Dpi – days post infection 
dsDNA – double-stranded DNA 
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dsRNA – double-stranded RNA 
DV – dengue virus  
E – viral envelope protein 
EBOV – ebola virus  
E.coli – escherichia coli 
EDTA - ethylenediaminetetraacetic acid 
EMEM – Eagle’s minimum essential medium 
EPR –electron paramagnetic resonance  
ER – endoplasmic reticulum 
FCS – foetal calf serum 
GAS – gamma-activated sequence 
Gb - gigabase 
gDNA – genomic DNA 
GFP – green florescent protein 
HA – hemagglutinin  
HCV – hepatitis C virus 
HIV – human immunodeficiency virus 
HPAI – high pathogenicity avian influenza 
HTNV - hantaan virus  
huIFITM -  human interferon-inducible transmembrane proteins 
HVT – herpes virus of turkeys 
IAV – influenza A virus 
IBDV –infectious bursal disease virus 
IBV – infectious bronchitis virus 
IFITM – interferon-inducible transmembrane proteins  
IFN – interferon 
IFNAR – interferon receptor 
IFNα – interferon-alpha 
IFNβ – interferon-beta 
IFNε – interferon- epsilon 
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IFNκ – interferon-kappa 
IFNω – interferon-omega 
IFNλ – interferon-lamda 
IFNγ – interferon-gamma 
IRES – internal ribosomal entry site 
IKK – I kappa B kinase 
IM – intramembrane 
IP – immunoprecipitation  
IRF 3/7 – interferon regulatory factor 3/7 
ISG – interferon stimulated gene 
ISGF3 – interferon stimulated gene factor 3 
ISP-1 – interferon promoter stimulator-1 
ISRE – IFN-stimulated response element 
JAK – janus kinase 
JEV – Japanese encephalitis virus  
Kb – kilobases 
kDa – kilodaltons 
LACV – la crosse virus  
LASV – lassa virus 
LB – Luria-Bertani broth 
LBV – Lagos bat virus 
LC-MS/MS – liquid chromatography-mass spectrometry/mass spectrometry 
LCMV – lymphocytic choriomeningitis virus  
LGP2 – laboratory of genetics and physiology 2 
LPAI - low pathogenic avian influenza 
LPS – lipopolysaccharide 
M1 - matrix protein 1 
M2 - M2 proton channel 
M41 – Massachusetts 41 
M – viral M protein 
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MARV - Marburg virus 
MAVS – mitochondrial antiviral signaling protein 
MDA5 – melanoma differentiation-associated protein 5 
MDCK – Madin-Darby canine kidney  
MDV - marek’s disease virus 
MEFs – murine embryonic fibroblasts  
MEM – minimum essential medium 
MERS-CoV – Middle East respiratory syndrome coronavirus 
MEXC – mex-3 RNA binding family member 3 
MIQE – minimum information for the publication of quantitative real-time PCR 
experiments 
MLV – murine leukemia virus 
MOI – multiplicity of Infection 
mRNA – messenger RNA 
MS – mass spectrometry 
Mx - myxovirus resistance protein 1 
N – viral nucleocapsid protein 
NA - neuraminidase 
NEP - nuclear export protein 
NF-κB – nuclear factor - kappa B 
NGS – next generation sequencing  
NMR – nuclear magnetic resonance  
NP - nucleoprotein 
NS1 – influenza A virus non-structural protein 1 
Nsp – non-structural protein 
NTD – N-terminal domain  
ORF – open reading frame 
PA - polymerase acidic protein 
PAMP – pathogen-associated molecular pattern 
PB1 - polymerase basic protein 1 
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PB2 - polymerase basic protein 2 
PBS – phosphate buffered saline  
PCR – polymerase chain reaction 
PFU – plaque forming unit 
PKR – protein kinase R 
PLA2 – phospholipase A2 group IV A 
PMA – phorbolmyristate acetate 
Pol II – polymerase II 
PolyI:C – polyinosinic:polycytidylic acid  
pp1a/1ab – polyprotein 1a/1ab 
PRR – pattern recognition receptor  
PTM – post-translational modification 
RABV – rabies virus 
RdRp – RNA-dependent RNA polymerase 
RIG-1 – retinoic acid-inducible gene I 
RIPLET – rING finger protein leading to RIG-1 activation  
RLR – RIG-1-like receptor 
RLU – relative light units 
RNA – ribonucleic Acid 
RNP – ribonucleoprotein 
RPL13 – ribosomal protein L13 
RPLPO – ribosomal phosphoprotein PO 
RPMI – Roswell Park Memorial Institute medium  
RT – reverse transcription 
RT-qPCR - reverse transcription quantitative polymerase chain reaction 
RTC – replication-transcription complex 
RVFV - Rift Valley fever virus 
S – viral spike protein 
SARS-CoV – severe acute respiratory syndrome coronavirus 
SDS-PAGE – sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
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SFV – Semliki forest virus  
SNP – single nucleotide polymorphism  
SPRY - SPla and the ryanodine Receptor 
sgRNA – sub-genomic RNA 
ssRNA – single stranded RNA 
STAT1/3 – signal transducer and activator of transcription 1/3 
TBK1 – TANK-binding kinase 1 
TBP – TATA box binding protein 
TNF – tumour necrosis factor 
TMD – transmembrane domain  
TPB – tryptose phosphate broth  
TRIM25 – tripartite motif-containing protein 25 
TRS – transcription regulatory sequence 
TYK2 – tyrosine kinase 2 
UTR – untranslated region 
VISA - mitochondrial antiviral-signaling protein 
VLP – virus like particle  
VSV – vesicular stomatis virus  
vRNA – viral RNA 
vRNP - viral ribonucleoprotein 
WNV – West Nile virus  
WT – wild-type 
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1.1 Poultry Industry and Avian Viral Diseases 
Domestic chickens (Gallus gallus domestica) belong to the order Galliformes, the family 
Phasianidae and genus Gallus (Figure 1.1). There are currently 281 recognized species of 
gamebirds distributed among 81 genera (Diamond, 1991;Hoyo et al., 1992;Roberts et al., 
1985). In 2004, a consortium sequenced the genome of Gallus gallus (UCD 001) making it 
the first ancestral agricultural animal and the first of the aves to have its genome 
sequenced (Hillier et al., 2004). This came just a year after the completion of the human 
genome project (HGP) (International Human Genome Sequencing, 2004). The chicken 
genome is only 1.09Gb, less than half the size of the human genome (Warren et al., 2017) 
and consists of 40 autosomes and 2 sex chromosomes, Z and W. In chickens, the males are 
the homogametic sex (ZZ) and females are the heterogametic sex (ZW) (Figure 1.2). This is 
in contrast to humans where the females are homozygous (XX). In comparison to mammals, 
there is a large variation in the size of the chicken chromosomes which range from 200Mb 
(macro-chromosomes) to 5Mb (micro-chromosomes)(Romanov et al., 2009).  
Chickens were first domesticated over 8,000 years ago in Southeast Asia, although one 
phylogenetic study suggests that divergence from the ancestral population occurred as 
early as 58,000 ± 16,000 years ago. While there are four ancestral members of genus Gallus 
(Table 1.1), phylogenetic analysis alongside biochemical and molecular techniques, have 
proposed a single common ancestor, the red junglefowl (Sawai et al., 2010;Kan et al., 
2010). Charles Darwin first proposed the single-origin hypothesis in 1868 after observing 
that only red junglefowl could produce fertile F1 offspring when mated with chickens 
(Murray, 2016). This finding was later confirmed by mitochondrial sequencing (Fumihito et 
al., 1996). The natural dissemination of chickens is unlikely as they are not a migratory 
species and they lack the ability to fly and swim for long distances. Therefore, their global 
distribution is directly attributed to human movement. The historical importance of the  
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Figure 1.1 Phylogenetic tree of the relationships among Galliformes. Taxonomic 
relationships were determined by using a nucleotide dataset of 13 mitochondrial protein-
coding genes. Gallus gallus (red junglefowl) is the last common ancestor of the 
domesticated chicken (Gallus gallus domestica) and is found in Southeast Asia. This tree 
demonstrates that ducks (Anasplatyrhynchos) and geese (Brantacanadensis) fall outside 
of the Galliforme order. Numbers beside the nodes specify bootstrap percentages from 
maximum likelihood (500 replicates) and maximum parsimony (1000 replicates), and 
posterior probabilities from Bayesian inference. [Taken from (Kan et al., 2010)] 
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Figure 1.2 Karyotype of the female chicken. There are 40 autosomal pairs and 2 sex 
chromosomes (Z and W) in a standard diploid cell. The chromosomes are comprised of 
micro- and macrochromosomes with estimates suggesting that 95% of the DNA is within 
chromosomes 1 – 28, 32, Z and W. [Taken from (Romanov et al., 2009)] 
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Binomial nomenclature Common name Geographic location 
G. lafayettei La Fayette's junglefowl Sri Lanka  
G. gallus Red junglefowl Extensive distribution 
throughout Southeast Asia 
G. varius Green junglefowl Indonesia 
G. sonnerati Gray junglefowl India 
Table 1.1 Members of the Gallus genus and their geographical distribution. 
Abbrev. G = Gallus 
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chicken trade is evident due to their extensive distribution throughout the world (Sawai et 
al., 2010). The poultry industry is critical in ensuring that high quality protein remains 
available to a rapidly increasing population. The United Nations estimates a global 
population of 9.7bn people by the year 2050, an increase of over 32% in 32 years (United 
Nations, 2015). In the United Kingdom alone, there are over 2,500 poultry farms that 
collectively produce approximately 875 million chickens each year (British Poultry Council, 
2016). Moreover, the volume of chicken being produced in the UK increased from 108,600 
tonnes in March 2017 to 119,200 tonnes in March 2018, representing an annual increase of 
9.8% (DEFRA, 2018). It is estimated that over 58bn chickens are produced annually 
worldwide (FAOSTAT, 2011). In comparison, only 269m cattle and 517m sheep are 
slaughtered each year. The significant increase in chicken production highlights the 
importance of poultry as a staple protein worldwide. Poultry meat is a good source of 
animal protein and is becoming more accessible around the world due to its relative 
affordability. The breeding efficiency of broiler chickens has increased over the years and 
currently, the average slaughter age is just 42 days (de Jonge and van Trijp, 2013). Other 
sources of animal protein, such as beef and pork, are prohibited in some regions due to 
local laws and customs that forbid its consumption. Furthermore, chickens have a high feed 
conversation ratio of just 1.7 in comparison to cattle and sheep (Salmon Farm Science, 
2012) which require over 10kgs of feed for 1kg of meat. These factors, taken together with 
versatile models of production, make poultry a readily available protein.  
Avian viruses present a current and persistent threat to both human health and global food 
security. Infections with endemic pathogens such as infectious bronchitis virus (IBV) and 
emerging viral pathogens such as Influenza A viruses (IAVs) decrease productivity through 
morbidity and increased mortality (Lv et al., 2015;Yunis et al., 2002). An incursion of avian 
influenza into the United Kingdom from the wild bird population remains a constant threat 
that could severely damage the poultry industry. In addition to protecting global food 
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security, controlling cross-species transmission events between birds, pigs and humans, as 
was seen in the 1997 Influenza outbreak (H5N1) which originated in Hong Kong (Bui et al., 
2017), is also a major concern. 
1.2 Influenza A Virus 
1.2.1 General overview 
Influenza viruses (IV) are comprised of four subtypes of influenza (A, B, C and D) grouped 
together depending on the genetic and antigenic properties of the virus (Ghebrehewet et 
al., 2016). Each genus belongs to the family Orthomyxoviridae and contains a single 
stranded, negative sense RNA (-ssRNA) genome (McGeoch et al., 1976). The number of 
segments, or molecules of RNA, is dependent on the subtype, although influenza A viruses 
(IAV) contain 8 segments with a total viral genome size of around 13.5kb (Ludwig et al., 
1999). The genome encodes for 10 core proteins which are conserved across different 
strains of IAV and are essential for replication (Table 1.2). In addition to these core proteins, 
there are many other proteins, which are not essential for virus replication, that are 
encoded by some, but not all strains of IAV.  
The natural host and reservoir of IAV are wild aquatic birds which are members of the 
orders Anseriformes and Charadriiformes and include species such as ducks and geese. In 
addition, IAV is able to infect a variety of avian and mammalian species, although for this to 
occur a number of host adaptations are required (Webster et al., 1992). Within the 
Influenza A genus, there are a number of different subtypes and these are grouped by the 
antigenicity of the surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA). 
Currently, 16 HA subtypes and 9 NA subtypes have been described and all of these have 
been found in avian viruses, in the majority of the HA-NA combinations that are possible. In 
contrast, only H1, H2 and H3 subtype viruses have been confirmed to persist in humans to  
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Segment Segment length in 
nucleotides 
Encoded 
Protein(s) 
Protein length in 
amino acids 
Protein function 
1 2341 PB2 759 Polymerase subunit; mRNA cap recognition (Blaas et al., 1982) 
2 2341 PB1 757 Polymerase subunit; RNA elongation (Braam et al., 1983) 
3 2233 PA 716 Polymerase subunit (Dias et al., 2009) 
4 1778 HA 550 Surface glycoprotein, involved in receptor binding and fusion 
(Skehel and Wiley, 2000) 
5 1565 NP 498 RNA binding protein; required for polymerase activity (Portela 
and Digard, 2002) 
6 1413 NA 454 Surface glycoprotein; sialidase activity, virus release (Shtyrya et 
al., 2009) 
7 1027 M1 252 Matrix protein involved in RNA nuclear export regulation and 
viral budding (Gomez-Puertas et al., 2000)  
  
M2 97 Ion channel; which is required for virus uncoating and assembly  
(Pielak and Chou, 2011) 
8 890 NS1 230 Interferon antagonist; regulation of host gene expression (Hale 
et al., 2008) 
  
NEP/NS2 121 Nuclear export of vRNA (O'Neill et al., 1998) 
Table 1.2 Core proteins of IAV that are conserved and essential for replication. Segment and protein sizes based on A/Puerto Rico/8/34 (H1N1). 
Adapted from: (Pleschka, 2013) 
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date, although infections with H5, H6,  H7, H9 and H10 subtypes have been confirmed 
(Schrauwen and Fouchier, 2014). Two further subtypes of HA (H17 and H18) and NA (N10 
and N11) have been described in bat isolates (Tong et al., 2012;Tong et al., 2013), although 
it is not currently known if these subtypes exist in any other host species.   
1.2.2 Maximising coding capacity of IAV 
IAV employs a number of different strategies for maximising its coding capacity, a process 
which is essential for viruses with limited genome sizes. Each segment contains one open 
reading frame (ORF) from which one or more protein products are produced. It is known 
that IAV utilises three main protein coding strategies; mRNA splicing in the case of 
segments 1, 7 and 8 (Yamayoshi et al., 2016;Lamb and Lai, 1980;Lamb and Choppin, 
1981;Alonso-Caplen et al., 1992;Shih et al., 1998;O'Neill et al., 1998;Selman et al., 2012), 
ribosomal frame-shifting for the expression of PA-X which is translated from the +1 reading 
frame of PA mRNA on segment 3 (Firth et al., 2012;Jagger et al., 2012), and alternative 
translation initiation mechanisms such as downstream AUGs of the primary AUG on 
segment 2 that allow for the translation of PB1-F2 (Wise et al., 2011). A number of non-
essential protein products are translated using these mechanisms.   
1.2.3 Influenza virion 
Influenza virions are pleomorphic with lab-adapted strains predominantly spheroidal with a 
typical diameter of 100nm (Figure 1.3). In contrast, clinical and field isolates are typically 
filamentous and are much larger, up to 20μm in length and 100nm in diameter (Mosley and 
Wyckoff, 1946;Harris et al., 2006). The virion is encased in a host cell-derived phospholipid 
bilayer which forms an envelope. This envelope is embedded with the two glycoproteins, 
HA and NA, which determine the viral subtype and antigenicity (Laver and Valentine, 1969). 
HA exists as a trimer, whilst NA is tetrameric. Beneath the envelope is a layer of 
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Figure 1.3 A schematic representation of an influenza A virion. Highlighted are the 
surface glycoproteins that determine the virus subtype (HA and NA), the matrix protein 
(M1), the ion pump (M2), the nucleoprotein that surrounds the viral RNA (NP) and the 8 
segments of negative sense viral RNA. [Taken from: (Horimoto and Kawaoka, 2005)]. 
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oligomerised M1 that provides the structural support for the virion. In addition, the lipid 
envelope also contains the homotetrameric integral membrane M2 proton channel 
(Zebedee and Lamb, 1988). The M2 ion channel is essential as it is a highly selective, pH-
regulated, proton-conducting channel (H+ ions) that mediates the acidification of the 
influenza virion and the release of the viral genome into the cytoplasm. 
1.2.4 Influenza cell entry 
IAV infection is initiated via the binding of the of virions HA protein to N-acetylneuraminic 
(sialic) acids which are located on the plasma membrane of the target host cell (Johnson et 
al., 1964). Spherical virions are internalised by clathrin-mediated endocytosis (Eierhoff et 
al., 2010) whilst filamentous virions enter via macropinocytosis (Rossman et al., 2012). 
Once the virus has been incorporated into host cell-derived endosomal compartments, a 
fusion event occurs which allows for the release of the virus into the cytoplasm. Following 
acidification of late endosomes, cleaved HA undergoes a pH-dependent conformational 
change (Jardetzky and Lamb, 2004). This process allows for the release of potential energy 
and results in the fusion of both the viral and endosomal membranes (Jardetzky and Lamb, 
2004). H+ ions are then pumped through the M2 proton channel acidifying the virion 
interior and disrupting the protein-protein interactions between M1 and the viral 
ribonucleoproteins (vRNPs) (Bui et al., 1996). The vRNPs that are no longer bound to M1 
are then able to translocate into the cytoplasm of the cell. 
1.2.5 Replication and transcription of the viral genome 
Replication and transcription of the viral genome is undertaken by the trimeric RNA 
dependent RNA polymerase (RdRp) which is comprised of the polymerase basic 1 (PB1), 
polymerase basic 1 (PB2) and polymerase acidic (PA) subunits. Initiation of replication is 
primer-independent and is achieved through base pair complementarity of the 5’ and 3’ 
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ends of the viral RNA (vRNA) which forms a pan handle structure (Luytjes et al., 1989). A 
positive sense copy of each vRNA segment is required for replication of the viral genome 
and this is mediated through the synthesis of an intermediate template termed 
complementary RNA (cRNA). This template is then used to produce further copies of vRNA, 
although the process is not yet fully understood (Deng et al., 2006;Flick et al., 1996;Fodor, 
2013). Newly synthesised vRNA is encapsidated with nucleoprotein (NP), undergoes nuclear 
export, packaging and ultimately egress. 
Transcription is mediated through the activities of cellular RNA polymerase II (Pol II) and the 
viral RdRp. During the initiation of cellular transcription, activation of the cellular cap 
synthesis complex is mediated through the phosphorylation of Serine 5 in the C-terminus of 
Pol II (Engelhardt et al., 2005). The mechanism of ‘cap-snatching’ involves the binding of 
host precursor mRNAs (pre-mRNAs) containing a 5’ 7-methylguanosine cap (m7GpppXm) 
(Plotch et al., 1981). The PB2 subunit allows for the binding of the polymerase to the host’s 
pre-mRNA 5’ cap (Blaas et al., 1982). The PA subunit of the polymerase cleaves the 5’ cap 
from the host pre-mRNA through its endonuclease activity (Hara et al., 2006;Dias et al., 
2009;Yuan et al., 2009).  The PB1 subunit of the RdRp complex mediates RNA elongation 
(Braam et al., 1983). Transcription is terminated at a 5 to 7 nucleotide long poly(uridine) 
(poly(U)) stretch located 15 to 17 nucleotides from the 5’ end of the vRNA template 
(Robertson et al., 1981) The polymerase cannot move any further due to steric hindrance 
causing the active site to pause over the poly(U) tract (Moeller et al., 2012;Poon et al., 
1998). 
It is not clearly understood how the viral polymerase distinguishes between transcription 
and replication, since the same promoter is used during both processes. Two models have 
been proposed, but conflicting data suggests that further investigations are required 
(Fodor, 2013). One model suggests that the accumulation of viral proteins, such as 
Chapter 1: Introduction 
39 | P a g e  
 
NS2/NEP, following translation, alters the function of the RdRp (Robb et al., 2009). The 
second model proposed by Moeller et al, states that the cRNA is produced when newly 
synthesised trans-acting polymerases associate with free 5’ ends of vRNA. In parallel, the 3’ 
end of the same vRNA is still associated with the original polymerase of the vRNP (Moeller 
et al., 2012). 
1.3 Infectious Bronchitis Virus 
 
1.3.1 General overview 
The coronavirinae subfamily is split into four genera, alpha (α), beta (β), gamma (γ) and 
deltacoronaviruses (Δ). Each genus is assigned based solely on the sequence of the virus. 
Infectious bronchitis virus (IBV) belongs to the Nidovirales order, the coronavirinae 
subfamily and the gammacoronavirus genus. Other notable members of the coronavirinae 
include the β-coronaviruses Severe Acute Respiratory Syndrome (SARS) and Middle East 
Respiratory Syndrome (MERS)-CoV which infect mammalian species, including humans. 
Coronaviruses have among the largest RNA genomes found in nature, typically ranging from 
26 – 32Kb in length. The genome is comprised of single-stranded positive-sense RNA 
(+ssRNA) and contains both a 5′ methylated cap and 3′ polyadenylated tail (Brian and Baric, 
2005;Masters, 2006). This means that the viral genome of coronaviruses can act directly as 
mRNA. The genome of the prototypic gammacoronavirus, IBV, is 26.7Kb long and is 
expressed as six mRNAs during infection. 
IBV establishes primary infection in the respiratory tract where it disseminates to the 
epithelial cells of the trachea and lung (Hofstad and Yoder, 1966;Ambali and Jones, 
1990;Lee et al., 2002;Meir et al., 2004). Although IBV is primarily detected in the respiratory 
tissues, several emerging strains of IBV, such as QX, have been isolated from other organs 
such as the caecal tonsil and the kidneys (Benyeda et al., 2009;Terregino et al., 2008). A 
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reverse genetics system for avian coronaviruses was developed in 2001 and this resulted in 
the production of an apathogenic laboratory attenuated strain of IBV, Beaudette (BeauR) 
which was generated using the background sequence of Beau-CK (Casais et al., 2001). This 
strain of IBV is not able to disseminate from the site of inoculation (eyelids and beak) and 
has very mild clinical signs. Massachusetts 41 (M41) is a pathogenic field strain that has 
been found in the tissues of the respiratory tract but it does not disseminate to other 
organs unlike QX (Cook et al., 2012). 
1.3.2 IBV virion 
Coronaviruses, including IBV, are enveloped, spherical viruses with typical sizes ranging 
from 80 to 120nm. The virion is encased in a host cell-derived phospholipid bilayer which 
forms an envelope and contains three viral proteins: the spike (S) protein, the membrane 
protein (M) and the envelope protein (E) (Figure 1.4). The spike is necessary for mediating 
viral entry into the host cell as well determining host range (Enjuanes et al., 2006;Perlman 
and Netland, 2009). The S protein assembles as a trimer which gives coronaviruses the 
distinctive “corona”, or crown-like appearance. The E protein is a small 10KDa protein 
which is found embedded into the envelop at low densities (Yu et al., 1994). The E protein 
re-arranges secretary organelles which increases the efficiency of viral replication, thus 
propagating the production of new virions (Ruch and Machamer, 2011;Ruch and 
Machamer, 2012). The N protein of IBV is known to associate with the nascent gRNA to 
form the nucleocapsid that is incorporated into new virions (Klumperman et al., 1994). The 
M protein is a transmembrane protein that interacts with E and N proteins to assemble 
new virions during infection (Neuman et al., 2011;Narayanan et al., 2000;Corse and 
Machamer, 2003;Lim and Liu, 2001). Within the lipid envelope is the vRNP which is released 
upon virion binding and subsequent fusion with the cellular membranes. 
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Figure 1.4 A schematic representation of an IBV virion. Highlighted is the surface 
glycoprotein spike (S), the membrane protein (M), the envelope protein (E), the 
nucleocapsid (N) that surrounds the viral RNA which is in the positive sense orientation. 
[Taken from: (Belouzard et al., 2012;Platanias, 2005)]. 
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1.3.3 IBV cell entry 
IBV utilises the S protein in order to gain entry into the host cell. The S protein is a large, 
type I transmembrane protein that is 1,160 amino acids in length. The S protein is split into 
two subunits, the N-terminal domain (S1) and the C-terminal domain (S2) which are cleaved 
by furin during infection (Yamada and Liu, 2009). The S1 domain mediates receptor binding 
and the S2 domain is responsible for fusion with the cell bilayer (Promkuntod et al., 2014). 
IBV attachment and entry is facilitated through the binding of the S protein to α-2,3-linked 
sialic acid, a ubiquitous cell surface molecule (Winter et al., 2006). Due to the restricted 
cellular tropism of IBV and the global distribution of sialic acid, it has been proposed that 
another unknown cell receptor is required for viral entry (Schultze et al., 1992;Winter et al., 
2006). The exact mechanism of IBV entry is currently unknown, although clatherin-
mediated endocytosis has been suggested (Yamada and Liu, 2009). It has been observed 
that IBV fusion is pH-dependent and the acidification of vesicular compartments mediates a 
conformational change in the S protein, revealing the fusion peptide within the S2 subunit. 
Release of the fusion peptide results in the fusion of the cellular and viral membranes, 
thereby releasing the vRNP into the cytoplasm (Bosch et al., 2003). 
1.3.4 Replication, transcription and translation of the viral genome 
Nidoviruses (which include coronaviruses) utilise complex methods of regulating replication 
and transcription of their polycistronic genomes (Snijder and Meulenberg, 1998;Lai and 
Cavanagh, 1997). As a positive sense RNA virus, viral genomic RNA acts directly as mRNA 
for the translation of the replicase polyproteins, pp1a and pp1ab, encoded by gene 1. The 
polyprotein pp1ab has an extended C-terminus and it is encoded for by two thirds of the 
viral genome. Translation of pp1ab occurs after a -1 frameshift which is found in the ORF of 
non-structural protein 11 (nsp11) (Brierley et al., 1987) and occurs when the ribosome 
encounters a slippery sequence when translating the coronavirus RNA. 
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nsp Alternative name 
Protein length 
(aa) 
Function 
2 p87 673 Unknown function 
3 PL-PRO 1594 
Primarily a papain-like proteases, with 
many other functions (Lim and Liu, 
1998) 
4 Peptide HD2 514 
Formation of DMVs (Oostra et al., 
2007) 
5 
3C-like 
proteinase 
307 
Cysteine-like protease, polyprotein 
processing (Fang et al., 2010) 
6 p34 293 
Formation of DMVs, induces 
autophagy (Maier et al., 2013a) 
7 p9 83 Unknown function 
8 p24 210 
Primase for the RNA polymerase (Tan 
et al., 2018) 
9 p10 111 
A protein of the Replicase complex 
(Chen et al., 2009) 
10 p16 145 
A protein of the Replicase complex  
(Fang et al., 2008) 
11   Unknown 
12 
RNA-directed 
RNA polymerase 
940 
RNA-dependent RNA polymerase 
(RdRp) (Tan et al., 2018) 
13 Helicase 600 Helicase (Seybert et al., 2005) 
14 Exoribonuclease 521 
3′ – 5′ exonuclease, RNA cap 
formation, methyltransferase (Xu et 
al., 2010) 
15 
Uridylate-specific 
endoribonuclease 
338 Endonuclease (Bhardwaj et al., 2012) 
16 
Putative 2'-O-
methyl 
transferase 
302 
RNA cap formation (Decroly et al., 
2008) 
Table 1.3 The size and function of the non-structural proteins (nsps) in IBV.  
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Figure 1.5 A schematic representation of coronavirus transcription. IBV utilises both continuous and discontinuous transcription of its genomic RNA. 
Continuous transcription is utilised by the virus for the creation of negative-sense full-length genome copies, which are then used as templates for new 
+ssRNA genomes. Discontinuous transcription creates a nested set of 5 negative-sense sgRNAs of varying lengths. These sgRNAs act as templates for the 
synthesis of positive-sense sgRNA, which are later translated into viral proteins. [Taken from: (van Marle et al., 1999)]. 
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For the frameshift to arise, the ribosome must pause over the target sequence and this is 
achieved through secondary structure (pseudoknot) termed the stimulatory element. Once 
paused, the pseudoknot unwinds, allowing translation to reinitiate in the -1 orientation. 
The final product is the replicase polypeptide pp1ab (Brierley et al., 1987;Inglis et al., 1990). 
These polyproteins are cleaved by the virally encoded proteases: nsp3 and nsp5, into 15 
individual nsps (Table 1.3). These nsps play a role in a multitude of functions, but are all 
associated with replication of the viral genome. A number of the nsps accumulate at the 
replication-transcription complex (RTC) and these are found in the cytoplasm of infected 
cells. (Ziebuhr et al., 2000). 
Continuous transcription is utilised by the virus for the creation of negative-sense full-
length genome copies, which are then used as templates for new +ssRNA genomes. To 
mediate expression of the structural and accessory proteins, IBV, and all viruses of the 
Nidovirales order, utilise a discontinuous method of RNA synthesis which produces sub-
genomic RNA (sgRNA) (Figure 1.5) (Lai and Cavanagh, 1997). The structural and accessory 
genes are located downstream of the replicase gene (pp1ab), in the 3′ third of the IBV 
genome. These genes are expressed from a set of at least five nested mRNAs and vary in 
length (Sawicki et al., 2007;van Vliet et al., 2002). A common leader sequence derived from 
the 5′ terminus of the viral genome is found on each of the mRNAs (Vandermost et al., 
1993). Together with the leader and coding sequences, the transcription regulating 
sequence (TRS) found at the 3′ end of the leader sequence is critical for sgRNA synthesis 
(Makino et al., 1991). Each viral sgRNA is capped at the 5′ end and polyadenylated at the 3′ 
end. The functions of the structural and accessory proteins are summarised in Table 1.4. 
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Protein Protein length 
(aa) 
Function 
Spike (S) 1,162 Receptor binding (S1) and 
membrane fusion (S2) (Casais et al., 
2003) 
Envelope (E)  109 Modulates the secretory pathway, 
promotes viral replication (Ruch 
and Machamer, 2011) 
3a 57 Supresses interferon expression 
(Kint et al., 2015) 
3b 64 Supresses interferon expression 
(Kint et al., 2015) 
Membrane (M) 225 Virion assembly (Narayanan et al., 
2000) 
5a 65 Unknown 
5b 82 Host translational shut-off (Kint et 
al., 2016) 
Nucleocapsid (N) 
409 Chaperone for viral RNA (Zuniga et 
al., 2010) 
Table 1.4 The size and function of the structural and accessory protein of IBV.  
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1.4 Herpes Virus of Turkeys 
Herpesvirus of Turkeys (HVT) is the third serotype within the Marek’s disease virus (MDV) 
group. This group contains viruses that are genetically and antigenically related 
lymphotropic avian herpesviruses (Afonso et al., 2001). MDV1 is the etiologic agent which 
manifests itself as a lymphoma causing disease in chickens and is of considerable economic 
importance to the poultry industry (Prasad, 1979). In comparison, HVT is a non-pathogenic 
virus in chickens, and because of this and the associated immune response due to viremia, 
it has been used extensively as a vaccine candidate for viruses that infect poultry (Witter, 
1972;Witter et al., 1970). Vaccine candidates have been produced for protection against: 
Newcastle disease virus (NDV) (El Khantour et al., 2017), infectious bursal disease virus 
(IBDV) (Darteil et al., 1995;Perozo et al., 2009), influenza A virus (IAV) (Kapczynski et al., 
2016;Rauw et al., 2012) and MDV (Gimeno et al., 2016). HVT contains a large dsDNA 
genome of 159kb encoding 99 functional genes (Afonso et al., 2001). Research conducted 
on MDV (the etiological agent) found that cell-free MDV has only been detected in the 
epithelial cells of the feather follicle. The initial infection of chickens with MDV is through 
the inhalation of cell-free virus from the skin and associated feather follicle epithelium 
(Beasley et al., 1970;Addinger and Calnek, 1973;Calnek, 2001). Subsequent infection is 
mediated exclusively through cell-to-cell transmission (Churchill and Biggs, 1967). Once 
infection has been established, the next stage is the cytolytic phase in lymphoid organs 
followed by the establishment of latency in T cells, which ultimately results in the 
transformation of those T cells (Abdul-Careem et al., 2009). 
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1.5 Interferon Induction and Signalling 
1.5.1 The interferons 
Interferons (IFNs) are the molecules that protect cells from viral infection and were first 
discovered in 1957 by Isaacs and Lindenmann (Isaacs and Lindenmann, 1957). IFNs are 
soluble cytokines that have potent antiviral activities and are critical in controlling viral 
infection by activating a cell-intrinsic antiviral state (Stetson and Medzhitov, 2006;Foster, 
1997). Following detection of a viral pathogen, cells secrete these cytokines which then 
bind to their cognate receptor, in an autocrine and paracrine fashion, resulting in the 
transcriptional activation and modulation of over 500 genes, collectively known as 
interferon stimulated genes (ISGs) (de Veer et al., 2001b;Santhakumar et al., 2017). 
Although the IFN response is robust, and in many cases will limit the severity of infection, it 
has been well established that viral pathogens have evolved various mechanisms to block 
the activation or effective signalling of IFNs (Randall and Goodbourn, 2008). There are three 
families of IFNs (type I, II and III) which are grouped according to their structure and 
function. Moreover, each family has its own specific receptor which allows for the 
propagation of an effective immune response (Platanias, 2005). In humans, type I IFNs 
include IFNα (13 different subtypes), IFNβ, IFNε, IFNκ, and IFNω (Platanias, 2005;Gibbert et 
al., 2013). The best characterised type I IFNs are IFNα and IFNβ, while the roles of IFNε, κ, 
and ω are less well understood. The type II IFN (IFNγ) is structurally different to the type I 
IFNs and is secreted by natural killer and activated T cells (Th1 CD4 and CD8 cytotoxic) 
(Farrar and Schreiber, 1993). IFNγ has an immunomodulatory role, not only protecting 
against intracellular pathogens, but also controlling tumour development (Schoenborn and 
Wilson, 2007). Type III IFNs include IFNλ1, IFNλ2, IFNλ3, and IFNλ4. It has been shown that 
type III IFNs are able to upregulate the expression of the same ISGs as type I IFNs, albeit at a 
lower level, in comparison to IFNα (Zhou et al., 2007). Moreover, it has been shown that 
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the expression of type III IFNs is restricted to mucosal epithelial cells which frequently 
encounter viral pathogens (Wack et al., 2015). Type I and type III IFNs are upregulated in 
direct response to viral infection and the binding of IFN to their cognate receptor results in 
the activation of the same downstream signalling molecules, such as those found in the 
canonical JAK/STAT pathway (Kotenko et al., 2003;Wack et al., 2015;Zhou et al., 2007). For 
the purposes of this thesis, I shall only make reference to IFNα and β (type I) and IFNγ (type 
II) and will not discuss any other subtypes or type III IFNs. 
1.5.2 Viral pathogen detection and interferon induction 
To detect invading viral pathogens, the immune system is equipped with specialised 
receptors known as pathogen recognition receptors (PRRs). These PRRs recognise a limited 
number of pathogen associated molecular patterns (PAMPs). One of the primary PAMPs 
that elicits IFN induction are non-host cell derived nucleic acids, such as dsRNA (Weber et 
al., 2006). However, other structures present on ssRNA viral genomes, such as 5’ 
triphosphate groups, also elicit an IFN response (Hornung et al., 2006;Pichlmair et al., 
2006). In mammals, the initial detection of virally-derived PAMPs is primarily mediated 
through Retinoic acid-inducible gene 1 (RIG-1) like receptors (RLRs) which are DExD/H box 
RNA helicases. There are three RLRs namely; retinoic acid-inducible gene 1 (RIG-1), 
melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and 
physiology 2 (LGP2). All three RLRs contain an RNA helicase domain and a C-terminal 
regulatory domain (CTD), although only RIG-1 and MDA5 contain caspase activation and 
recruitment domains (CARD). LGP2 does not contain a CARD domain and has been 
implicated in regulating the function of RIG-1 and MDA5. During viral infection and upon 
the recognition of PAMPs, the CTD of RIG-1 and MDA5 binds to viral RNA, activating the 
CARD domains (Satoh et al., 2010;Yoneyama et al., 2005;Takahasi et al., 2008;Rehwinkel et 
al., 2010;Loo and Gale, 2011).  
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It is known that the primary PRR during IAV infection in humans is RIG-1, although the 
contribution of MDA5 has been shown to be important during in vivo infections (Graham et 
al., 2013;Benitez et al., 2015). For full activation, the CARD of RIG-1 is poly-ubiquitinated by 
either tripartite motif-containing protein 25 (TRIM25) (Gack et al., 2007), RING finger 
protein leading to RIG-1 activation (RIPLET) (Oshiumi et al., 2009), or Mex-3 RNA Binding 
Family Member C (MEXC) (Kuniyoshi et al., 2014). Poly-ubiquitination of the CARD domain 
results in the formation of a hetero-tetrameric complex of RIG-1 (with ubiquitin) which is 
essential for downstream signal transduction (Jiang et al., 2012). CARDs of RIG-1 then 
interact with the CARD of interferon promoter stimulator-1 (ISP-1) (also known as MAVS, 
VISA or Cardif) which acts as a signal adaptor molecule (Kawai and Akira, 2009). This results 
in the activation of I kappa B kinase (IKK) and TANK-binding kinase 1 (TBK1) (Loo and Gale, 
2011). TBK1 and IKK then phosphorylate and activate the transcription factors interferon 
regulatory factor-3 (IRF3) and interferon regulatory factor-7 (IRF7) which dimerise and 
subsequently localise to the nucleus. This results in the activation and expression of type I 
IFNs. An overview of the process described above is illustrated in in Figure 1.6.      
1.5.3 Interferon signalling 
Once translated, IFN α/β is secreted from infected cells where it acts in an autocrine and 
paracrine manner, binding to the IFNα/β receptor (IFNAR) of the same, or neighbouring 
cells. The IFNAR receptor is a heterodimeric transmembrane receptor, which consists of the 
IFNα receptor 1 (IFNAR1) and IFNα receptor 2 (IFNAR2) subunits (Ivashkiv and Donlin, 
2014). Binding of IFNα/β to the IFNAR activates a complex downstream signalling cascade 
which results in the synthesis and upregulation of ISGs with a number of antiviral and anti-
proliferative functions (Schneider et al., 2014). Activation of innate immune pathways in 
uninfected cells ‘prime’ these cells, hindering viral infection. IFNα/β binding to IFNAR 
activates janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), which results in the  
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Figure 1.6 A schematic representation of PAMP recognition and IFN induction. The 
cytoplasmic dsRNA sensor RIG-1 is poly-ubiquitinated by TRIM25 which allows for the 
CARD of RIG-1 to interact with the CARD of ISP-1 (MAVS). This results in the activation of 
TBK I and IKKε which in turn phosphorylate and active the transcription factors IRF-3 and 
IRF-7. Homodimers then translocate into the nucleus and bind to the corresponding 
promoter sequences, inducing the expression of type I IFNs. [Taken from: (Nan et al., 
2014)].  
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phosphorylation of signal transducer and activator of transcription 1 and 2 (STAT1 and 
STAT2) (Randall and Goodbourn, 2008). The phosphorylated STAT1/STAT2 heterodimer 
interacts with interferon regulatory factor 9 (IRF9) forming a complex called the interferon 
stimulated gene factor 3 (ISGF3) (Fu et al., 1990;Schindler et al., 1992). ISGF3 translocates 
to the nucleus and binds to IFN-stimulated response elements (ISREs) (Levy et al., 1986). 
ISREs are found in the promoter sequences of all ISGs which allows for the universal 
modulation of ISG expression through interferon signalling. This process also acts as a 
positive feedback mechanism, enhancing the type I IFN response. In contrast IFNγ binds to 
IFN-γ receptors 1 (IFNGR1) and 2 (IFNGR2) which results in the phosphorylation and 
homodimerization of STAT1 (Shuai et al., 1992). The activated STAT1 complex then 
undergoes nuclear translocation, and binds to the gamma-activated sequence (GAS) 
elements upstream of IFN-γ-induced genes (Decker et al., 1991). Interferon signalling is an 
essential process which allows for the modulation of ISG expression and protects the cell 
from invading viral pathogens. Figure 1.7 is a schematic illustrating interferon signalling in 
human cells.   
1.5.4 Interferon induction and signalling in Galliformes 
The general principals of interferon activation and signalling outlined in mammals are 
broadly transferable to chickens, although there are some notable exceptions. One of the 
most striking features of innate immunity in Galliformes is the absence of RIG-1 as a 
cytosolic sensor of virally-derived PAMPs (Karpala et al., 2011). However, this does not 
mean that chickens are unable to mount a potent innate immune response. It has been 
demonstrated that MDA5, which detects long dsRNAs in humans, is able to detect both 
short and long dsRNA’s in chickens, suggesting some functional redundancy (Hayashi et al., 
2014). In addition, chicken LGP2 has an MDA5-like helicase domain and a RIG-1-like C- 
terminal domain which is able to bind dsRNA (Uchikawa et al., 2016). It is currently  
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Figure 1.7 A schematic representation interferon signalling. IFNα/β bind to the IFNAR 
receptor which leads to the activation of TYK2/JAK1, activation and heterodimerisation 
of STAT1/2 and the formation of the ISGF3 complex through an interaction with IRF9. 
ISGF3 undergoes nuclear export where it binds to the ISRE promoter. In comparison IFNγ 
binds to the IFNGR receptor, leading to the activation of TYK2/JAK1, activation and 
homodimerisation of STAT1 which then binds to the GAS promoter. Both lead to the 
upregulation and modulation of ISGs. [Taken from: (Platanias, 2005)]. 
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unknown if this plays a significant role in PAMP detection. In addition, comparative 
genomics suggest that IRF3 and IRF9 are absent from the chicken genome. IRF7 and IRF10 
are the only members of the transcription factor family that have been identified in 
chickens to date (Santhakumar et al., 2017). Despite significant improvements over the past 
decades, the sequence and annotation of the chicken genome is still incomplete. Therefore, 
it is unclear if IRF3 and IRF9 are actually missing or whether they are yet to be identified. 
This is exemplified by a recent manuscript which claims to have found tumour necrosis 
factor-α (TNFα) in birds, a cytokine that was thought to be absent from the chicken genome 
(Rohde et al., 2018). In humans, there are 7 type I IFNs (IFNα, IFNβ, IFNε, IFNκ, IFNω, IFNδ, 
and IFNτ) whereas only 2 type I IFNs have been identified in chickens; IFNα and β. This 
highlights the vast difference between the innate immune systems of chickens and humans. 
For a complete overview, avian IFNs and innate immunity has been reviewed by 
Santhakumar et al, 2017 (Figure 1.8).      
1.5.5 Viral evasion of the interferon response 
Viral pathogens have evolved mechanisms to evade restriction by interferon and ISGs. The 
main interferon antagonist of IAV is the NS1 protein which utilises many mechanisms to 
evade the cellular innate immune responses. NS1 is able to bind to RIG-1 directly as well as 
to the E3 ligases TRIM25 and RIPLET, which are necessary for the poly-ubiquitination and 
activation of RIG-1 (Rajsbaum et al., 2012;Gack et al., 2009;Mibayashi et al., 2007). NS1 also 
inhibits the transcription factors AP-1, IRF3 and NF-κB (Talon et al., 2000;Wang et al., 
2000;Ludwig et al., 2002). It has been observed that other IAV proteins, such as the RdRp 
and PA-X, are also able to reduce the effectiveness of the interferon response, by inducing 
host shut-off mediated by endonuclease events required for the translation of IAV-derived 
mRNAs. This is likely reduces the translation of host mRNAs which reduces the cells ability 
to increase expression of IFNs/ISGs (Bercovich-Kinori et al., 2016). It has also been shown  
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Figure 1.8 A schematic representation of chicken interferon induction and signalling. The pathways and proteins utilised in human and chicken cells for 
the activation of a cell-intrinsic antiviral state are broadly similar although some notable differences include a lack of RIG-1, IRF3 and IRF9. It is also 
unknown what molecule interacts with STAT1/STAT2 to form the ISGF3 complex. [Taken from: (Santhakumar et al., 2017)]. 
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that HA of IAV is able to bind directly to the IFNAR receptor, inducing ubiquitination and 
therefore selecting them for degradation via the proteasome (Xia et al., 2016). A role has 
also been implicated for PB1-F2. It has been shown that PB1-F2’s association with MAVS 
reduces the membrane potential across the mitochondria which interferes with IFN 
induction (Varga et al., 2012).The mechanisms employed by IBV to circumvent the 
interferon response are currently unknown. However, the mechanisms used by other 
coronaviruses have been investigated and includes the targeting of many of the same 
proteins as observed with IAV. For example, it has been observed that the N protein of 
SARS-CoV inhibits the ubiquitination of RIG-1 by binding to the SPRY domain of TRIM25 (Hu 
et al., 2017). In addition, the nsp1 of α and β-coronaviruses has been shown to induce host 
cell shut-off, selectively targeting host cell mRNAs for degradation and limiting the 
effectiveness of the interferon response (Kamitani et al., 2006).  
1.6 Mammalian IFITMs 
16.1 Early characterisation 
The human IFITM proteins were discovered in 1984, making them amongst the first ISGs to 
be characterised (Friedman et al., 1984). The nomenclature was initially very different to 
what is used currently. They were originally named 9–27(IFITM1), 1-8D (IFITM2), and 1-8U 
(IFITM3). Further characterisation of these genes was undertaken in 1996 (Alber and 
Staeheli, 1996) where the authors noted that vesicular stomatis virus (VSV) could be 
inhibited by IFITM1, although the inhibition was less potent than with MxA. Moreover, 
when huIFITM1 was overexpressed in mouse cells, these cells were more refractory to 
infection with VSV than the wildtype controls. Interestingly, the authors noted that IAV was 
less potently inhibited by IFITM1 than VSV, a finding which is contradictory to the current 
literature (Huang et al., 2011). A further study examined the relationship between hepatitis 
C virus (HCV), IL-1 and 1-8U (IFITM3) and found that increased expression of 1-8U was 
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associated with a decrease in HCV mRNA, although no specific conclusions regarding 
antiviral activity were made from this study (Zhu and Liu, 2003).  
In 2009, two separate IAV-targeting RNA interference studies identified huIFITM1, 2 and 3 
as potential restriction factors against IAV (Brass et al., 2009;Shapira et al., 2009). In the 
study by Brass et al which aimed at selectively targeting IFITM3 through siRNA treatment, 
they found that this targeted inhibition of IFITM3 rescued H1N1 (A/PR/8/34) replication in 
U2OS cells that had been treated with IFNγ. Further characterisation was performed, and 
the authors observed that the overexpression of IFITM1, IFITM2, or IFITM3 suppressed the 
replication of H1N1 (A/PR/8/34) and H3N2 (A/Udorn/72) in A549, U2OS, and MDCK cell 
lines as well as in chicken embryo fibroblasts (CEFs). They also found that murine leukemia 
virus (MLV) was not be restricted by the overexpression of these IFITMs, suggesting 
specificity in the viral pathogens that the IFITM proteins are able to target for restriction. In 
the same study, murine embryonic fibroblasts (MEFs), that lack the ifitm locus (ifitm-/-), 
were developed. When these cells were challenged with IAV or retroviruses pseudotyped 
with H1, H3, H5, and H7, viral replication was significantly restricted when compared to the 
wildtype controls. Moreover, West Nile Virus (WNV) and Dengue Virus (DV) were potently 
restricted in A549 or U2OS cells stably overexpressing IFITM3. Conversely, when IFITM3 
expression was knocked down via siRNA transfection, an increase in viral replication was 
observed, demonstrating that IFITM3 is a true restriction factor of IAV, WNV and DV. In 
contrast, there was no observed restriction of three arenaviruses, namely lymphocytic 
choriomeningitis virus (LCMV), Lassa virus (LASV) or Machupo virus (MACV), suggesting that 
there is some degree of specificity of IFITM restriction. The findings published in these 
studies prompted further research by many groups that sought to understand the 
mechanisms underpinning the antiviral activities of the mammalian IFITMs.  
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1.6.2 Vertebrate orthologues of IFITMs 
Assigning vertebrate orthology is challenging due to the positive selection and divergence 
of innate immune genes, including the IFITM family (Zhang et al., 2012;Webb et al., 2015). 
There is a constant arms race between the virus and host which intensifies the process of 
positive selection of the innate immune genes (tenOever, 2016). Moreover, when one 
considers that chickens and humans diverged more than 300 million years ago (mya) it is 
not surprising that sequence homology is low and orthology is difficult to assign (Burt et al., 
1999). There are 3 clades of IFITM genes, clade I contains IFITM1, IFITM2 and IFITM3 (as 
well as murine Ifitm6 and Ifitm7), clades II and III contain just 1 gene, IFITM5 and IFITM10, 
respectively. The identification of IFITM family members is through the conserved CD225 
domain (Siegrist et al., 2011). The two terminal regions of the IFITM genes are 
hypervariable and this is thought to correlate with viral specificity (Compton et al., 2016). 
The majority of mammals have a locus containing at least the clade I IFITM genes, alongside 
birds (such as turkeys and chickens), fish (such as stickleback and zebra fish) and 
amphibians (frog) (Bailey et al., 2014;Zhang et al., 2012;Siegrist et al., 2011). Although 
syntenic, the IFITM locus is not always found on the same chromosome when comparing 
among species. For example, the IFITM locus is located on chromosome 11 in humans, 
chromosome 7 in the mouse and on chromosome 5 in the chicken. There are two 
conserved genes that flank the IFITM locus of all species ranging from mammals to 
amphibians (Smith et al., 2013), independent of the chromosome the locus is located on; 
the telomeric β-1,4-N-acetyl-galactosaminyl transferase 4 (B4GALNT4) and the centromeric 
acid trehalase-like 1 (ATHL1) gene. The identification of these two conserved genes makes 
the identification of the IFITM locus possible between species. A combination of BLAST 
searches and the use of synteny, led to the successful identification of the chIFITM locus by 
Smith et al., 2013 via bioinformatics analysis.      
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1.6.3 Conservation and post-translational modifications 
IFITM proteins are small polypeptides of approximately 130 amino acids with a conserved 
CD225 domain, comprised of an intramembrane (IM) domain, a transmembrane domain 
(TMD) and a cytoplasmic intracellular loop (CIL). The CD225 domain is conserved both 
within paralogues and between orthologues from different species. The amino acids within 
the CD225 domain are subject to post-translational modifications (PTMs) such as 
palmitoylation, ubiquitination and methylation. These PTMs confer specific functions that 
are linked to restriction. The palmitoylation of two cysteine residues (Cys 71 and 72) 
situated within the IM domain are critical (especially Cys 72) for the restriction activity of 
huIFITM3 (Yount, 2012 and Yount 2010). Another Cys residue at position 105, located at the 
junction between the CIL and TMD, is also palmitoylated but the role of this poorly 
conserved residue does not seem essential for viral restriction. It is thought that the 
palmitoylation of these residues is important not only for restriction and IFITM subcellular 
localisation, but also for their association with lipid rafts. It has been shown that 
incremental mutagenesis of the Cys residues results in a reduction of antiviral activity 
(Yount et al., 2010;Yount et al., 2012). It is thought that ubiquitination enhances the 
stability of the proteins and mediates protein turnover. The ubiquitination of lysine 
residues located throughout the conserved domain (Lys24, Lys83, Lys88, and Lys104) of the 
IFITM proteins, has been shown to be unfavourable for IFITM restriction. However, studies 
on IFITM3 observed that a ubiquitinated IFITM3 is more stable and localises more 
consistently to the correct intracellular compartment (Yount et al., 2012). It has also been 
shown that Lys88 of IFITM3 can undergo monomethylation by set7 (Shan et al., 2013). 
Increased methylation at this position is correlated with a loss of restrictive function, whilst 
decreased methylation resulted in an enhanced restrictive phenotype (Chesarino et al., 
2014b). Phosphorylation of Tyr20 is less conserved and is only present in huIFITM2 and 3 
(and related orthologues) and regulates IFITM expression and sub-cellular localisation (Jia 
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et al., 2012). The hydrophobic N-terminal domains (NTDs) have a greater degree of 
heterogeneity in terms of length and sequence diversity, which could be critical in 
conferring specific antiviral function, and may explain potential differences in virus 
specificity (John et al, 2013).   
1.6.4 Membrane topology and mechanism of action 
Although the huIFITM proteins have been studied extensively, only a single study provides 
evidence that predicts the protein topology of huIFITM3 (Ling et al., 2016). Using nuclear 
magnetic resonance (NMR) and electron paramagnetic resonance (EPR) on huIFITM3 in 
detergent liquid micelles, Ling et al postulate the proposed type II transmembrane protein 
topology model for huIFITM3. Furthermore, PTMs of the NTD, particularly the 
ubiquitination of Lys24 and phosphorylation of Tyr20, suggest that the NTD resides 
intracellularly, as access to cytosolic enzymes such as ubiquitin ligases and protein kinases 
is essential (Jia et al., 2012;Yount et al., 2012). Evidence for the localisation of the C-
terminal domain (CTD) is less definite, although additional studies assessing the PTMs in 
this region suggest that the CTD of murine ifitm1 could also reside intracellularly (Yount et 
al., 2012;Hach et al., 2013b). Conversely, models of murine ifitm3 and huIFITM1 suggest 
that the CTD resides extracellularly (Bailey et al., 2014;Weston et al., 2014).   
The broad spectrum of viral restriction by IFITM proteins means that identifying the 
molecular mechanism(s) of specific viral restriction remains elusive. It is still not known why 
some viruses are insensitive to IFITM restriction whereas others are potently restricted. A 
study published in 2014 demonstrated that huIFITM3 interacts with Vesicle-membrane-
protein-associated protein A (VAPA) which in turn prevents its association with oxysterol-
binding protein (OSBP). This interaction disrupts cholesterol homeostasis and inhibits viral 
entry via cholesterol accumulation (Amini-Bavil-Olyaee et al., 2013). Two further studies 
found that host cell membranes underwent a loss of fluidity after an overexpression of 
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huIFITM1 which may be explained by the findings of Amini-Bavil-Olyaee et al (Li et al., 
2013;Lin et al., 2013). In contrast, other studies suggest that IFITM-mediated viral 
restriction is independent on cholesterol and propose an alternate mechanism whereby 
IFITM3 has an ability to block fusion pore formation at a post-hemifusion stage. It is 
proposed that this process stabilises the cytoplasmic leaflet of endosomal membranes 
either directly or indirectly through proteins/lipid independently of cholesterol (Desai et al., 
2014). In addition, further co-immunoprecipitation studies suggest that ZMPSTE24 can 
interact with members of the huIFITM protein family and the data implies that ZMPSTE24 
expression is essential for IFITM antiviral activity (Fu et al., 2017). These studies 
demonstrate the complexity of the mechanisms of IFITM-mediated restriction. It may also 
be possible that more than one mechanism is utilised during infection.     
1.6.5 Cellular localisation 
All of the huIFITMs are constitutively expressed (Everitt et al, 2013); however, type I IFN 
signalling enhances the expression of these genes. Human and mouse IFITM proteins have 
been extensively studied, and their localisation well characterised. Human IFITM1 has been 
shown to localise at the plasma membrane, with the C-terminal domain (CTD) available for 
cleavage by extracellular proteases (such as trypsin), which suggests that the CTD of 
huIFITM1 resides extracellularly (Weston et al., 2014). However, data generated by electron 
microscopy suggests that a fraction of huIFITM1 localises at intracellular compartments 
such as the golgi apparatus. Human IFITM3 has been shown to stain in consistent punctate 
structures at the early/late endosomes, co-localising with proteins such as Rab and 
Lamp1/2 (Weston et al., 2014;Narayana et al., 2015). A study has shown that localisation of 
huIFITM3 at the endosomes is important for the restriction of viruses such as IAV, which 
enter through the acidification of late endosomes (Yoshimura et al., 1982).   
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The localisation of huIFITM2 is more controversial. Some data suggests that it localises to 
similar compartments as huIFITM3, in punctate spots at the early/late endosomes 
(Narayana et al., 2015). Other groups report staining in punctate structures at the nucleus 
(Weston et al., 2014). Many studies have reported the possible implications of using tagged 
constructs, as the proteins may incorrectly localise and the function of the protein may be 
altered. At present, tagged constructs remain necessary because the antibodies against the 
different IFITM proteins cross-react (Zhao et al., 2014;Weston et al., 2014;Wrensch et al., 
2015). In one study, it was observed that anti-IFITM1-NTD antibody detects both IFITM1 
and IFITM3, whilst an anti-IFITM3-NTD antibody detects IFITM3 and IFITM2 (Weston et al., 
2014). 
1.6.6 Restriction of viral pathogens 
Human IFITM proteins restrict the entry and replication of several highly pathogenic human 
viruses, including influenza A viruses (IAVs), flaviviruses (Dengue virus), filoviruses (Ebola 
virus and Marburg virus) and coronaviruses such as severe acute respiratory syndrome 
(SARS) and human immunodeficiency virus 1 (HIV-1) (Brass et al., 2009;Foster et al., 
2016;Yu et al., 2015;Tartour et al., 2014;Lu et al., 2011;Compton et al., 
2014;Chutiwitoonchai et al., 2013).  
The evidence for IAV restriction is abundant and includes data generated from in vitro 
models and in vivo studies. Initial investigations using siRNA screens during IAV infection 
found that the IFITM proteins were able to potently restrict IAV (Brass et al., 2009). Since 
this time, IFITM3 has been found to be the most potent member of the IFITM family in 
restricting IAV, although IFITM2 and 1 do reduce IAV infectivity (Huang et al., 2011;Everitt 
et al., 2012). It has been shown that IAV is potently restricted by ifitm3 in mice (Bailey et al., 
2012). A mouse model with a disruptive insertion in exon 1 of ifitm3 which abolishes gene 
function (Lange et al., 2008), (ifitm3-/-), found that a usually low pathogenicity H3N2 (A/X-
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31) IAV resulted in weight loss of >25% and severe signs of clinical illness. Even though 
there are many different strains of IAV due to the many possible HA and NA combinations, 
there have been no reports of IAV escape from IFITM-mediated restriction (Bailey et al., 
2014).  
A wide range of other enveloped viruses are also restricted by the IFITM protein family. 
Flaviviruses, including DENV1 and DENV2, Japanese encephalitis virus (JEV), and WNV are 
all potently restricted (Brass et al., 2009;Huang et al., 2011;Jiang et al., 2010;John et al., 
2013). It is believed that flaviviruses are restricted in the same manner as IAV because both 
viruses share a common method for viral entry; fusion with host cell membranes. In 
contrast, filoviruses (EBOV and MARV) and coronaviruses (SARS-CoV and MERS-CoV) 
require delayed proteolytic cleavage of the fusion peptide in order to enter the cytoplasm 
from the endosomes, therefore endosomal-viral fusion occurs much later on (Huang et al., 
2006;Chandran et al., 2005). In general, these viruses are more sensitive to IFITM1 
restriction than IAV (Huang et al., 2011). The bunyaviruses Andes virus (ANDV), Hantaan 
virus (HTNV), La Crosse virus (LACV) and Rift Valley fever virus (RVFV) are restricted by all of 
the IFITM proteins, with the notable exception of RVFV which is not restricted by huIFITM1 
(Mudhasani et al., 2013).   
The evidence regarding the restriction of HIV-1 by the IFITM proteins is not as clear as the 
data generated for the restriction of IAV. Initial work conducted by Brass et al (2009) failed 
to demonstrate that the overexpression of either IFITM1, 2 or 3 restricted HIV-1 infection 
(Brass et al., 2009). However, subsequent work observed that the overexpression of IFITM2 
or 3 did in fact restrict HIV-1 infection. These results were verified by the ablation of IFITM2 
or 3 expression using shRNA (Schoggins et al., 2011). Moreover, further experiments 
focussing on the overexpression of IFITM genes, showed that IFITM1, 2 and 3 are able to 
decrease HIV-1 replication whilst the overexpression of IFITM2 and 3, but not IFITM1, 
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inhibit HIV-1 entry (Lu et al., 2011). As well as preventing replication and/or entry, IFITM 
proteins are also able to directly inhibit HIV-1 protein synthesis (Chutiwitoonchai et al., 
2013). Promoter sequences with rev elements have been shown to be inhibited by the 
IFITMs, suggesting that they are able to selectively target RNA with specific secondary 
structure. HIV-1 can effectively mutate away from IFITM1-mediated restriction (Ding et al., 
2014). As well as restricting intracellular infection, the IFITM proteins have been found in 
nascent HIV-1 virions and this is thought to reduce the infectivity of these particles as the 
infection spreads to neighbouring cells (Tartour et al., 2014;Compton et al., 2014).   
In addition to restricting enveloped viruses, IFITMs are also able to restrict two strains of 
non-enveloped reoviruses (Anafu et al., 2013). Reoviruses enter the cytoplasm through the 
endosomal pathway and escape from these endosomes by perforating the membranes. 
Unlike IAV, reoviruses require acid-dependent cathepsins for the removal of the outer 
capsid, ensuring their genome is delivered into the cytoplasm for replication (Ebert et al., 
2002). Interestingly, reoviruses are able to bypass IFITM3-mediated restriction through the 
production of subvirion particles which do not require endosomal proteolysis for entry 
(Chandran and Nibert, 1998;Anafu et al., 2013). Thus, restriction of reoviruses must occur in 
the endosomes.  
Work has also been undertaken to understand the genetic predispositions within the 
huIFITM locus that result in differential susceptibility to disease. It has been proposed that 
the single nucleotide polymorphism (SNP) rs12252-C alters the splice acceptor site of 
huIFITM3, truncating the protein by 21 amino acids at the N-terminus. During the 2009-
2011 pandemic of pH1N1/09, genetic analysis of IFITM3 from patients hospitalised with 
either seasonal or pandemic influenza viruses, was conducted. In this study, it was found 
that a statistically significant number of patients had an enriched minor CC genotype (SNP 
rs12252-C in huIFITM3) although the mechanism of the risk phenotype was unclear (Everitt 
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et al., 2012). Moreover, the Han-Chinese population appear to have a greater frequency of 
this allele within the population in comparison to a similar European cohort. Data suggests 
that patients who are homozygous for the rs12252-C SNP are more likely to have a poor 
clinical outcome when infected with seasonal IAV. In another study, patients who were 
homozygous for this allele experienced a more severe disease phenotype after infection 
with H7N9 IAV when compared to either the heterozygote or rs12252-T/T patients (Wang 
et al., 2014b). Further associations between the CC minor allele (rs12252-C) and the 
outcome of clinical disease have been observed with coronary artery lesions (Bowles et al., 
2014), HIV-1 (Zhang et al., 2015) and the onset of mild clinical disease with IAV infection 
(Mehrbod et al., 2017). However, the evidence linking the rs12252-C allele and its 
association with severe clinical outcomes is contradictory, with some reports suggesting 
that there is no such association (or cannot be proven with such small sample sizes and low 
frequencies within the population), while other studies question the antiviral activity of 
IFITM3Δ21 in vitro (Williams et al., 2014;Lopez-Rodriguez et al., 2016;Mills et al., 2014). More 
recently, data obtained from RNA sequencing experiments suggest that truncated IFITM3 
transcripts cannot be detected under mock conditions or during viral infection with 
pdm2009 H1N1 or non-replicative H7N1. However, full length IFITM3 mRNA transcripts are 
detected regardless of whether the individual was heterozygous, homozygous for the 
rs12252-C allele or have the wildtype IFITM genotype (Makvandi-Nejad et al., 2018). This 
work suggests that the association between the prevalence of the rs12252-C SNP (within 
huIFITM3) and the outcome of clinical disease is complex and may be difficult to 
conclusively demonstrate. 
Up until 2016 it was thought that alphaviruses were not sensitive to IFITM restriction, 
however it has now been shown that Sindbis and Semliki Forest virus (SFV) are both 
sensitive to restriction by IFITM3 and to a lesser extent IFITM2, but not IFITM1 (Poddar et 
al., 2016;Weston et al., 2016). There are still a number of different viruses that are not 
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thought to be restricted by the IFITM proteins; namely murine leukemia virus (MLV) and 
every arenavirus tested, including LASV and MACV (Diamond and Farzan, 2013). 
1.7 Avian IFITMs 
In comparison to mammalian IFITMs, very little research has been conducted on avian 
IFITMs. Thus, big gaps exist in our knowledge of chIFITM-mediated restriction, their 
localisation and functional motifs/residues that are important in mediating this effect. 
Moreover, apart from chickens and ducks, there are no studies that investigate avian 
specific restriction of viruses and therefore our knowledge in this area is severely lacking. 
One of the problems facing researchers in this field is the incomplete genome build of many 
avian species, however, the IFITM locus in chickens has been resolved and there is now a 
contiguous sequence which will aid further research (Bassano et al., 2017).   
 
Research has been conducted by two groups which aim to investigate the localisation of the 
chicken and duck IFITMs in vitro. In one study, Smith et al, (2013) showed that chIFITM1 
and 2 localised at the plasma membrane, while chIFITM3 localised at the endosomes (Smith 
et al., 2013). The localisation of chIFITMs in this study was broadly similar to those reported 
for huIFITMs, with the notable exception of chIFITM2 that appears to localise at the plasma 
membrane and not at intracellular compartments. In the study focussing on the localisation 
of duck IFITMs (dIFITMs), Blyth et al (2016) observed that dIFITM1 and 3 localise to similar 
compartments as their mammalian counterparts, namely the plasma membrane and late 
endosomes, respectively. The localisation of dIFITM2 and 5 was less certain with only 
partial co-localisation observed at the endosomes. It is possible that the localisation of 
these two proteins has not been fully resolved and it would be useful to further investigate 
the localisation of avian IFITMs in other cell lines and tissues. In addition, there is currently 
no information available on the membrane topology or mechanism of restriction for the 
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chIFITMs. Moreover, it is known that the amino acid homology between human and 
chicken IFITMs is low, reaching only 36% for IFITM3. This makes inferring membrane 
topology and function difficult as it is not possible to simply use the huIFITMs for 
comparison. The CD225 domain within all IFITM sequences is well conserved across species 
and this could suggest that this region is essential for function.  
 
Smith et al. conducted the very first experiments into chicken, indeed avian, IFITM-
mediated viral restriction. In these experiments the authors examined the responsiveness 
of DF-1 cells to IFNα and γ and found that there was a modest induction in chIFITM3 
expression after treatment with IFNα (2.5 fold higher than control) with no induction 
observed with IFNγ treatment (Smith et al., 2013). Furthermore, they utilised a human cell 
line (A549) stably expressing chIFITM2 or 3 alongside DF-1 cells either transiently 
overexpressing chIFITM3 or treated with a siRNA against chIFITM3 (which ablated 
endogenous expression). Using lentiviral vectors pseudotyped with the Lagos bat virus 
(LBV), rabies virus (RABV) or influenza (H1 [human], H5 [human], H7 [bird], or H10 [bird]) 
glycoproteins, they assessed percentage infection by FACS or viral titres by plaque assay 
titration (Smith et al., 2013). In brief, they found that cells stably expressing chIFITM2 or 3 
were resistant to infection with all of the pseudotyped viruses as measured by GFP 
expression. Moreover, DF-1 cells depleted of chIFITM3 through siRNA transfection were 
more permissive to infection with WSN/33. In contrast, cells transiently overexpressing 
chIFITM3 were more refractory to infection with IAV (not pseudotyped).  A second study 
primarily focussing on chIFITM10 induction in CEF cells observed that after treatment with 
IFNα, there was an increase in chIFITM2 (used as the positive control) expression but no 
significant upregulation in chIFITM10 expression (Okuzaki et al., 2017). In addition, they 
found that chIFITM10 was able to restrict both infection and fusion of VSV-G when 
overexpressed in HeLa cells. It has also been shown that chIFITM3 is able to restrict 
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pseudotyped VLPs that have the surface glycoproteins of either avian sarcoma and leukosis 
virus (ASLV), VSV or IAV. In these experiments the authors measure fusion via the BlaM 
assay (Desai et al., 2017). This work showed that chIFITM3 was able to potently restrict all 
of these viruses in vitro and that the pH of fusion does not appear to have a significant 
effect on restriction. Work has also been performed examining the role of chIFITM-
mediated restriction of the Avian Tembusu Virus (ATMUV) (Chen et al., 2017). In this study, 
they found that chIFITM1, 2 and 3 were upregulated in DF-1 cells that were either pre-
treated with IFNα or infected with ATMUV. Moreover, ablation of chIFITM1 and chIFITM3 
expression promotes ATMUV replication in DF-1 cells as measured by TCID50. Conversely, 
when chIFITM1 and 3 were transiently overexpressed in DF-1 cells the authors noticed a 
significant decrease in viral titre and this could also be replicated using dIFITM1 or 3. 
Another study examined chIFITM and dIFITM expression in lung samples infected with a 
high pathogenicity avian influenza (HPAI) (H5N1) and found that the chIFITMs were only 
modestly upregulated in comparison with the corresponding dIFITMs (Smith et al., 2015). It 
is unclear whether the magnitude of upregulation plays a significant role in restriction or 
whether different strains of IAV may differentially upregulate both chicken and duck 
IFITMs. To date, there has only been one publication demonstrating the functional 
restriction of IAV by dIFITM3 (Blyth et al., 2016) where they show that the overexpression 
of dIFITM3, but not dIFITM1 or 2, reduces the percentage of IAV-infected DF-1 cells in vitro. 
In contrast to mammalian IFITM3, neither dIFITM1, 2 or 3 are able to restrict rVSV-GFP-
infected DF-1 cells in vitro (Brass et al., 2009;Weidner et al., 2010b;Jia et al., 2012;Jia et al., 
2014;Amini-Bavil-Olyaee et al., 2013;Marini et al., 2014). The authors also found that the 
endosomal localisation motif (YEML) found in the N-terminus of IFITM3 is dispensable in 
ducks for localisation and function. In contrast, a chimeric dIFITM1 containing the N-
terminus of dIFITM3 was localised to the endosomes and its antiviral activities were 
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increased in comparison to the wildtype dIFITM1. This may suggest that the N-terminus of 
dIFITM3 is responsible for its antiviral activity.  
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1.8 Aims and Objectives 
The main aims of this project were to investigate the architecture of the chIFITM locus, 
examine the expression of the chIFITM genes and to elucidate which viruses are restricted 
by chIFITM expression. A series of objectives were established to achieve this aim. 
Objective 1 
Re-sequence the chIFITM locus of the Gallus gallus reference alongside avian cell lines. 
Objective 2 
Examine the constitutive transcriptional profile and localisation of the chIFITMs in avian 
cells. 
Objective 3 
Investigate the transcriptional profile of the chIFITMs in response to a exogenous type I and 
II IFNs, poly(I:C) or viral infection. 
Objective 4 
Determine which avian viral pathogens are sensitive to chIFITM-mediated restriction. 
Objective 5 
Examine which regions or specific amino acids are necessary for the antiviral activity of 
chIFITM3.  
Objective 6 
The final objective was to utilise mass spectrometry to determine any cellular proteins that 
interact with chIFITM1, 2 or 3 that may allude to function. 
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2.1 Materials 
2.1.1 Suppliers of general reagents 
General purpose reagents were supplied by Life Technologies, New England Biolabs, Fisher 
Scientific, Invitrogen and Sigma. The Pirbright Institute Central Services Unit (CSU) made 
and supplied phosphate buffered saline (PBS) and double distilled water (ddH2O). Other 
reagents and their corresponding suppliers are listed below. 
Agarose for electrophoresis                                                                                    Invitrogen                                          
Agar for plaque assay titration                                                                               Thermo Scientific                                                        
DNA blood and tissue extraction kit                                                                      Qiagen                                                                                                                                   
DNA molecular weight markers                                                                              Invitrogen                                                                             
DNA plasmid miniprep kit                                                                                        Qiagen                                                                                  
DNA plasmid maxiprep kit                                                                                       Qiagen                                                                           
HiPerfect                                                                                                                     Qiagen                                       
Lipofectamine 2000                                                                                                  Invitrogen                                                       
Lipopolysacchride (LPS)                                                                                            Sigma                                                    
Luciferase assays                                                                                                       Promega                          
PCR purification kit                                                                                                    Qiagen                                                
Polyacrylamide gels                                                                                                  Bio-Rad                                                                               
Polyinosinic:polycytidylic acid (poly I:C)                                                                InVivoGen                                                                
Protein molecular weight markers                                                                         Bio-Rad                                       
Quantitative RT-PCR system                                                                                    Life Technologies                                                   
RNA extraction kit                                                                                                     Qiagen                                                                             
Tris-acetate-EDTA                                                                                                      Thermo Fisher                                                 
Tris/Borate/EDTA (TBE) buffer                                                                                Thermo Fisher      
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Trizol Reagent                                                                                                            Invitrogen                        
Western blot transfer kit                                                                                          Bio-Rad       
 
2.1.2 Enzymes 
The following enzymes were supplied by the stated suppliers, and were used according to 
manufacturer’s instructions unless otherwise stated: 
DNase                                                                                                                   Qiagen                               
DNA restriction endonucleases                                                                       New England Biolabs.                                      
Reverse transcriptase                                                                                       Invitrogen                                          
Taq DNA polymerase                                                                                         Invitrogen                                               
Taqman fast universal PCR master mix                                                          Applied Biosystems                                                        
T4 DNA ligase                                                                                                     New England Biolabs.                      
L-1-tosylamide-2-phenylethyl chloromethyl ketone - (TPCK) –                                                                                
treated bovine pancreatic trypsin                                                                   Sigma                                                  
SYBR green PCR master mix                                                                             Primer Design   
 
2.1.3 Antibodies and dyes 
Unless stated otherwise, the following antibodies were purchased from Sigma, Abcam and 
Thermo Fisher (Table 2.1).   
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Table 2.1 List of antibodies used for Western blot and Immunofluorescence 
Name Target Application Dilution Source 
Monoclonal anti-FLAG M2 
(Ms) 
FLAG tag WB 1:1000 Sigma 
Monoclonal anti-FLAG M2 
(Ms) 
FLAG tag IF 1:200 Sigma 
Polyclonal anti-FLAG (Rb) FLAG tag WB 1:1000 Sigma 
Polyclonal anti-FLAG (Rb) FLAG tag IF 1:200 Sigma 
Monoclonal anti-Xpress (Ms) Xpress epitope WB 1:1000 Sigma 
Polyclonal anti-c-Myc (Rb) Myc tag WB 1:1000 Sigma 
Monoclonal anti-HA (Ms) HA tag WB 1:1000 Millipore 
Polyclonal anti-Chicken 
Interferon Alpha (Rb) 
IFNα WB 1:250 AbD Serotec 
Monoclonal anti-β-Actin 
(Ms) 
β-Actin WB 1:1000 Sigma 
Polyclonal anti-β-Actin (Rb) β-Actin WB 1:1000 Invitrogen 
Monoclonal anti-Pan 
cadherin (Ms) 
Pan cadherin IF 1:200 Abcam 
Polyclonal anti-Rab7 (Rb) Rab7 IF 1:200 Abcam 
Polyclonal anti-Lamp1 (Rb) Lamp1 IF 1:200 Abcam 
Polyclonal anti-MBP-NP  
(2915) (Rb) 
Nucleoprotein 
of IAV 
IF 1:200 (Noton et 
al.,2007) 
Polyclonal anti-chIFITM1 
(Rb) 
chIFITM1 WB 1:250 Custom made, 
Genscript 
Polyclonal anti-chIFITM2 
(Rb) 
chIFITM2 WB 1:250 Custom made, 
Genscript 
Monoclonal anti-chIFITM3 
(Ms) 
chIFITM3 WB 1:250 Custom made, 
Abmart 
Polyclonal anti-chIFITM5 
(Rb) 
chIFITM5 WB 1:250 Custom made, 
Genscript 
In order to ensure that the custom made chIFITM antibodies did not cross react with one 
another, western blots were performed on transiently overexpressed DF-1 cell lysates. 
Lysates were separated by SDS-PAGE, proteins were transferred to a nitrocellulose 
membrane and a western blot was performed using an antibody specific to each chIFITM or 
against the C-terminal tag (FLAG or HA). Cellular β-actin was used as a loading control.  
WB – western blot; IF – Immunofluoresence; Ms – mouse; Rb - rabbit 
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Table 2.2 List of secondary antibodies used for western blot and Immunofluorescence 
Antibody Application Dilution Source 
Donkey anti-Mouse IgG (H+L) 
Secondary Antibody, Alexa 
Fluor® 488 conjugate 
IF 1:1000 Thermo Fisher 
 
Donkey anti-Rabbit IgG (H+L) 
Secondary Antibody, Alexa 
Fluor® 488 conjugate 
IF 1:1000 Thermo Fisher 
 
Donkey anti-Mouse IgG (H+L) 
Secondary Antibody, Alexa 
Fluor® 568 conjugate 
IF 1:1000 Thermo Fisher 
 
Donkey anti-Rabbit IgG (H+L) 
Secondary Antibody, Alexa 
Fluor® 568 conjugate 
IF 1:1000 Thermo Fisher 
IRDye® 800CW Donkey anti-
Rabbit IgG (H + L), 0.5 mg 
WB 1:10000 Li-Cor 
IRDye® 800CW Donkey anti-
Mouse IgG (H + L) 
WB 1:10000 Li-Cor 
IRDye® 680LT Donkey anti-
Mouse IgG (H + L) 
WB 1:10000 Li-Cor 
IRDye® 680LT Donkey anti-
Rabbit IgG (H + L) 
WB 1:10000 Li-Cor 
 
Table 2.3 List of fluorescent dyes used for Immunofluorescence 
Antibody Application Dilution Source 
4',6-Diamidino-2-
Phenylindole, 
Dihydrochloride (DAPI) 
IF 1:20000 Thermo Fisher 
 
Figure 2.1 Mono and polyclonal chIFITM antibodies do not cross react with other 
chIFITM proteins.  DF-1 cells were transfected with 1ug plasmid encoding chIFITM1, 2, 3 
or 5 for 24 hours. Lysates were separated by SDS-PAGE and proteins were transferred to 
a nitrocellulose membrane and a western blot performed using an antibody specific to 
each chIFITM or against the C-terminal tag (FLAG or HA) as well as cellular β-actin.  
 
WB – western blot; IF – Immunofluoresence; Ms – mouse; Rb - rabbit 
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2.1.4 Eukaryotic cell & bacterial culture medium 
2.1.4.1 Eukaryotic cells 
Madin-Darby Canine Kidney Cells (MDCK)                                                                                 ATCC 
Human Embryonic Kidney 293T Cells (HEK 293T)                                                                     ATCC 
HD11 cells                                                                                   A kind gift from Prof Bernd Kaspers                                     
DF-1 cells                                                                                                                                          ATCC                          
OU-2 cells                                                                                                                                          CSU          
Chick Kidney (CK) cells: Primary chick cells derived from 3 week old Rhode Island Red (RIR) 
specific pathogen free (SPF) chicks. Briefly, the kidneys are extracted and trypsinised to 
release the cells, which are then are cultured.  
Chicken Embryonic Fibroblasts (CEFs): Primary chick cells derived from 10 day old Rhode 
Island Red (RIR) specific pathogen free (SPF) embryonated hens eggs. Briefly, the embryo is 
decapitated, detached from the egg and the gastrointestinal tract is removed. The embryo 
is then homogenised and trypsinised and the resulting cells are cultured.  
All primary chicken cells were prepared by the central services unit at The Pirbright 
Institute.                  
2.1.4.2 Eukaryotic cell culture 
Media and additives used for culturing eukaryotic cells were purchased from the following 
suppliers: 
Dulbecco’s Modified Eagle Medium (DMEM)                                                     Life Technologies   
Roswell Park Memorial Institute medium (RPMI-1640)                                    Life Technologies         
Eagle's Minimum Essential Medium (EMEM)                                                      Life Technologies                                   
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Fetal bovine serum (FBS)                                                                                         Life Technologies         
Chicken serum (CS)                                                                                                   Life Technologies            
Penicillin/streptomycin                                                                                            Life Technologies                                       
Zeocin                                                                                                                          Life Technologies                                   
0.25% Trypsin-EDTA                                                                                                  Life Technologies                                                  
Opti-MEM                                                                                                                   Life Technologies  
Calcium/magnesium-free phosphate buffered saline                                       CSU              
Tryptose phosphate broth (TPB)                                                                            Life Technologies 
 
2.1.4.3 Bacterial culture                                                                                                                          
Media and additives used for culturing bacterial cells were purchased from the following 
suppliers: 
Luria broth                                                                                                                  Life Technologies                                  
LB agar                                                                                                                      CSU                                                        
Ampicillin sodium salt used at 100μg/μl                                                               Sigma                                                             
Kanamycin sulfate salt used at 50μg/μl                                                                 Sigma 
 
2.1.5 Western blotting  
Lysis buffer (Laemmli’s 2x sample buffer)  65.8mM Tris-HCL (pH 6.8), 26.3% (w/v) glycerol,           
v                                                                          2.1% SDS, 0.01% bromophenol blue, 5% β-           
v                                                                          mercaptoethanol                                                   
SDS-PAGE running buffer                               25mM Tris, 192mM glycine, 0.1% (w/v) SDS.   
Tris-Glycine transfer buffer                            25mM Tris, 192mM glycine, 20% (v/v) methanol                                                                                
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Blocking solution                                              PBS/5% (w/v) skimmed milk                                     
Antibody binding solution                              PBS/0.1% (v/v) Tween20, 5% (w/v) skimmed milk 
Wash buffer                                                      PBS/0.1% (v/v) Tween20 
 
2.1.6 Immunofluorescence 
Fixing solution                                                               H2O/4% (v/v) paraformaldehyde (PFA)                                                   
Permeabilisation solution                                           PBS/1% (w/v) saponin                                                                                                        
Blocking solution                                                          PBS/1% (w/v) bovine serum albumin (BSA)                                
Wash solution                                                               PBS                                                                                                                      
2.1.7 Protein pulldown buffers                                                                             
FLAG® Immunoprecipitation Kit (Sigma-Aldrich)                                                                                  
Lysis buffer                                                                   50mM Tris HCl, pH 7.4, with 150mM NaCl,     
v                                                                                      1mM EDTA, and 1% TRITON® X-100         
10x wash buffer                                                           0.5M Tris HCl, pH 7.4, with 1.5M NaCl 
2.1.8 Agarose gel electrophoresis                                                                 
TAE running buffer                    40mM Tris, 20mM acetic acid, 1mM EDTA.                                           
TBE running buffer                     89mM Tris-borate and 2mM EDTA, pH 8.3                                 
6x DNA loading dye                   10mM Tris-HCl (pH 7.6) 0.03%  bromophenol blue, 0.03%           
v                                                     xylene cyanol FF, 60% glycerol 60mM EDTA.                        
SYBR™ Safe DNA Gel Stain        0.5X, 45mM Tris-borate, 1mM EDTA, pH ~8.3 (TBE)                        
b                                                     1X, 40mM Tris-acetate, 1mM EDTA, pH ~8.3 (TAE) 
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2.1.9 Plasmids 
Table 2.4 List of plasmids 
Name Description Source 
pEGFP-N1 
Constitutively expresses eGFP under control of CMV 
promoter. MCS upstream allows opportunity to clone 
C-terminally tagged proteins. 
Clontech 
pcDNA3.1 
Mammalian expression vector under the control of a 
CMV promoter for high level expression. 
Invitrogen 
pcDNA4myc/HIS B 
Under the control of a CMV promoter with a zeocin 
selection marker suitable for the creation of stably-
expressing cell lines. 
Invitrogen 
pGEM-T 
Under the control of T7 and SP6 RNA polymerase 
promoters with a region encoding for β-galactosidase. 
Promega 
pFLAG-CMV-1 
Mammalian expression vector under the control of a 
CMV promoter for high level expression. 
Sigma 
pGL3-P-chMx-luc 
Firefly luciferase under control of chicken Mx 
promoter. 
Gift from Prof 
Steve 
Goodbourna 
pGL3-P-chIFN-β-luc 
Firefly luciferase under control of chicken IFNβ 
promoter. 
Gift from Prof 
Steve 
Goodbourna 
pcDNA3-SHK-Mx1 
Mx expression vector under the control of a CMV 
promoter. 
Gift from Dr  
Laurence Tileyb 
pGEM-chIFITM1 
Untagged vector used for chIFITM1 standard curve in 
RT-qPCR. 
 
pGEM-chIFITM2 
Untagged vector used for chIFITM2 standard curve in 
RT-qPCR. 
 
pGEM-chIFITM3 
Untagged vector used for chIFITM3 standard curve in 
RT-qPCR. 
 
pGEM-chIFITM5 
Untagged vector used for chIFITM5 standard curve in 
RT-qPCR. 
 
pBNHA-chIFITM5 
Lentiviral vector with a C-terminal HA tag under the 
control of a SFFV promoter. For expression of 
chIFITM5 
Gift from Dr 
Sarah Smithc 
pFLAG-IFITM1 
chIFITM1 expression vector under the control of a 
CMV promoter with a C-terminal FLAG tag. 
 
pFLAG-IFITM2 
chIFITM2 expression vector under the control of a 
CMV promoter with a C-terminal FLAG tag. 
 
pFLAG-IFITM3 
chIFITM3 expression vector under the control of a 
CMV promoter with a C-terminal FLAG tag. 
 
pFLAG-IFITM3.1 
Alanine scanning mutant of the chIFITM3 expression 
vector under the control of a CMV promoter with a C-
terminal FLAG tag. 
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pFLAG-IFITM3.2 
Alanine scanning mutant of the chIFITM3 expression 
vector under the control of a CMV promoter with a C-
terminal FLAG tag. 
 
pFLAG-IFITM3.3 
Alanine scanning mutant of the chIFITM3 expression 
vector under the control of a CMV promoter with a C-
terminal FLAG tag. 
 
pFLA-IFITM3.4 
Alanine scanning mutant of the chIFITM3 expression 
vector under the control of a CMV promoter with a C-
terminal FLAG tag. 
 
pFLAG-IFITM3.5 
Alanine scanning mutant of the chIFITM3 expression 
vector under the control of a CMV promoter with a C-
terminal FLAG tag. 
 
pFLAG-IFITM3.6 
Alanine scanning mutant of the chIFITM3 expression 
vector under the control of a CMV promoter with a C-
terminal FLAG tag. 
 
pFLAG-IFITM3.7 
Alanine scanning mutant of the chIFITM3 expression 
vector under the control of a CMV promoter with a C-
terminal FLAG tag. 
 
pFLAG-IFITM3.8 
Alanine scanning mutant of the chIFITM3 expression 
vector under the control of a CMV promoter with a C-
terminal FLAG tag. 
 
pFLAG-IFITM3.9 
Alanine scanning mutant of the chIFITM3 expression 
vector under the control of a CMV promoter with a C-
terminal FLAG tag. 
 
pFLAG-IFITM3.10 
Alanine scanning mutant of the chIFITM3 expression 
vector under the control of a CMV promoter with a C-
terminal FLAG tag. 
 
pFLAG-IFITM3.11 
Alanine scanning mutant of the chIFITM3 expression 
vector under the control of a CMV promoter with a C-
terminal FLAG tag. 
 
pFLAG-IFITM3.12 
Alanine scanning mutant of the chIFITM3 expression 
vector under the control of a CMV promoter with a C-
terminal FLAG tag. 
 
pFLAG-IFITM3.13 
Alanine scanning mutant of the chIFITM3 expression 
vector under the control of a CMV promoter with a C-
terminal FLAG tag. 
 
pFLAG-IFITM3.14 
Alanine scanning mutant of the chIFITM3 expression 
vector under the control of a CMV promoter with a C-
terminal FLAG tag. 
 
pFLAG-SCD-MYC 
SCD expression vector under the control of a CMV 
promoter with a C-terminal MYC tag. 
 
pFLAG-SOAT1-MYC 
SOAT1 expression vector under the control of a CMV 
promoter with a C-terminal MYC tag. 
 
pFLAG-STAT3-MYC 
STAT3 expression vector under the control of a CMV 
promoter with a C-terminal MYC tag. 
 
a St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK.                                  
b University of Cambridge, Department of Veterinary Medicine, Madingley Road, Cambridge 
CB3 0ES, UK.                                                                                                                                                
c Wellcome Trust Sanger Institute, Hinxton, CB10 1SA, UK. 
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2.1.10 Viruses 
2.1.10.1 IAV 
A/Chicken/Pakistan/UDL-01/08 (H9N2) 
A/duck/Ukraine/63 (H3N8) 
A/duck/Sing-Q/119/97 (H5N3) 
2.1.10.2 IBV 
M41-CK: Pathogenic strain of IBV that has been adapted to grow in CK cell cultures. 
Beau-R: The molecular clone of Beaudette-CK (Beau-CK) that has been adapted to grow in a 
range of cell types by serial passage in embryonated hen’s eggs. 
QX: D388, sourced from the Netherlands (GD Animal Health).  
2.1.10.3 HVT 
FC126: This virus was obtained from the Avian Disease and Oncology Laboratory (ADOL) 
East Lansing, MI, USA. 
2.1.11 Oligonucleotides 
DNA oligonucleotides were synthesised by and purchased from Sigma or invitrogen. 
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Table 2.5 Primers for pGEM-chIFITM cloning 
Primer Sequence (5’ to 3’) Description 
IFITM1 Forward ACAGCTGCCCTCCAGCACCAT Cloning of chIFITM1 into 
pGEM-T IFITM1 Reverse TAGAATGGGGAAGAAGCTTTA 
IFITM2 Forward ATGAAGCCGCAACAGGCGGAGG Cloning of chIFITM2 into 
pGEM-T IFITM2 Reverse CTATCTGCTGATCGCGGTGAT 
IFITM3 Forward CACCGGGCTGCGGGGAAACGAA Cloning of chIFITM3 into 
pGEM-T IFITM3 Reverse GTGGGACAAAAGTGAAAGATACC 
IFITM5 Forward GCTGGGGGAAGGAGAAAC Cloning of chIFITM5 into 
pGEM-T IFITM5 Reverse TTCGAGATGGGTGAGATGATTT 
 
Table 2.6 Primers for chIFITM-FLAG cloning 
Primer Sequence (5’ to 3’) Description 
IFITM1-FLAG Forward CTCGGATCCATGCAGAGCTACCCCCA 
Cloning of chIFITM1 
into pFLAG_CMV1 IFITM1-FLAG Reverse 
ATAAGCGGCCGCCTACTACTTGTCGTC
ATCGTCTTTGTAGTCAGGCCGCACTGT
GTACAGGGGC 
IFITM2-FLAG Forward CTCGGATCCATGAAGCCCCAGCA 
Cloning of chIFITM2 
into pFLAG_CMV1 IFITM2-FLAG Reverse 
ATAAGCGGCCGCCTACTACTTGTCGTC
ATCGTCTTTGTAGTCTCTGCTGATGGC
GGTGATGAAC 
IFITM3-FLAG Forward CTCGGATCCATGGAAAGAGTGC 
Cloning of chIFITM3 
into pFLAG_CMV1 IFITM3-FLAG Reverse 
ATAAGCGGCCGCCTACTACTTGTCGTC
ATCGTCTTTGTAGTCTGTAGGTCCGAT
GAACTCGGGG 
IFITM3MUT-FLAG Forward GCCAACGTCGCCTGCCTCGGCTTC SDM of chIFITM3 
(C71/72A) IFITM3MUT-FLAG Reverse GAAGCCGAGGCAGGCGACGTTGGC 
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Table 2.7 Primers and probes for house-keeping genes (RT-qPCR)  
Primers were used at a final concentration of 0.5µM and probes at 50nM. 
 
 
 
Gene Full name Forward Primer Reverse Primer Probe 
β2M Beta-2-microglobulin AAGGAGCCCGCAGGTCTAC CTTGCTCTTTGCCGTCATAC 
(FAM)CCGGGATGAGCACGGTCTGAAGAAT(
TAMRA) 
β-Actin Beta Actin CAGGTCATCACCATTGGCAAT GCATACAGATCCTTACGGATATCCA 
(FAM) 
CACAGGACTCCATACCCAAGAAAGATGGC(T
AMRA) 
PLA2 Phospholipase A2 group IV A GCACAAGACATTTGGCAGTTGT TGTGACATTTGTGGCTTTCCTTA 
(FAM)CAACACATTGTGGTGGAACACCAGTA
CTCA(TAMRA) 
RPL13 Ribosomal protein L13 TCGTGCTGGCAGAGGATTC TCGTCCGAGCAAACCTTTTG 
(FAM)TAATGCCCGCCAGTTTAAGCTCTTCTA
GGC(TAMRA) 
RPLPO 
Ribosomal phosphoprotein 
PO 
TTGGGCATCACCACAAAGATT CCCACTTTGTCTCCGGTCTTAA 
(FAM)CATCACTCAGAATTTCAATGGTCCCTC
GGG(TAMRA) 
TBP TATA box binding protein CTTCGTGCCCGAAATGCT GCGCAGTAGTAACGTGGTTCTCTT 
(FAM)CTCATAATAACAGCAGCAAAACGCTT
GGA(TAMRA) 
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Table 2.8 Primers and probes for targets of interest (RT-qPCR)  
Gene Full name Forward Primer Reverse Primer Probe 
IFITM1 Interferon-inducible 
transmembrane protein 1 
TGTGCTCTCTCATACTCCATCA TCTTCGCTGTCCTCCCATAG (FAM)CCTACGAAGTCCTTGGCGATGATCCTA
TCC(MGB) 
IFITM2 Interferon-inducible 
transmembrane protein 2 
GCTTCGCTCTCGCCTACC CAGTCGCGGGCCTTGAT (FAM)TGCTTCTGCTTCCCCTCGCTCATCTT(M
GB) 
IFITM3 Interferon-inducible 
transmembrane protein 3 
TCTTCTCCGTGAAGTCCAGG GGCGATGATGAGGATGATGAG (FAM)ATGGCTCCACTGCGAAGTACCTGAAC
A(MGB) 
IFITM5 Interferon-inducible 
transmembrane protein 5 
CACAAGCGGGACTCATCTCC CCGGTCCCGTGCCTTGA (FAM)CACCATCTACATGAACTTCTGCTGCCT
CGG(MGB) 
IFITM10 Interferon-inducible 
transmembrane protein 10 
CAGGCAAGCGTACTCTTCCT CTCCGTCTCTTTTCCTCCCAA (FAM)ACCCTTTCCTACAGCAGCACGTACTGG
TT(MGB) 
Mx Myxovirus  Resistance TTACTCGCTGTCCTCTGGAAC TTCTTATTGCTTTCTTCACCTCTGA (FAM)ACCCCTTTCCATTCCTGCGGAGCTGTC(
MGB) 
IL-6 Interleukin 6 AACATGCGTCAGCTCCTGAAT TCTGCTAGGAACTTCTCCATTGAA (FAM)AGCAGCACCTCCCTCAAGGCACC(TA
MRA) 
IL-6 primers were used at a final concentration of 0.5µM and probes at 50nM. The IFITM and Mx assays were designed by Primer Design and final 
concentrations are proprietary  
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Table 2.9 Primers and probes for viral quantification (RT-qPCR)  
Gene Full name Forward Primer Reverse Primer Probe 
M gene Matrix gene of IAV AGATGAGTCTTCTAACCGAGGTC
G 
TGCAAAAACATCTTCAAGTCTCTG (FAM)TCAGGCCCCCTCAAAGCCGA(TAMRA) 
N 
message 
N message of IBV GCTTTTGAGCCTAGCGTT TTGTCCCGCGTGACCTCTC (FAM)ACAAAGCAGGACAAGCA(TAMRA) 
 
Table 2.10 Sequencing primers 
Gene Full name  Primer 
CMV Forward Cytomegalovirus  CGCAAATGGGCGGTAGGCGTG  
 
T7 Forward T7 RNA polymerase TAATACGACTCACTATAGGG  
 
PR8 Seq M 
Forward 
PR8 M segment ATGGTCTTCTAACCGACGTCG  
 
PR8 Seq M 
Reverse 
PR8 M segment TAGTTTTTTACTCCAGCTCTATG  
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2.1.12 Drugs 
Ampicillin sodium salt used at 100μg/μl                 CSU                                                                  
Kanamycin sulfate salt used at 50μg/μl                  CSU                                                                 
Chicken recombinant IFNα                                        AbD Serotec                                                               
Chicken IFNβ                                                                Mohammad Munir (The Pirbright Institute) 
Chicken IFNγ                                                                 Lonneke Vervelde (The Roslin Institute)                                                                                                              
Polyinosinic-polycytidylic acid (PolyI:C)                   Invivogen 
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2.2 Methods 
2.2.1 Ethics Statement 
All in vivo animal work was approved and regulated by the UK government Home Office 
under the project licence (PPL 30/2952). All personnel involved in the procedures were 
licensed by the UK Home Office under the ‘Animals (scientific procedures) Act 1986’. 
Euthanasia of chickens was carried out by intravenous administration of sodium 
pentobarbital and confirmed through cervical dislocation. 
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2.2.2 Recombinant DNA Techniques  
2.2.2.1 DNA extraction from cells 
Cell were dissociated from the flask using a 0.25% trypsin-EDTA solution (life technologies), 
centrifuged at 1000rpm for 5 minutes and resuspended in 200µl of PBS containing 
proteinase K. Total DNA was extracted using the DNeasy® Blood & Tissue kit (Qiagen) 
according to the manufacturer’s protocol. The DNA was eluted in 100µl of sterile DNase-
free water and was stored at -20 °C. DNA quantified was performed using a Nanodrop Lite 
(ThermoFisher) and the 2200 TapeStation (Agilent). 
2.2.2.1.1 BAC preparation for sequencing 
The BAC clone was delivered as a stab culture and single colonies were isolated by streaking 
directly on Luria Broth (LB) agar (chloramphenicol 12.5 μg/mL). After incubating the plates 
overnight, single colonies were picked and the LB media was inoculated and then incubated 
overnight at the designated growth temperature. Plasmid DNA was then extracted and 
purified using a Qiagen Plasmid DNA kit and following the manufacturer’s protocol. The 
resulting plasmid DNA (3μg) was sent to The Wellcome Trust Sanger Institute for 
sequencing using two NGS technology platforms, the Illumina MiSeq and PacBio RSII. 
2.2.2.2 Primers and DNA fragments 
The primers used for cloning are outlined in Tables 2.5 and 2.6. Where cloning primers are 
not listed, DNA fragments were synthesised by GeneArt (Invitrogen). 
2.2.2.3 Polymerase chain reaction 
End-point polymerase chain reaction (PCR) was performed using GoTaq DNA polymerase. 
Briefly, 1x GoTaq Reaction Buffer alongside 0.5μM of forward and reverse primers, 1.25U 
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GoTaq DNA polymerase and 0.2mM dNTPs (Promega) were added to a final volume of 20μl. 
The PCR was run according to the following cycling conditions: 95oC for 5 mins, 30 cycles of 
[95oC for 1 min, 50oC for 1 min, 72oC for 1 min/kb] then 75oC for 15 mins.  
2.2.2.4 Site-directed mutagenesis  
Site-directed mutagenesis (SDM) was performed using the QuikChange II Site-Directed 
Mutagenesis Kit (Agilent) as per the manufacturer’s instructions. In brief, 125ng of each 
primer, 100mM of the dNTP mix, 50ng DNA template, 1x PfuUltra II reaction buffer and 1μl 
of PfuUltra II are added to a final volume of 50µl. The PCR was run according to the 
following cycling conditions: 95 °C for 30 sec, 16 cycles of [95 °C for 30 sec, 55 °C for 1 min, 
68 °C for 1 min/kb] followed by 2 mins on ice. To digest methylated DNA, 1μl of the 
restriction enzyme DpnI (NEB) was added and the reaction was incubated at 37 °C for 2 
hours.   
2.2.2.5 Agarose gel electrophoresis 
To visualise samples, 6x sample buffer was added to PCR products and these were loaded 
into wells alongside 5μl of 1 Kb DNA Ladder (Invitrogen). Gels were run on a 1% TBE/TAE 
containing SYBR safe (Invitrogen) at 50 V for approximately 1 hour. Gels were then 
visualised using a Gel Doc EZ Gel Documentation System (BIORAD).    
2.2.2.6 Restriction digests 
All PCR products and their corresponding vectors were digested using Not1 and BamH1 in 
buffer 3.1 at 37oC for 1 hour. Enzymes were deactivated by heating to 50°C for 10 minutes 
before ligation and transformation.   
2.2.2.7 Gel extraction/ PCR purification  
PCR products and digested DNA fragments were purified using the QIAquick PCR 
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Purification Kit (Qiagen). Quantification and purity of the PCR products was calculated using 
the Nanodrop Lite . For purification of DNA fragments from digested plasmids, DNA was 
separated by gel electrophoresis in a 1% TAE/TBE gel containing SYBR Safe (ThermoFisher). 
DNA was extracted from exercised gel segments using the QIAquick Gel Extraction Kit 
(Qiagen). DNA was eluted in 20μl of RNase-free water and quantified using the Nanodrop 
Lite . 
2.2.2.8 Ligation 
Ligations were performed using T4 Ligase (NEB) according to the manufacturer’s protocol. 
An insert: vector molar ratio of 3:1 was used, and the reaction was performed at room 
temperature for 10 minutes.  
2.2.2.9 Transformation of Escherichia coli 
Turbo Competent E. coli (NEB) was used for routine cloning, whilst high efficiency XL1-Blue 
E. coli (Aglient) was used for site directed mutagenesis. For transformation, 3µl of the 
ligation mixture made in 2.2.2.8 was added to a 50µl aliquot of competent cells. Cells were 
incubated on ice for 30 mins, then heat shocked for 30 seconds at 42oC, and then returned 
to ice for 5 mins. SOC media was added to the transformation mix and this was placed in 
the shaking incubator at 37oC, 200 revolutions per minute (RPM) for 1 hour. After 1 hour, 
350μl of the transformation mix was plated onto Lysogeny broth-agar (LB-agar) plates 
containing ampicillin (100μg/ml) or kanamycin (50μg/ml). The plates were incubated for 16 
hours at 37 °C. 
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Table 2.11 Reagent concentrations for Lysogeny broth 
Component Final Concentration 
Bacto tryptone 1% w/v 
Yeast extract 0.5% w/v 
NaCl 170 mM 
 
2.2.2.10 Bacterial propagation 
Appropriate volumes of liquid LB cultures, containing ampicillin (100μg/ml) or kanamycin 
(50μg/ml), were incubated while shaking at 200 RPM and 37OC. 
2.2.2.11 Plasmid DNA Miniprep 
Bacterial cultures were placed in a 1ml eppendorf and centrifuged at 13,000 rpm for 5 
minutes to pellet the bacteria. Plasmids were then purified using the Plasmid Miniprep Kit 
(Qiagen) according to manufacturer’s instructions. Plasmids were eluted in 30μl of sterile 
RNase-free water. Plasmids were then sequenced by Sanger sequencing (Source 
Bioscience). 
2.2.2.11 Plasmid DNA Maxiprep 
After sequence conformation, 1ml of the plasmid positive LB culture was transferred to 100 
ml of LB containing either ampicillin (100μg/ml) or kanamycin (50μg/ml) and incubated 
overnight in a shaker at 200 RPM and 37°C. Bacterial cultures were placed in 50 ml falcon 
tubes and centrifuged at 4,500 rpm for 1 hour to pellet the bacteria. Plasmids were then 
purified using the Plasmid Maxiprep Kit (Qiagen) according to manufacturer’s instructions. 
Plasmids were eluted in 100μl of sterile RNase-free water. Plasmids were then sequenced 
by Sanger sequencing (Source Bioscience). 
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2.2.2.13 Sequencing 
Plasmids were sent to Source Bioscience for sequencing by Sanger sequencing. Primers for 
sequencing of plasmids were provided by Source Bioscience. If custom primers were 
required, these were sent as per the sequencing specifications. The sequences of primers 
are shown in Table 2.9. 
2.2.3 Cell Culture Methods 
2.2.3.1 Eukaryotic cell culture media  
All cell culture techniques were performed in a class II cabinet, unless otherwise stated. 
Table 2.12 Components of cell culture medium 
Name Composition Application 
Complete Media 
Dulbecco's Modified Eagle's Medium 
10% heat inactivated Foetal Bovine 
Serum 
Routine cell culture 
Selection Media for 
Stably-Expressing DF-1 
cells 
Dulbecco's Modified Eagle's Medium 
10% heat inactivated Foetal Bovine 
Serum 
100μg/ml Zeocin 
Culturing chIFITM 
stably-expressing 
DF-1 cells 
CEF Media 
Eagle's Minimum Essential Medium 
0.35% Bovine Serum Albumin 
1x Penicillin-Streptomycin 
0.25μg/ml TPCK treated trypsin 
Culturing CEFs 
CKC Media 
1x Eagle's Minimum Essential Medium 
10% TPB 
0.2% BSA 
20mM N, N bis(2-hydroxemethyl)-2-
aminoethanesulfonic acids (BES) (Sigma) 
0.4% sodium bicarbonate 
2mM L-Glutamine 
250U Nystatin 
100U Penicillin/Streptomycin 
Culturing CKCs 
HD11 Media 
RPMI-1640 
2.8% heat inactivated Foetal Bovine 
Serum 
2.8% chicken serum 
10% TPB 
Culturing HD11 cells 
OU-2 Media EMEM Culturing OU-2 cells 
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6% heat inactivated Foetal Bovine 
Serum 
2% chicken serum 
12% TPB 
IAV Plaque Assay 
Overlay Media 
0.6% agarose (Oxoid) 
Eagle's Minimum Essential Medium 
0.21% Bovine Serum Albumin 
1 mM L-Glutamate 
0.15% Sodium Bicarbonate 
10mM Hepes 
1x Penicillin-Streptomycin 
0.01% Dextran DEAE 
2μg/ml TPCK treated trypsin 
Titration of 
influenza virus by 
plaque assay 
IBV Plaque Assay 
Overlay Media 
2x Eagle's Minimum Essential Medium 
20% TPB 
0.4% BSA 
40 mM N, N bis(2-hydroxemethyl)-2-
aminoethanesulfonic acids (BES) (Sigma) 
0.8% sodium bicarbonate 
4mM L-Glutamine 
500U Nystatin 
200U Penicillin/Streptomycin 
Titration of 
infectious bronchitis 
virus by plaque 
assay 
 
2.2.3.2 General cell culture protocols   
Chicken macrophage-like HD11 cells (CSU, The Pirbright Institute) were cultured at 41oC 
and 5% CO2 until confluent. Chicken embryonic fibroblast (CEF), chick kidney (CK), DF-1, 
canine Madin-Darby canine kidney (MDCK) (CCL-34, ATCC) and OU-2 cells (CSU, The 
Pirbright Institute) were cultured at 37oC and 5% CO2 until confluent. All primary, ex vivo 
cell cultures (CEF and CK cells) (Rhode Island Red) were generated at the Pirbright Institute. 
Continuous cell lines were routinely passaged twice weekly: cells were washed once with 
PBS and dissociated from the flask using a 0.25% trypsin-EDTA solution (life technologies). 
Cells were resuspended in complete DMEM and typically split 1 in 10. Primary cells were 
prepared every Friday and cells were not passaged.  
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2.2.3.3 Cell counting  
Cells to be seeded were dissociated from the flask using a 0.25% trypsin-EDTA solution (life 
technologies). Cells were resuspended in complete DMEM and 10µl of the cell suspension 
was added into the chamber of a cell counting slide (BIORAD). The slide was inserted into 
the TC20 automated cell counter and the total cell population was calculated.   
2.2.3.4 DNA transfection of primary and continuous cell cultures  
Cells were transfected with lipofectamine 2000 reagent (Invitrogen) following the 
manufacturer’s instructions. Transfection of primary cell cultures, namely CEFs, required a 
higher concentration of DNA than continuous cell cultures. The DNA:Lipofectamine ratio 
and volumes were scaled accordingly (4µl:1µg DNA) and the DNA:Lipofectamine complexes 
were diluted in Opti-MEM Reduced Serum Medium (Gibco) before being added dropwise 
onto the cell monolayer. Transfections were left for the time points indicated in the 
experimental protocol. 
2.2.3.5 Generation of stably-expressing DF-1 cell lines  
This work was done in collaboration with Dr Andrew Broadbent and Ms Alice Gray. 
Plasmids (Table 2.4) designed for stable incorporation of exogenous DNA were transfected 
into DF-1 cells (2.2.3.4). After 24 hours the media was aspirated from the cells, washed with 
PBS and replaced with complete media supplemented with 100μg/ml zeocin. Zeocin 
resistant DF-1 cells were further characterised.  
2.2.3.6 siRNA knockdown assays 
DF-1 cells were transfected with 20nM or 80nM small interfering RNA (siRNA) 
against chIFITM1, 2, 3 and 5 or a non-specific siRNA (Table 2.12). Transfections were 
performed using HiPerFect (Qiagen) as per the manufacturer’s protocol. The 
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siRNA:HiPerfect ratio and volumes were scaled accordingly (12µl:10nM siRNA) and the 
siRNA:HiPerfect complexes were diluted in Opti-MEM Reduced Serum Medium (Gibco) 
before being added dropwise onto the cell monolayer, 24 hours prior to infection. 
Table 2.13 siRNAs used to knockdown chIFITM expression 
Gene siRNA Sequence 
IFITM1 
1 UCAACUUUGUGCUGUGCAAUU 
2 CAGCGAAGAUCUUUAACAUUU 
3 GGAUCAUCGCCAAGGACUUUU 
4 GGGAUAGGAUCAUCGCCAAUU 
IFITM2 
1 GCCAAGGUGCUGAACAUCAUU 
2 GUGCUGAACAUCAUCUUCUUU 
3 CCAAGGUGCUGAACAUCAUUU 
4 GGGCCAAGGUGCUGAACAUUU 
IFITM3 1 GCGAAGUACCUGAACAUCACG 
IFITM5 
1 UCAACACCAUCUACAUGAAUU 
2 ACACCAUCUACAUGAACUUUU 
3 GGUCCAUCUUCAACACCAUUU 
4 CCAGCGAUGACGAGGACAAUU 
Negative 
Scramble 
1 UUCUCCGAACGUGUCACGUGU 
 
2.2.3.7 Firefly and Renilla luciferase assays 
HD11 cells were transfected (2.2.2.4) and stimulated as per the experimental design. Cells 
were washed once with PBS and lysed in 100μl of 1 X passive lysis buffer (Promega). Plates 
were frozen for 30 min at -80 °C and defrosted before reading. 10μl of lysate was loaded 
onto a 96-well opaque white plate (Pierce) and analysed on a GloMax Multi plate reader 
(Promega) with 50μl of LARII and Stop and Glo reagents (Promega). Firefly luciferase signals 
were normalized to Renilla signals. 
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2.2.3.8 Chicken interferon (IFNβ) and Mx reporter assays 
To determine chicken IFNβ and Mx promoter activities, pGL3 Luciferase (luc) reporter 
vectors containing the promoter regions from either IFNβ or Mx upstream of a Firefly luc 
gene, were used. In triplicate, cells were transfected with 250ng/well of pGL3-P-chIFN-β-luc 
or pGL3-P-chMx-luc and 100ng/well of a plasmid constitutively expressing Renilla luciferase 
using the method outlined in 2.2.2.4. After transfection, 2000U IFNα, 50μl of IFNβ or IFNγ 
cell supernatants from stably-expressing COS cells (The Pirbright and Roslin Institute’s) or 
500ng of HMW poly I:C were added passively to the cell culture media.  
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2.2.4 Virological Methods  
2.2.4.1 Virus propagation in embryonated hen’s eggs 
Embryonated chicken eggs (VALO GmB) were incubated at 37°C, 40-50% humidity, for 10 
days after which they were candled to check viability of the embryo prior to infection (this 
was done by animal services, The Pirbright Institute). Virus to be inoculated was diluted to 
104 pfu/ml in PBS. The shell was sterilised with 70% (v/v) ethanol and a small hole was 
punctured in the egg shell just below the line of the air sac. The allantoic cavity was 
inoculated with 100μl of diluted virus stock and the hole was sealed using autoclave tape. 
The inoculated eggs were incubated at 37° C, 40-50% humidity, for 72 hours or until 
embryonic lethality. Eggs were culled using a schedule one method (chilling overnight at 4° 
C) and death was confirmed by decapitation. The allantoic fluid was harvested, centrifuged 
(4000 rpm, 10 min), and stored at -80°C.   
 
2.2.4.2 Virus infection  
Routinely, cells were seeded at 80-90% 1 day prior to infection. Once confluent, cells were 
washed once with sterile PBS to remove any residual serum. Influenza, infectious bronchitis 
virus or herpes virus of turkeys was diluted in an appropriate volume of serum-free media 
(Table 2.11). Cells were incubated at 37°C and 5% CO2 for 1 hour, shaking every 20 minutes. 
The virus was removed by washing the monolayer twice with sterile PBS. An appropriate 
volume of maintenance media was added to the cells and infection was left for the time 
indicated. For multicycle infections, cells were overlaid with virus growth medium.  
2.2.4.3 Titration of influenza viruses by plaque assay 
Material to be assayed was 10-fold serially diluted in serum-free DMEM and used to infect 
MDCK cells in 12-well plates. After 1 hour of incubation, the inoculum was removed, 
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washed twice with sterile PBS and the cells were overlaid with the appropriate volume of 
overlay media containing 2% agar. After 3 days, the overlay was removed, and the cells 
were stained with crystal violet (Sigma) to determine the pfu/ml. All plaque assays were 
performed in a technical duplicate and biological triplicate, and samples re-titrated if the 
results were inconsistent. 
2.2.4.4 Titration of infectious bronchitis viruses by plaque assay 
Material to be assayed was 10-fold serially diluted in 1x BES and used to infect CK cells in 
12-well plates. After 1 hour of incubation, the inoculum was removed, washed twice with 
sterile PBS and the cells were overlaid with the appropriate volume of 2x BES containing 2% 
agar. After 3 days, the overlay was removed, the cell fixed with 10% paraformaldehyde (in 
PBS) and the cells were stained with crystal violet to determine the pfu/ml. All plaque 
assays were performed in a technical duplicate and biological triplicate, and samples re-
titrated if the results were inconsistent. 
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2.2.5 Protein Methods  
2.2.5.1 Cell lysis 
Cells were treated as per the experimental design. Cells were placed on ice and washed 
twice with ice cold PBS then lysed by adding an appropriate volume of 2x laemmli’s sample 
buffer (containing 5% β-mercaptoethanol) or FLAG® Immunoprecipitation lysis buffer. The 
cells were incubated on ice for a minimum of 20 minutes to ensure complete cell lysis. 
Lysates were centrifuged at 13,000 rpm for 10 minutes at 4oC and the supernatants were 
harvested and stored at -20oC for future applications.  
2.2.5.2 SDS- polyacrylamide gel electrophoresis (PAGE)                                                          
Cell lysates were denatured in 2x laemmli sample buffer (BIORAD) containing β-
mercaptoethanol, sonicated and then heated to 100 °C for 10 minutes. Protein samples and 
standards were loaded into Mini-PROTEAN TGX™ Precast Gels (4-20%) (BIORAD) immersed 
in 1 x Tris/Glycine/SDS buffer (BIORAD). Gels were run at 80 V for approximately 90 minutes 
until resolved.  
2.2.5.3 Western blotting 
Proteins separated by SDS-PAGE were transferred to nitrocellulose membranes using the 
Transblot Turbo Transfer System (BIORAD). In brief, six sheets of filter paper were saturated 
in Semi-Dry Transfer Buffer, alongside a nitrocellulose membrane (0.2 μm) (BIORAD). The 
Transblot cassette was loaded as per the manufacturer’s instructions, the unit sealed and 
run at 25 V/2.5 A for 3 min. Following transfer, membranes were incubated for 1 hour in 5% 
milk powder (Marvel) in PBS at R/T, then washed once in 0.1% Tween in PBS (PBS-T). The 
membrane was then incubated in PBS-T containing 5% milk powder and a specified amount 
of primary antibody (Table 2.1) for 1h at R/T and then washed 3x in PBS-T. The membrane 
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was then incubated in the dark in PBS-T containing 5% milk powder and an appropriate 
IRDye secondary antibody (Table 2.2) (LI-COR) for 1 h then rewashed as above. The 
membrane was finally washed once in PBS and imaged using an Odyssey CLx (LI-COR) 
imager. Densitometric analysis was performed using Image Studio™ Software (LI-COR), and 
the intensities were normalised to β-actin. 
2.2.5.4 Immunohistochemistry  
Cells were seeded at 1×105/well on coverslips in a 12-well plate 1 day prior to the 
experimental procedure. All steps were performer on a rocker. Cells were fixed with 500µl 
4% paraformaldehyde for 10 minutes followed by permeabilisation with 0.1% saponin in 
PBS.  Cells were blocked in 1% bovine serum albumin (BSA) for 30 minutes after which they 
were then incubated with a specified amount of primary antibody (Table 2.1) for 1h at R/T, 
and washed five times in PBS, followed by incubation with a secondary antibody conjugated 
to Alexa Fluor 568 or 488 (Table 2.2) (Life Technologies). After 1 hour the cells were washed 
five times with PBS. The nuclei of the cells were stained with DAPI (Table 2.3) and mounted 
onto slides with Vectashield Antifade Mounting Media (Vector Laboratories).   
2.2.5.5 Immunoprecipitation 
2.2.5.5.1 Cell Lysis 
Cells were transfected as described in 2.2.3.4. Cells were washed twice with PBS and then 
500µl of cell lysis buffer (2.1.7) containing protease inhibitor cocktail (Sigma) was added to 
each well of a 12 well plate. Cells were then Incubated for 15–30 minutes on a shaker to 
ensure complete lysis. The cell lysates were then harvested and centrifuged for 10 minutes 
at 13,000rpm. The supernatants were transferred to a chilled test tube and were stored at -
20oC if they were not being used immediately.  
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2.2.5.5.2 Immunoprecipitation of chIFITM-FLAG 
The ANTI-FLAG M2 affinity gel was centrifuged at 5,000g for 30 seconds and was washed 3 
times in IP wash buffer (2.2.5.5.1) before being incubated with the cell lysates overnight at 
4 °C with regular agitation. Beads were washed three times with IP wash buffer (Table 
2.1.7). Protein-antibody complexes were eluted using 100µl of 3x FLAG peptide in IP wash 
buffer (150ng/ml). Samples were stored at -20 °C until processing at the University of 
Liverpool. 
2.2.5.6 Liquid Chromatography-Mass Spectrometry/Mass 
Spectrometry 
Eluted samples were processed for LC-MS/MS analysis by Dr Stuart Armstrong (University 
of Liverpool) who supplied the following protocol. Samples were diluted 1:1 volume with 
50mM ammonium bicarbonate (NH4HCO3). Proteins were reduced by the addition of 
dithiothreitol (Sigma) (3mM final) and heated at 60 °C for 10 minutes. The samples were 
returned to room temperature, and iodoacetamide (Sigma) (9mM final) added for 30 
minutes in the dark to alkylate the proteins. Proteins were digested with 0.2μg of 
proteomic grade trypsin (Sigma) and left to incubate at 37 °C overnight. The resulting 
peptide samples were then acidified with trifluoroacetic acid (1% (v/v) final). Peptides were 
concentrated and desalted using C18 Stage tips (ThermoFisher Scientific) and then the 
samples were dried using a centrifugal vacuum concentrator (Eppendorf). Peptides were 
resuspended in 0.1% (v/v) trifluoroacetic acid and 5% (v/v) acetonitrile.  
NanoLC MS ESI MS/MS analysis 
Peptides were analysed by on-line nanoflow LC using the Ultimate 3000 nano system 
(Dionex/Thermo Fisher Scientific). Samples were loaded onto a trap column (Acclaim 
PepMap 100, 2 cm × 75 μm inner diameter, C18, 3 μm, 100 Å) at 5μl min−1 with an 
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aqueous solution containing 0.1%(v/v) TFA and 2%(v/v) acetonitrile. After 7 min, the trap 
column was set in-line an analytical column (Easy-Spray PepMap® RSLC 50 cm × 75μm inner 
diameter, C18, 2μm, 100Å) fused to a silica nano-electrospray emitter (Dionex).  The 
column was operated at a constant temperature of 30°C and the LC system coupled to a Q-
Exactive HF mass spectrometer (ThermoFisher). Chromatography was performed with a 
buffer system consisting of 0.1 % formic acid (buffer A) and 80% acetonitrile in 0.1% formic 
acid (buffer B). The peptides were separated by a linear gradient of 3.8 – 50% buffer B over 
30 minutes at a flow rate of 300nl/min. The Q-Exactive HF was operated in data-dependent 
mode with survey scans acquired at a resolution of 60,000 and scan range 350-2000 m/z. 
Up to the top 10 most abundant isotope patterns with charge states +2 to +5 from the 
survey scan were selected with an isolation window of 2.0 Th and fragmented by higher 
energy collisional dissociation with normalized collision energies of 30. The maximum ion 
injection times for the survey scan and the MS/MS scans were 100 and 45ms respectively, 
and the ion target value was set to 3E6 for survey scans and 1E5 for the MS/MS scans. 
MS/MS events were acquired at a resolution of 30,000. Repetitive sequencing of peptides 
was minimized through dynamic exclusion of the sequenced peptides for 20s, (Tyanova et 
al., 2016;Cox et al., 2014).  
2.2.5.6.1 LC-MS/MS analysis 
MS spectra data was analysed by label-free quantification using the MaxQuant software (v 
1.5.5.1, 1) and searched against a Gallus gallus protein database (Uniprot release-2017_03; 
29,736 sequences) and the relevant bait protein sequences using the Andromeda search 
engine. The false discovery rate (FDR) was set to 0.01, and a decoy database was included 
in the search to help identify and remove false-positives. LFQ results were further 
processed with Perseus software (v 1.5.1.6, 2) to determine significance between FLAG 
alone compared to FLAG tagged chIFITM proteins. Statistical t-test analysis was used to 
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analyse intensity values. Proteins with a p-value <0.05 and a fold change >2 were 
considered statistically significant. Identification and statistical analysis of the mass 
spectrometry data were performed by Stuart Armstrong. 
2.2.5.7 Co-Immunoprecipitation  
Plasmids encoding the sequences of potential interacting partners were co-transfected into 
DF-1 cells according to section 2.2.3.4. After incubation for 24 h, cells were lysed in FLAG 
immunoprecipitation cell lysis buffer containing a protease inhibitor cocktail (Sigma). The 
cell lysates were then harvested and centrifuged for 10 minutes at 13,000rpm, after which 
the supernatant was collected and the cell pellet discarded. The ANTI-FLAG M2 affinity gel 
was centrifuged at 5,000g for 30 seconds and was washed 3 times in IP wash buffer before 
being incubated with the cell lysates (2.2.5.5.1) overnight at 4 °C with regular agitation. 
Beads were washed three times with IP wash buffer (Table 2.1.7). Protein-antibody 
complexes were eluted using 100µl of 3x FLAG peptide in IP was buffer (150ng/ml). 
Western blot analysis was then performed (2.2.5.2 – 2.2.5.3) using anti-FLAG and anti-MYC 
antibodies to assess possible protein-protein interactions.  
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2.2.6 Transcriptional Analysis  
2.2.6.1 Total RNA extraction from tissues  
In total, 19 tissues were removed from Rhode Island Red chickens at 3 weeks of age and 
immediately stored in RNAlater® (ThermoFisher) at -80 °C. For tissue homogenisation, 100 
mg of each tissue sample was placed into 350μl of RLT buffer (Qiagen) in a safelock tube 
containing a sterile metal bead (Qiagen). Tissues were disrupted in a bead beater until fully 
homogenised. Tissue debris was left to settle at room temperature for 5 mins before the 
liquid phase was transferred to a column from an RNeasy Mini Kit (Qiagen). The rest of the 
extraction was performed according to manufacturer’s protocol. The RNA was eluted in 
30μl RNase-free water and quantified on a NanoDrop Lite (ThermoFisher).  
2.2.6.2 Total RNA extraction from cells 
Cell were lysed in RLT buffer (Qiagen) containing 5% β-mercaptoethanol. Total RNA was 
extracted with the RNeasy Mini Kit (Qiagen) according to the manufacturer’s protocol. 
RNAse free DNase (Qiagen) was also used according to the manufacturer’s protocol. RNA 
was stored at -80 °C and quantified using a Nanodrop Lite (ThermoFisher). 
2.2.6.3 Reverse transcription 
Reverse transcription of 1µg total RNA was performed using the Superscript III Reverse 
Transcriptase kit (Invitrogen) according to the manufacturer’s protocol using random 
primers (Promega). The cDNA was stored at -20°C. 
2.2.6.4 Quantitative real-time PCR with SYBRgreen 
Quantitative RT-PCR was performed using 2x PrecisionPlus Master Mix with ROX premixed 
with SYBRgreen (Primerdesign Ltd). The components for quantitative RT-PCR were added in 
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a 10μl reaction and the plate sealed. The thermal cycling conditions included an initial 
enzyme activation step at 95 °C for 2 minutes and 40 cycles at 95 °C for 5 seconds 
(denaturation) and 60 °C for 20 seconds (data collection step). A dissociation stage was also 
added for melt curve analysis. 
2.2.6.5 Reference gene stability analysis by geNorm 
The Ct values of each candidate reference gene across all of the samples were calculated 
using either the 7500 Fast Real-Time PCR Software version 2.3 (Life Technologies) or 
QuantStudio 5 Software v1.4.3. Raw Ct values were exported to Microsoft Excel for quality 
control and imported into the qbase+ real-time qPCR software version 3.0 (Biogazelle). The 
software, using the geNorm algorithm (Vandesompele et al., 2002), calculate the geNorm 
M value representing the stability of each reference genes and the geNorm V value which 
suggest the optimal reference gene number. All quantitative RT-PCR samples were run in 
technical triplicate. 
2.2.6.6 Quantitative real-time PCR (TaqMan) 
Quantitative RT-PCR was performed using TaqMan Universal Master Mix II, no UNG (Life 
Technologies). The components for quantitative RT-PCR were added in a 10μl reaction and 
the plate sealed. The thermal cycling conditions included an initial enzyme activation step 
at 95 °C for 10 minutes and 40 cycles at 95 °C for 15 seconds (denaturation) and 60 °C for 1 
minute (data collection step). 
2.2.6.7 Real-time quantitative PCR data analysis 
The Ct values of each reference gene and gene(s) of interest, across all of the samples, were 
calculated using either the 7500 Fast Real-Time PCR Software version 2.3. (Life 
Technologies) or QuantStudio 5 Software v1.4.3. Raw Ct values were exported to Microsoft 
Excel for quality control and imported into the qbase+ real-time qPCR software version 3.0 
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(Biogazelle). Raw Ct values were normalised to those of the reference genes and the 
relative fold change in expression of each gene was calculated. Technical replicates were 
analysed, and where a difference of ≥ 0.5 cts was found, a value could be omitted from 
further analysis. All quantitative RT-PCR samples were run in technical triplicate. 
2.2.6.8 Extraction and sequencing of viral RNA (vRNA) 
Viral RNA (vRNA) was extracted from 140μl of allantoic fluid using the QIAamp Viral RNA 
Mini Kit (Qiagen) according to the manufacturer’s instructions. Universal influenza primers 
and Superscript III (Invitrogen) were used to produce cDNA, according to the 
manufacturer’s instructions (section 2.2.6.3). Segment specific primers were used in a PCR 
from cDNA using PfuUltra II (Aglient). PCR products were purified using agarose gel 
electrophoresis (section 2.2.2.5) followed by a QIAquick Gel purification Kit (Qiagen) 
(section 2.2.2.7). The resulting product was sequenced via Sanger sequencing (section 
2.2..2.13). 
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2.2.7 Bioinformatic and Statistical Analysis   
2.2.7.1 chIFITM amino acid alignments  
The amino acid sequences of the avian IFITM proteins (1, 2, 3 and 5) were downloaded 
from Uniprot and saved in a word document in fasta format. Multiple sequence alignments 
were calculated using Clustal Omega (EMBL-EBI) using the default settings. The resulting 
alignment was formatted using Genedoc.    
2.2.7.2 chIFITM DNA sequence alignments  
Raw HiSeq DNA sequences in FastQ format were aligned to the Gallus gallus v5 reference 
genome using the Burrow Wheeler Aligner, BWA (v0.7.8) with the BWA-MEM alignment 
algorithm. Reads were then pre-processed with SAM tools v0.1.19 to convert the SAM files 
into BAM files and sorted. For local realignment and base quality score recalibration of the 
mapped reads, the tool Haplotype Caller from GATK (Genome Analysis Toolkit) v3.1 
software package was applied. All tools were used with the recommended standard 
settings. This workflow is in accordance with the best practices from the Broad Institute. 
Variants were called with the tool UnifiedGenotyper from GATK. The resulting indexed BAM 
files were visualised using integrative genome viewer (IGV). 
2.2.7.3 Modelling chIFITM protein topology 
Amino acid sequences were imported into the Phyre2 software package (developed by 
Structural Bioinformatics Group, Imperial College, London) and protein structures were 
modelled using the intensive mode setting. Models are generated by PSI-BLAST searches 
against known homologues, secondary structure is modelled against Psi-pred and Diso-pred 
databases and from this data a hidden Markov model (HMM) is generated. Transmembrane 
helices and protein topology prediction is made by memsat-svm 
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2.2.7.4 Statistical analysis 
All graphs were created and statistical analysis performed using GraphPad Prism 7/8 
(GraphPad Software Inc). For each data set, the number of biological replicates and the 
type of data analysis, including the relevant key, is noted in the figure legend. 
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3.1 Introduction 
The discovery of the human IFITM proteins occurred many decades ago, making them 
amongst the first ISGs to be characterised (Friedman et al., 1984). The nomenclature was 
initially very different to what is used currently and they were termed 9–27(IFITM1), 1-8D 
(IFITM2), and 1-8U (IFITM3). Further characterisation of these genes was undertaken in 
1996 (Alber and Staeheli, 1996), 2003 (Zhu and Liu, 2003) and then in 2009. Two different 
IAV-targeting RNA interference studies identified huIFITM1, 2 and 3 as potential restriction 
factors against IAV (Brass et al., 2009;Shapira et al., 2009), with five similar studies 
published within weeks of one another. The findings published in these studies resulted in 
further experiments by many groups that sought to understand the mechanisms 
underpinning the antiviral activities of the mammalian IFITMs.  
In addition, work has been undertaken to understand the genetic predispositions within the 
huIFITM locus that result in an increased susceptibility to disease. Specifically, the single 
nucleotide polymorphism (SNP) rs12252-C was proposed to alter the splice acceptor site, 
truncating huIFITM3 by 21 amino acids at the N-terminus. This variation has been 
associated with an increase in an individual’s susceptibility of developing a severe Influenza 
A viral infection,  specifically in the Han-Chinese population (Everitt et al., 2012;Zhang et al., 
2013;Wang et al., 2014a;Yang et al., 2015;Pan et al., 2017;David et al., 2018). Further 
associations between the CC minor allele (rs12252-C) and the outcomes of clinical disease 
have been observed with coronary artery lesions (Bowles et al., 2014), HIV-1 (Zhang et al., 
2015) and the onset of mild clinical disease with IAV infection (Mehrbod et al., 2017). 
However, the evidence linking the presence of the rs12252-C allele and its association with 
severe clinical outcomes is contradictory, with other reports suggesting that such an 
association does not exist (or cannot be proven with such small sample sizes and low 
frequencies within the population) with others questioning the antiviral activity of 
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IFITM3Δ21 in vitro (Williams et al., 2014;Lopez-Rodriguez et al., 2016;Mills et al., 2014). More 
recently, data obtained from RNA sequencing experiments has suggested that truncated 
IFITM3 transcripts cannot be detected under mock conditions or during viral infection with 
H7N1 but full length IFITM3 mRNA transcripts are detected regardless of the genotype of 
the individual (Makvandi-Nejad et al., 2018). This work suggests that the association 
between the prevalence of the rs12252-C SNP (within IFITM3) and the outcome of clinical 
disease is a complex phenotype and may be difficult to conclusively demonstrate. 
This level of genetic analysis has not been conducted in chickens because the chicken IFITM 
locus was only recently correctly annotated in the chicken genome (Bassano et al., 2017). 
To date, only one study has looked at basal chIFITM expression (excluding chIFITM5) in 
chicken tissues, highlighting variable expression between the tissues studied (Smith et al., 
2013). Furthermore, work has not been undertaken to investigate the locus architecture, 
the variation within the locus, nor the possible interacting partners which modulate the 
chIFITM expression or its antiviral activity.  
This chapter characterises the chIFITM locus and describes novel sequencing approaches of 
a BAC clone used in the sequencing of the reference Red Jungle fowl genome sequence, to 
generate an accurate, contiguous sequence for downstream applications. Constitutive 
levels of chIFITM expression were examined in vivo as well as in commonly used chicken 
cell lines. Aligning the avian IFITMs sequence against the Galgal 5 reference genome was 
performed in order to assess the level of sequence conservation and to identify conserved 
regions which may be important for viral restriction. Furthermore, the novel sequencing 
strategy developed by Bassano et al. (2017) was used to sequence three avian cell lines in 
order to identify genetic variation that may influence the cell line specific chIFITM-
restriction. In addition, the cellular localisation of these proteins was characterised in vitro 
alongside any cellular interacting partners that may influence restriction or may control 
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how the genes are expressed under native conditions. Taken together, these data will allow 
for the characterisation of the chIFITM locus and may suggest the mechanisms 
underpinning chIFITM restriction. 
3.2 chIFITM locus architecture  
Prior to 2013, nothing was known about the chIFITM locus architecture or the gene content 
within this locus. Moreover, only chIFITM5 was partially annotated in the Galgal4 genome 
and this was because of the relatively high level of sequence homology between the 
chicken and human IFITM5 genes and amino acid sequences (Tables 3.1 and 3.2). The 310 
million years of evolutionary distance between mammals and aves, and the constant arms 
race between virus and host, have resulted in low level sequence conservation between 
human and chicken IFITMs, with huIFITM3 and chIFITM3 sharing only 36% amino acid 
identity. This makes searching for orthologues difficult as they are not easily identifiable by 
performing BLAST searches, and this partially explains why a gap in Gallus gallus 
chromosome 5 existed for so many years. Moreover, this region is difficult to sequence 
using traditional sequencing methods, contributing to the lack of sequencing data available. 
In this chapter the chIFITM locus was characterised and further analysis was undertaken to 
understand the genetic diversity within the locus and the basic characteristics underpinning 
their mode of action.   
As the IFITM genes were not annotated in the genome, bioinformatic analysis was 
conducted by researchers in the Genetics and Genomics group at the Pirbright Institute. 
The two genes flanking the putative IFITM locus in chickens are the telomeric β-1,4-N-
acetyl-galactosaminyl transferase 4 (B4GALNT4) gene and the centromeric acid trehalase-
like 1 (ATHL1) gene. Both of these genes are highly conserved between species, from 
mammals to amphibians (Smith et al., 2013). Once B4GALNT4 and ATHL1 had been 
identified on chromosome 5 of the Gallus gallus genome, the identification of the individual  
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chIFITM1 chIFITM2 chIFITM3 chIFITM5 
huIFITM1 47.3 
   
huIFITM2 
 
41.9 
  
huIFITM3 
  
50.9 
 
huIFITM5 
   
67.2 
 
chIFITM1 chIFITM2 chIFITM3 chIFITM5 
huIFITM1 36.8 
   
huIFITM2 
 
28 
  
huIFITM3 
  
35.8 
 
huIFITM5 
   
56.8 
Table 3.1: Percentage (%) identity between human and 
chicken IFITM DNA sequences. 
Table 3.2: Percentage (%) identity between human and 
chicken IFITM amino acid sequences. 
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IFITM1 IFITM3 B4GALNT4 IFITM2 IFITM5 ATHL1 
Human Chr. 11 
            
IFITM1 IFITM3 B4GALNT4 IFITM2 IFITM5 ATHL1 
Chicken Chr. 5 
Direction of transcription 
  
Figure 3.1 The chIFITM locus architecture. The IFITM locus on Gallus gallus chromosome 5 and the genes present are flanked by genes ATHL1 and 
B4GALNT4. This region is syntenic with the IFITM gene cluster on human chromosome 11. Note that the change in the direction of transcription of 
chIFITM2 and chIFITM1 makes the assignment of orthology difficult; therefore, the chicken genes are named by gene order and conservation of specific 
functionally defined amino acid residues. The coloured boxes and dashes denoted orthology as assigned by sequence similarity and conversation. [Taken 
from: (Smith et al., 2013)].  
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chIFITM genes were made based on the sequence conservation within the cytoplasmic 
intracellular loop (CIL). The sequence conservation in this region exists between the 
chIFITM genes which means that the nomenclature was predominantly based on synteny, 
rather than sequence data. Furthermore, due to the lack of functional data, it was not clear 
if the nomenclature was correct. However, without conclusive evidence demonstrating the 
function of the genes, this would have been entirely speculative to have altered the 
nomenclature and would not have added to our current understanding. The nomenclature 
used in this thesis represents the nomenclature presented in the schematic above (Figure 
3.1) and the current annotation in NCBIv5.  
The coloured blocks in the schematic denote genes annotated in the genome before 2013, 
and their corresponding positions within the locus, whether on the chicken or human 
chromosome. The gene blocks shown in white were not annotated in the genome and the 
names assigned to the blocks are based on synteny. The direction of transcription is in a 
different orientation for chIFITM1 and 2, indicating gene transversion, which further 
complicates the nomenclature and assigning orthology. In fact, it is still not clear if 
chIFITM1, 2 and 3 are correctly named and this is primarily because of the low sequence 
identity between mammalian and avian genes. Drawing conclusions remains challenging 
and is further complicated by the 21 amino acid truncation of chIFITM2 which makes it 
similar to chIFITM1, in that both the YEML motif and phosphorylated Tyr20 are missing 
from this protein.   
Taken together, assigning orthology remains challenging, and it is clear that this cannot be 
done based on sequence data alone. Studies focussing on the functionality of the chIFITM 
proteins will be essential as they may provide an insight into their restrictive profile, cellular 
localisation and regulation which may allow for a more systematic process of naming the 
genes.  
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3.3 Re-sequencing the chIFITM locus  
Accurate assembly of the chIFITM locus is problematic due to the large gaps that exist in 
the genomic sequence (poor sequence coverage is not only a feature of the chIFITM locus, 
but has also been found across all species that have been sequenced to date, using NGS 
technologies). The chIFITM locus does not appear to be made up of a high percentage of 
repetitive sequences or have an unusually high GC content; characteristics that are known 
to affect sequencing coverage across a genome. Therefore, it remains unclear as to why this 
specific locus is difficult to sequence. The gaps in the sequencing data result from low 
confidence in the sequence and makes more comprehensive genetic analysis unfeasible. 
Moreover, it is difficult to design laboratory reagents without a contiguous, accurate 
sequence 
To generate a contiguous sequence, the BAC clone (CHI261-109H20) from Red Jungle Fowl 
isolate inbred line (UCD001) covering the predicted IFITM locus (Figure 3.2) was purchased 
from BACPAC Resources Centre at the Children's Hospital Oakland Research Institute, 
United States (Bassano et al., 2017). The resulting plasmid DNA (3μg) was sent to The 
Wellcome Trust Sanger Institute for sequencing using two NGS technology platforms, the 
Illumina MiSeq and PacBio RSII. Quality control was conducted by The Wellcome Trust 
Sanger Institute’s core sequencing facility. Once sequencing of the BAC clones was 
complete, Dr Irene Bassano (collaborator, Imperial College London) analysed the data and 
produced a contiguous sequence covering the entire chIFITM locus using de novo assembly 
(Bassano et al., 2017). In this study, it was essential to generate a contiguous sequence 
across the IFITM locus with a high degree of accuracy. It was known that the coverage 
across the chIFITM locus in v4 was poor and this resulted in gaps which could not be 
resolved without resequencing the locus using a different approach. The incorporation of 
the long PacBio sequencing reads has significantly improved the coverage across the  
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Figure 3.2 Isolating the BAC clone for chIFITM locus re-sequencing. The IFITM locus on 
Gallus gallus chromosome 5 is poorly annotated in the Galgal4 genome assembly. This 
region is flanked by genes ATHL1 and B4GALNT4 and this allowed for the identification of 
putative genes. Prior to 2013, only chIFITM5 was already annotated in the genome. The 
BAC clone (CH261-109H20) was identified as covering the predicted chIFITM locus and 
was acquired from the Children’s Hospital Oakland Research Institute (CHORI), United 
States. The BAC clone was streaked onto LB-agar, single colonies isolated and plasmid 
DNA extracted according to the manufacturers protocol. Regions highlighted included the 
chIFITM locus and the flanking genes ATHL1 and B4GALNT4.  
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most recent version of the chicken genome (v5), including the IFITM locus. However, when 
aligning the MiSeq reads against v5 it is clear that gaps within the locus still exist (Figure 
3.3B). When sequencing an entire genome, errors in assembly can occur due to gene 
duplication and paralogous gene families, both of which affect the accuracy of the 
alignment. The IFITM gene family is one of the most highly paralogous families known with 
multiple copies of the IFITM genes as well as pseudogenes (John et al., 2013;Smith et al., 
2013).  
To reduce error, only a relatively small region of chromosome 5 (203kb) containing the 
IFITM locus was sequenced at high coverage with both PacBio and Illumina MiSeq. Two 
different methods of sequencing were used to increase the sequence coverage across the 
IFITM locus and to minimize sequence gaps that may result from one single sequencing 
methodology. The average PacBio read length is >10kb but this is dependent on the activity 
of the polymerase (Eid et al., 2009;Au et al., 2012). Furthermore, it is accepted that raw 
PacBio reads have a higher error rate compared to other technologies (14% versus 0.1 to 
1% for Illumina) but a high-quality consensus sequence can be obtained from overlapping 
reads. In contrast, the average read length on the Illumina MiSeq is 300bp which allows for 
enhanced coverage over the region of interest (Schirmer et al., 2015). Although the BAC 
clone (CH261- 109H20) does not include chIFITM10 because of its different chromosomal 
location, using a clone from the BAC library used to generate the original Gallus gallus 
genome allows for a more complete and robust assessment of the chIFITM locus when 
compared to the publically available genomes, namely v4 and v5. The sequencing results 
are summarised in a study published in BMC Genomics (Bassano et al., 2017). In brief, there 
was good coverage across the loci with both Miseq and PacBio Sequencing platforms. The 
differences in coverage were apparent when using the two most recent versions of the 
Gallus gallus genome assemblies as scaffolds. When aligning the MiSeq reads against the 
Gallus gallus v4 genome assembly (Figure 3.3A), it is clear that there are gaps within the  
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Figure 3.3 MiSeq and PacBio sequence analysis of the CH126-109H20 BAC clone. The 
BAC clone (CH126-109H20) was streaked onto LB-agar, single colonies isolated and 
plasmid DNA extracted according to the manufacturers protocol. The plasmid DNA was 
then sequenced at The Wellcome Trust Sanger Institute. (A) Sequence coverage over the 
chIFITM locus using MiSeq DNA sequencing. This reference was built using the annotation 
of Gallus gallus v4 as scaffold. (B) Sequence coverage over the chIFITM locus using MiSeq 
DNA sequencing. This reference was built using the annotation of Gallus gallus v5 as 
scaffold. (C) Sequence coverage over the chIFITM locus using PacBIO RSII DNA 
sequencing. This reference was built using the annotation of Gallus gallus v5 as scaffold. 
(D) Artemis coverage and stack view of Illumina MiSeq reads mapped against PacBio 
consensus sequence, producing a de novo assembly. The assembly is in the reverse 
orientation. Dr Irene Bassano (Imperial College London) prepared the figures and 
conducted DNA sequence analysis.  
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chIFITM locus and this highlights the substantial deficiencies to the v4 genome assembly. In 
contrast, the Gallus gallus v5 genome assembly which incorporates new PacBio sequencing 
in its assembly, is greatly improved over the previous assembly having fewer large 
sequence gaps. There is however, the addition of a small INDEL within the intronic region of 
chIFITM3 which is unlikely to have any significant effect although this has not been 
demonstrated (Figure 3.3B). The advantage of PacBio sequencing in this instance is that it 
generates read lengths of >10kb which are likely to reduce sequencing gaps within the 
regions that were poorly sequenced using MiSeq DNA sequencing. The sequencing data 
using this long read technology (Figure 3.3C) demonstrates that the coverage over the 
chIFITM locus increases dramatically in comparison to using MiSeq sequencing alone. 
Moreover, the coverage over the chIFITM coding regions is much better, even in 
comparison to other regions within the larger 203kb region.    
These results demonstrate that the longer PacBio reads map well to the most current 
version of the reference chicken genome. In contrast, Illumina MiSeq raw reads are not 
sufficient to assemble this region de novo as there are a number of gaps within the locus 
that cannot be resolved. However, Illumina MiSeq raw reads do map accurately to the de 
novo PacBio reference (Figure 3.3D). Utilising two methods of sequencing has resulted in a 
contiguous, high coverage sequence across the chIFITM locus which can be used when 
designing new reagents and can act as the new reference sequence for further analysis.  
3.4 Basal expression of chIFITM transcripts in chicken tissues  
It has been established that the huIFITM proteins are present at basal levels (Zhao et al., 
2014;Huang et al., 2011;Diamond and Farzan, 2013), however, the expression of IFITM 
mRNA and constitutive levels of protein differ between species, and therefore it was 
necessary to investigate the basal levels in chicken cells and tissues. Additionally, IFITM 
expression has also been found to be cell type or tissue specific (Tanaka et al., 2005;Lu et 
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al., 2017) and increases after the addition of exogenous type I interferons such as IFNα and 
IFNβ (Warren et al., 2014). The constitutive levels of chIFITM transcript abundance were 
assessed (Smith et al., 2013;Smith et al., 2015) and variable levels of chIFITM1, 2 and 3 gene 
expression were observed, although chIFITM5 was not investigated. To expand on the data 
already available, the current study focused on a wider range of tissues and included 
chIFITM5. In mammals, IFITM5 is expressed only in the bone marrow and its function is 
restricted to bone mineralisation (Kasaai et al., 2013;Liu et al., 2012;Moffatt et al., 2008). 
There is little data suggesting a role of chIFITM5 in the chicken host. Constitutive levels of 
chIFITM5 mRNA expression may provide insight into the functional role this IFITM may play 
in chickens.  
In order to assess tissue-specific chIFITM gene expression, RNA was extracted from 
nineteen tissues from 3, 3-week-old Rhode Island Red (RIR) chickens. The tissues that were 
extracted include: brain, bursa of Fabricius, caeca, lower GIT (colon), Mid GIT, spleen, 
thymus, bone marrow, heart, liver, eye lid, trachea, pancreas, lung, skin, muscle (breast), 
gall bladder, caecal tonsil and kidney. These samples were chosen because they include a 
wide range of tissues, many of which show tissue tropism for one or more avian virus. For 
example, IBV is known to infect the trachea of chickens and this is a primary site of virus 
replication (Abdel-Moneim et al., 2009;Thiel, 2007). Understanding the constitutive levels 
of expression may give an insight into the immunocompetence of that tissue in response to 
infection. Tissue samples were harvested, homogenised using the TissueLyser, RNA was 
extracted and reverse transcribed into cDNA, which was used in relative quantitative RT-
PCR. Copies of the chIFITMs were calculated from a standard curve using plasmids encoding 
the target sequence at known concentrations.  
Expression of chIFITM1 mRNA was largely variable across the different tissues analysed 
reaching the highest levels of expression in the bursa of Fabricius, the gastrointestinal tract, 
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and the caecal tonsil. Detectable levels of chIFITM1 expression were also found in other 
tissues such as the trachea, lung and thymus but these were at much lower levels 
(approximately a 1 to 2 log10 decrease depending on the tissue being examined). In 
contrast, expression of chIFITM2 and 3 mRNA was detected in all tissues, with expression, 
on average, higher than chIFITM1 expression. Lower levels of chIFITM2 and 3 expression 
were found in the brain, pancreas, muscle (breast) and brain. Finally, expression of 
chIFITM5 mRNA was also variable with levels of expression higher in the gastrointestinal 
tract, brain, lung and caecal tonsil. Moreover, the levels of chIFITM5 expression were 
consistently lower than expression of chIFITM1, 2 or 3 in all tissues studied. However, it is 
interesting to note that although levels of expression are low, they are detectable. This is a 
marked difference in the data presented in the mammalian field and may suggest a 
different function for chIFITM5. It is unclear at the moment if enhanced distribution of 
expression necessarily results in a function that has yet to be described (Figure 3.4).  
3.5 Basal expression of chIFITM transcripts in chicken cell lines and ex 
vivo cell cultures 
The constitutive levels of chIFITM expression have been quantified in a range of different 
chicken tissues and this allows for a more robust assessment of quantitative RT-PCR data 
where relative fold change is used. It is important to put quantitative RT-PCR data into 
context as cells with a higher constitutive level of expression may have a lower relative fold 
change compared with cells expressing lower levels of chIFITM transcript abundance. 
Moreover, this data endorses chIFITMs as restriction factors insomuch that a basal level of 
expression is one of the classical definitions used to classify genes as host cell restriction 
factors. Avian cell lines are generally poorly characterised, especially in regard to 
endogenous chIFITM mRNA expression. To characterise chIFITM transcription in vitro 
without infection or stimulation, quantitative RT-PCR was performed on three chicken 
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Figure 3.4 Endogenous levels of chIFITM expression in the tissues of Rhode Island Red (RIR) chickens. Nineteen tissues from 3 week old RIR chickens 
were removed, homogenised, the RNA extracted, reverse transcribed and the endogenous expression of chIFITM1, 2, 3 and 5 was assessed by 
quantitative RT-PCR. Relative quantification of chIFITM transcripts was performed and copy numbers were determined from standard curves produced by 
using plasmids encoding the template at known concentrations. Error bars show standard deviations of the means from 3 chickens (n =3). 
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cell lines (DF-1, HD11 and OU-2) and two ex vivo cell cultures (CEF and CKC) routinely used 
for research purposes. Samples were harvested, cells were lysed, RNA extracted, reverse 
transcribed and chIFITM, β-Actin and RPL13 mRNA expression levels were measured by 
quantitative RT-PCR. Two reference genes, RPL13 and β-actin were used as endogenous 
controls and amplified well in all cell lines tested (Figure 3.52A and B). Interestingly, the 
amplification of β-actin in DF-1 cells, although stably expressed, was lower than in any of 
the other cell lines and the reason for this remains unclear. The amplification of the 
reference genes was otherwise comparable and stable across the cell lines and ex vivo cell 
cultures that were assayed. Amplification of chIFITM1, 2, 3 and 5 cDNA was variable across 
the cell lines that were assayed (Figure 3.5C – F). OU-2 cells have the greatest level of basal 
chIFITM transcriptional expression, with average 40-CT values of 9.8, 17.8, 22 and 7.3, for 
chIFITM1, 2, 3 and 5, respectively. The transcriptional expression of the chIFITM genes in 
DF-1 and HD11 cells were broadly comparable to each other. As well as assessing 
continuous cell lines, the basal level of expression for chIFITMs in ex vivo cells including 
chicken embryonic fibroblasts (CEFs) and chick kidney (CK) was also examined. The average 
CT values of these two ex vivo cultures were also broadly similar to each other with the 
greatest variation seen in chIFITM5, with a difference of 4 CTs.  
These data demonstrates that the chIFITMs are expressed at basal levels in all of the cell 
lines examined. It is also clear that a similar pattern of expression exists between the cell 
lines and the in vivo tissue samples that were examined. Expression of chIFITM1 and 5 are 
lower and more variable across all of the samples. Conversely, chIFITM2 and 3 are more 
highly expressed and the data suggests that there is less variation in expression, although 
some tissues and OU-2 cells do appear to have a generally higher level of expression. This 
may imply that chIFITM2 and 3 are more tightly regulated in comparison to chIFITM1 and 5. 
Moreover, there is a large degree of variation in chIFITM expression in DF-1 cells and the 
reasons behind this are unclear. It is known that interferon expression and the  
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Figure 3.5 Endogenous levels of chIFITMs in avian cell lines. (A and B) Average CT value 
of two reference genes, RPL13 and β-actin were measured by quantitative RT-PCR and 
then subtracted from the number of cycles (40). (C-F) Average CT value of chIFITM1, 2, 3 
and 5 were measured by quantitative RT-PCR and then subtracted from the number of 
cycles (40). Input RNA was normalised to 1μg by Tapestation 2200 and then Nanodrop 
Lite. Error bars show standard deviations of the means of 3 biological replicates for the 
ex vivo cultures and 6 biological replicates of the continuous chicken cell lines. 
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upregulation of interferon is reduced in DF-1 cells and this has been attributed to a higher 
level of SOCS1 expression (Giotis et al., 2017). The suppression of innate immune responses 
in this cell line may contribute to the variation in expression, although other mechanisms 
may be mediating this effect.  
3.6 Multiple key residues are conserved among chIFITM sequences in 
Galliformes 
Using the recently published and most accurate genomic sequence for the IFITM locus for 
Gallus gallus (Bassano et al., 2017) it was possible to accurately compare avian and 
mammalian sequences for this gene family. To identify conserved domains, avian amino 
acid sequences were aligned against human and mouse IFITM sequences, identifying critical 
residues and regions that are known to modulate either the expression or antiviral activity 
of these mammalian proteins. For example, it is well documented that the cysteine residues 
at position 71 and 72 of huIFITM3 are critical in mediating viral restriction; if they are 
missing or mutated through site directed mutagenesis (SDM), the antiviral activity of 
huIFITM3 is diminished (Yount et al., 2010;Yount et al., 2012). Moreover, it has been shown 
that this effect is incremental and indirectly proportional to the number of mutated 
palmitoylated cysteine residues; the more mutated cysteine residues, the less antiviral 
activity is observed (Yount et al., 2010;Narayana et al., 2015). In addition to aligning the 
sequences based on the conservation of key resides, it is also known that the CD225 region 
is homologous between the sequences of different species and conservation within this 
region is high. The CD225 domain includes the IMD and CIL regions and is present in many 
prokaryotic and eukaryotic proteins. This domain is conserved between all species that 
have been studied thus far including mammals, aves and amphibians. 
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To examine sequence homology, all of the available avian IFITM amino acid sequences were 
aligned to ensure sufficient breadth to the investigation in conjunction with the most 
detailed analysis undertaken to date. Amino acid sequences of avian IFITM proteins were 
downloaded from UNIPROT and aligned in order to assess the degree to which previously 
published important residues/motifs (Bailey et al., 2014), identified in huIFITMs, are 
conserved in a number of divergent avian species (Figure 3.6). Many of the key residues are 
conserved between the avian species analysed, with specific emphasis on the palmitoylated 
Cys72, which is conserved in all but two species (hummingbird and medium ground finch) 
that were aligned, for the IFITM5 sequence. It has already been established that Cys72 is a 
critical residue in huIFITM3-mediated restriction of influenza and mutation causes it to mis-
localise and attenuation of restriction is observed (Yount et al., 2012). Other residues such 
as Cys105 (also palmitoylated) and Lys24 are less well conserved, suggesting that only 
residues that are absolutely essential for function and viral restriction are conserved 
through evolutionary divergence. Strikingly, the alignment of chicken, mallard and turkey 
IFITM2 amino acids sequences reveals an N-terminal truncation which lacks the YEML motif 
(Y20). This motif interacts with the μ2 subunit of AP-2 complex and targets the protein for 
internalisation via clathrin-mediated endocytosis (Jia et al., 2014).  For this reason, this 
truncation may impact the restrictive profile of chIFITM2, although at present there is 
limited information available to confidentially conclude. Currently the only functional data 
has been published by Smith et al (2013) who show that chIFITM2 is able to restrict 
lentiviral vectors at least as proficiently as chIFITM3. These results demonstrate that the 
avian species examined are missing the YEML motif which is essential for the localisation of 
the proteins to the endosomes (Jia et al., 2014). This may result in avian IFITM2 localising to 
different compartments which may impact restriction, although this has yet to be 
determined in chickens. In a study published in 2016, it was found through confocal 
microscopy that duck IFITM2 only partially localises with 
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Figure 3.6 Multiple key residues are conserved among chIFITM sequences in Galliformes. The amino acid sequences of the avian IFITM proteins (1, 2, 3 
and 5) were downloaded from Uniprot and saved in a word document in fasta format. Multiple sequence alignments were calculated using Clustal Omega 
(EMBL-EBI) using the default settings. The resulting alignment was formatted using Genedoc. The amino acid sequences of the chIFITM genes (1, 2, 3 and 5) 
were compared to various avian and mammalian homologs. The highlighted domains are N-terminal domain (NTD), intramembrane domain (IMD), 
conserved intracellular loop (CIL), transmembrane domain (TMD) and the C-terminal domain (CTD). Site specific similarities between amino acids are 
highlighted by the coloured letters. The YEML motif (red letters, Y20 arrow) promotes protein internalisation and localisation to the endosomes, 
ubiquitination of K24 and methylation of K88; F75 and F78 have been implicated in dimerization (blue) and palmitoylation of Cys71; Cys72 and Cys105 (red) 
have been shown to play a critical role in subcellular localisation and viral restriction. The species listed include: ch (chicken), hu (human), m (mouse), tu 
(turkey), sw (swift), Ib (ibis), ma (mallard), ba (little brown bat), ca (canary), gt (ground tit), sp (sparrow), cc (common canary), hb (hummingbird), mf 
(medium-ground finch), z (zebra finch), rct (red-crested turaco), cu (cuckoo roller), se (red-legged seriema), ri (rifleman).  
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Lysosomal-associated membrane protein 1 (LAMP1). The co-localisation was not as 
profound as the signal between duck IFITM3 and LAMP1 which may suggest differential 
localisation (Blyth et al., 2016). It is has also been observed that a number of residues are 
altered from chIFITM3, including Lys24, Phe78 and Cys105. At this time, it is unclear what 
impact this may have on chIFITM3-mediated restriction, although studies suggest that the 
impact may be minimal (Yount et al., 2012;Yount et al., 2010;Shan et al., 2013). Research 
published on huIFITM5 conclusively shows that the expression of this gene is restricted to 
the bone marrow and its primary function is involved in bone mineralisation. It has been 
shown that huIFITM5 does not function as an ISG (Farber et al., 2014;Moffatt et al., 
2008;Tsukamoto et al., 2013). Interestingly, both chIFITM5 and huIFITM5 contain Cys71, 
Cys72 and Cys105 alongside Lys83 and Lys88 which are conserved between orthologues. 
We have established that chIFITM5 expression is not restricted to bone marrow (Figure 
3.4), however, it is unclear if this is linked to its function and if chIFITM5 is an ISG.  
There is a large degree of heterogeneity between mammalian and avian IFITM protein 
sequences, although a greater degree of conservation is observed within the IM1, CIL and 
IM2 domains. Chicken, mallard and turkey IFITMs appear to share similar amino acids at 
these important positions which is in contrast with the consensus amino acid sequence 
which is derived from the huIFITM sequences. It is not yet known if functional residues at 
these positions are important, nor if the high degree of sequence homology indicates that 
IFITMs from different avian species act in a similar manner. 
3.7 Sequence variation within the chIFITM locus of commonly used 
chicken cell lines 
Now that a contiguous sequence has been generated, it is possible to interrogate the 
chIFITM locus in continuous avian cell lines that are routinely used in the laboratory. It is 
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unknown if these cell lines have an intact chIFITM locus or whether there are SNPs or other 
polymorphisms within the chIFITM locus compared to the Gallus gallus reference sequence. 
To answer this question sequencing was performed. This approach ensured that the 
reagents that have been developed (quantitative RT-PCR primers and probes, siRNAs and 
antibodies) were suitable across all of the cell lines that were used throughout the course 
of the project. Moreover, sequencing these cell lines allowed for the natural variation to be 
determined and may provide further insight into any observed differences in viral 
restriction between the cell lines. In order to sequence the chIFITM locus in three chicken 
cell lines, HD11, DF1 and OU-2 cells were cultured, the cells lysed and genomic DNA 
extracted. The quality and quantity of the DNA was analysed using both the Nanodrop and 
TapeStation 2200. The DNA was enriched using SureSelect pull down probes of the IFITM 
locus and sequenced using PacBio sequencing technology at the Wellcome Trust Sanger 
Institute. The DNA sequences were analysed for SNPs by Dr Angela Steyn (Genetics and 
Genomics group, The Pirbright Institute) but any further analysis regarding SNP location 
and/or possible putative function was conducted by myself.  
There was relatively little sequence diversity within the chIFITM locus and only two 
mutations were found within the coding regions. These mutations were located within 
chIFITM1 at position GGA5:1,552,864 and chIFITM3 at position GGA5:1,550,177. As these 
were synonymous mutations, it is likely there will be no change in the antiviral properties of 
either protein. In total there were 27 single nucleotide polymorphisms (SNPs) within the 
chIFITM locus, and these were identified within the 5’ untranslated region (UTR), the 
introns and in the 3’ UTR. There was also a 3bp insertion into the 5’ UTR of chIFITM2 and 
two deletions (8 and 9bp) within the intronic region of chIFITM3 (Figure 3.7). Variants 
within the introns can have profound effects on expression, splicing and gene regulation 
(Anna and Monika, 2018;Strobel and Abelson, 1986) . It is unknown if these variants 
impacted on the expression of the chIFITM genes or whether there were any effects on the  
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Figure 3.7 Sequence variation within the chIFITM locus of commonly used chicken cell 
lines. HD11, DF1 and OU-2 cells were cultured, the cells lysed and DNA extracted using a 
Qiagen blood and cell culture mini kit, as per the manufacturer’s instructions. The quality 
and quantity of the DNA was analysed using both the Nanodrop and TapeStation 
2200. The DNA was enriched using SureSelect pull down probes of the IFITM locus and 
sequenced using PacBio sequencing technology. The DNA sequences were analysed by Dr 
Angela Steyn (Genetics and Genomics group, The Pirbright Institute). 
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resultant polypeptide, as studies have not focused on these regions and very little is 
understood regarding regulation of chIFITM expression. Interestingly, SNPs that have been 
identified are present in >90% of reads in HD11 cells which means that these SNPs can be 
called with confidence. In contrast, the same SNPs are present in ~60% and ~70% reads in 
DF-1 and OU-2 cells respectively. Although the SNPs in these two cell lines are present in 
fewer reads, it is likely that they are true SNPS, not a result of sequencing error, due to the 
concurrent presence of these SNPs in HD-11s. The SNP identified within chIFITM3 at 
position GGA:1,550,053 has not been identified in HD11 cells and the percentage of reads 
with this variant in DF-1 cells is 64% and OU-2 cells is 74%. Therefore, it is difficult to 
confidently call whether this variant is a true SNP although it is present in more than one 
cell line.  
Taken together, resequencing the chIFITM locus, aligning a diverse range of avian IFITM 
protein sequences and utilising new sequencing approaches to sequence commonly used 
chicken cell lines now allows for a comprehensive assessment of the chIFITM locus. This 
data provides information that allows for a greater understanding of this region and may 
provide insights into which regions are important for mediating restriction.   
3.8 Predicted structures of the chIFITM proteins and their 
corresponding membrane topologies  
Although the huIFITM proteins have been studied extensively, only a single report provides 
convincing evidence that predicts the protein topology of huIFITM3 (Ling et al., 2016). Even 
with new structural insights, the mechanism of restriction remains largely unknown. Using 
nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) on 
huIFITM3 in detergent liquid micelles, Ling et al proposed the type II transmembrane 
protein topology model for huIFITM3. Furthermore, PTMs of the NTD, particularly the 
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ubiquitination of Lys24 and phosphorylation of Tyr20, suggest that the NTD resides 
intracellularly, as access to cytosolic enzymes such as ubiquitin ligases and protein kinases, 
is essential (Yount et al., 2012;Jia et al., 2012). Evidence for the localisation of the C-
terminal domain (CTD) is less definite, although additional studies assessing the PTMs in 
this region suggest that the CTD of murine ifitm1 could also reside intracellularly (Yount et 
al., 2012;Hach et al., 2013a). Conversely, models of ifitm3 and huIFITM1 suggest that the 
CTD resides extracellularly (Bailey et al., 2014;Weston et al., 2014). The conflicting data 
makes it difficult to determine the correct membrane topology of the human or extrapolate 
for the chicken IFITM proteins. It will not be until crystal structures of the proteins are 
generated that the structure will finally be determined. In the meantime, data collected 
though biochemical experiments and structural proteomic techniques will provide a more 
fundamental understanding of the protein topology and how this may influence viral 
restriction.  
Amino acid sequences were imported into the Phyre2 software package (developed by 
Structural Bioinformatics Group, Imperial College, London) and protein structures were 
modelled using the intensive mode setting (Figure 3.8 A, C, E). In brief, models are 
generated by PSI-BLAST searches against known homologues, secondary structure is 
modelled against Psi-pred and Diso-pred databases and from this data a hidden Markov 
model (HMM) is generated. Intensive mode allows for further analysis as templates are 
selected to increase the coverage (Figure 3.8 B, D, F and H). Transmembrane helices and 
protein topology prediction is made by memsat-svm. 
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Figure 3.8 Predicted structures of the chIFITM proteins and their corresponding 
membrane topologies. (A, C, E and G) Amino acid sequences were inputted into the 
Phyre2 software package (developed by Structural Bioinformatics Group, Imperial College, 
London) and structures were modelled using the intensive mode setting. In brief, models 
are generated by PSI-BLAST searches against known homologues, secondary structure is 
modelled against Psi-pred and Diso-pred databases and from this data a hidden Markov 
model (HMM) model is generated. Intensive mode allows for further analysis as templates 
are selected to increase the coverage. (B, D, F, H) Transmembrane helix and topology 
prediction by memsat-svm.  
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Figure 3.9 Three models of IFITM protein transmembrane topology. (A) A type III 
transmembrane topology model which has been proposed based on flow cytometry 
studies. (B) An intramembrane topology with both the N and CTD in the cytosol proposed 
on findings implicated through the availability of enzymes for PTMs. (C) A type II 
transmembrane topology model that has been proposed by Ling et al based on NMR and 
EPR studies of huIFITM3. Figure taken from (Bailey et al., 2014). 
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The protein modelling software generated 4 protein models alongside the membrane 
topologies that were expected given the structure generated (Figure 3.8A-H). The models 
are very similar between the different chIFITMs and suggest that each has a similar 
structure. In a review published in 2014 (Figure 3.9), Bailey et al show three different 
models that are proposed based on the different evidence that has been generated thus 
far. The models generated by Phyre2 most closely resemble a type III transmembrane 
topology and this has also been proposed by a number of other studies (Brass et al., 
2009;Weidner et al., 2010a;Li et al., 2013;Bailey et al., 2013). This model stipulates that the 
NTD of IFITM1 or IFITM3 is located towards the exterior of the membrane in which the 
protein is located. The confidence key generated by the software package suggests that 
there is a high degree of confidence in the transmembrane domains but the N or CTDs have 
low confidence scores which means that it is not possible to draw confident conclusions on 
the locations of these on modelling alone. Further studies are required to strengthen the 
hypothesis that the chIFITM proteins fold in a manner similar to the type III transmembrane 
topology model as is being proposed.  
3.9 Cellular localisation of chIFITM1, 2 and 3 in vitro 
IFITM proteins are constitutively expressed (Smith et al., 2013;Everitt et al., 2013); 
however, IFITM expression can be further enhanced through type I IFN signalling. Human 
and mouse IFITM proteins have been extensively studied, and the localisation of these 
proteins has been well characterised although different groups still report different 
outcomes. Human IFITM1 has been shown to localise both at the plasma membrane and at 
intracellular compartments such as the Golgi apparatus (Weston et al., 2014). Human 
IFITM3 has been shown to consistently form punctate structures at the early/late 
endosomes, co-localising with Rab and Lamp1/2 proteins (Weston et al., 2014;Narayana et 
al., 2015). The localisation of huIFITM2 is more controversial. Some data suggests that 
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huIFITM2 localises to similar compartments as huIFITM3, in puncta at the early/late 
endosomes (Narayana et al., 2015). Other groups report staining in punctate structures 
within the nucleus (Weston et al., 2014). Many studies have reported the possible 
implications of using tagged constructs, although at present tagged constructs remain 
important as antibodies against IFITMs have been reported to cross-react (Zhao et al., 
2014;Weston et al., 2014;Wrensch et al., 2015). In one study it was found that Anti-IFITM1-
NTD antibody detects both IFITM1 and IFITM3, whilst an Anti-IFITM3-NTD antibody detects 
IFITM3 and IFITM2 (Weston et al., 2014). In chickens, the localisation of the chIFITM 
proteins remains largely understudied and the available antibodies are poor. Smith et al, 
2013 showed that chIFITM1 and 2 localised at the plasma membrane, while chIFITM3 
localised at the endosomes (Smith et al., 2013). The only other avian IFITM proteins to have 
been investigated are the duck IFITMs (dIFITMs) (Blyth et al., 2016). In this study it was 
found that dIFITM1 and 3 localise to similar compartments as their mammalian 
counterparts, namely the plasma membrane and late endosomes, respectively. The 
localisation of dIFITM2 and 5 was far less convincing with only partial co-localisation of 
staining observed at the endosomes. It is likely that the localisation and their function is 
linked to the restrictive profile of the IFITM proteins. 
       
To assess the subcellular localisation of chIFITM1, 2 and 3, DF-1 cells were transiently 
transfected with separate expression plasmids containing the chIFITM gene sequences with 
a C-terminal FLAG-tag. DF-1 cells were transfected with 1μg of a plasmid encoding 
chIFITM1, 2 or 3 for 24 hours. Cells were fixed with 4% paraformaldehyde for 10 minutes 
and permeabilised with 0.1% saponin in PBS. Cells were blocked in 1% bovine serum 
albumin (BSA) for 30 minutes. The FLAG epitope was targeted by an anti-FLAG M2 
antibody, followed by incubation with a secondary antibody conjugated to Alexa Fluor 594. 
The plasma membrane was stained with a Pan-Cadherin antibody plasma membrane) and  
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Figure 3.10 Cellular localisation of transiently overexpressed chIFITM proteins in DF-1 
and HD11 cells. (A-D) Confocal microscopy in DF-1 cells transfected with plasmids 
expressing chIFITM1, 2 and 3. Panels show nuclei stained with DAPI (4’, 6-diamidino-2-
phenylindole [blue]), chIFITM protein stained with an antibody against the FLAG-tag 
epitope (red) and the intracellular compartments stained with Pan-Cadherin, Rab-7 or 
Lamp-1 (green) and then merged. 
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the (endosomes were visualized by a Rab7 antibody (late endosomes), and Lamp1 antibody 
(lysosomes) followed by incubation with a secondary antibody conjugated to Alexa Fluor 
488. In DF-1 cells, chIFITM1 did not localise with any particular marker whilst CHIFITM2 
predominantly localised with the plasma membrane, with chIFITM2 co-localising with pan-
cadherin (Figure 3.10A and B). In contrast, there was a perinuclear localisation for 
chIFITM3, consistent with that of huIFITM3 (Figure 3.10C and D).  
 
The localisation of huIFITM1, 2 and 3 has been postulated to have an impact on their 
restrictive profile, with huIFITM3 localising at the endosomes and restricting viruses such as 
IAV, which enter through the acidification of late endosomes (Yoshimura et al., 1982). In 
this part of the chapter, the localisation of transiently overexpressed FLAG-tagged 
chIFITM1, 2 and 3 was examined in DF-1 cells. The data suggests that both chIFITM1 and 2 
predominately localise at the plasma membrane, whereas chIFITM3 failed to localises with 
Rab7, a marker for the late endosomes, or any other marker that was assessed (data not 
shown). Previous data has shown that huIFITM1 has been shown to localise at the plasma 
membrane, whereas huIFITM2 was shown to localise at internal membrane compartments, 
distinct from the observation of chIFITM2 in avian cells. Alignment of the human and 
chicken IFITM2 amino acids sequences reveals that chIFITM2 has an N-terminal truncation, 
lacking the YEML motif (Figure 3.10) and this truncation may explain why chIFITM2 resides 
primarily at the plasma membrane and may impact the restrictive profile of chIFITM2.  
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3.10 Identifying proteins that interact with chIFITM1, 2 and 3 
3.10.1 Mass spectrometry analysis of chIFITM-FLAG immunoprecipitations 
Interacting partners have been identified through a variety of experimental methods such 
as immunoprecipitations, yeast-2-hybrids and biochemical assays. This has resulted in a 
range of cellular factors that have been implicated in binding to the huIFITM proteins and it 
has been hypothesised that these interactions modulate the antiviral phenotype of the 
IFITM proteins. A study published in 2013 demonstrated that huIFITM3 interacts with 
Vesicle-membrane-protein-associated protein A (VAPA) which in turn prevents its 
association with oxysterol-binding protein (OSBP). This interaction disrupts cholesterol 
homeostasis and inhibits viral entry via cholesterol accumulation (Amini-Bavil-Olyaee et al., 
2013). Two further studies found that host cell membranes underwent a loss of fluidity 
after overexpression of huIFITM1 which may be explained by the findings of Amini-Bavil-
Olyaee et al (Li et al., 2013;Lin et al., 2013). In contrast, other studies suggest that IFITM-
mediated viral restriction is not dependent on cholesterol and propose a mechanism 
whereby IFITM3 has an ability to block fusion pore formation at a post-hemifusion stage. It 
is proposed that this process stabilises the cytoplasmic leaflet of endosomal membranes 
either directly or indirectly through proteins/lipid independently of cholesterol (Desai et al., 
2014). In addition, further co-immunoprecipitation studies suggest that ZMPSTE24 can 
interact with members of the huIFITM protein family and the data implies that ZMPSTE24 
expression is essential for IFITM antiviral activity (Fu et al., 2017). These studies 
demonstrate the uncertainty regarding the mechanism of IFITM-mediated restriction, 
although it is possible that more than one mechanism is utilised during infection.     
Mass spectrometry was utilised to identify any interacting partners for chIFITM1, 2 or 3, 
that may help to determine the mechanism of restriction utilised by the chIFITM proteins 
alongside any additional functions that are, as of now, unknown. DF-1 cells were 
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transfected with 1µg chIFITM-FLAG or pFLAG-CMV1 control expression vectors. After 24 
hours, cells were lysed and chIFITM-FLAG or FLAG immunoprecipitation was performed 
using a FLAG Immunoprecipitation Kit (Sigma Aldrich). This assay was completed in 
triplicate for each plasmid, performed on different days. Eluate samples were analysed by 
western blot to confirm successful immunoprecipitation of chIFITM-FLAG (Figure 3.11A). 
Eluates were then sent to the University of Liverpool and were analysed by liquid 
chromatography mass spec/mass spec (LC-MS/MS) by Dr Stuart Armstrong. In total 269, 
230 and 142 proteins were identified in significantly higher levels in the chIFITM1, 2 or 3-
FLAG eluate respectively, compared to the FLAG only control (Appendix, Table 7.1, 7.2 and 
7.3). Proteins were identified by comparing unique peptides to a database of chicken 
proteins. As the chicken genome contains regions of poor coverage, thus poor annotation, 
some sequences were manually mined in order to identify the peptide of interest. In order 
to reduce the chance of misidentification of interacting proteins, proteins where only a 
single unique peptide was identified were removed. For each protein identified, the fold-
change (Log2) in relative abundance was calculated by comparing chIFITM1, 2 or 3-FLAG to 
the FLAG control. The p-value, as determined by two-way ANOVA, was calculated from the 
three independent biological replicates. A p-value above one (-Log10) along with a fold-
change (Log2) above two were considered significant interactions and had the highest 
chance of interacting with one of the chIFITM proteins. For each protein, the confidence 
score (-Log2) was calculated, which is the cumulative value of p; the probability of the 
identified peptide sequence occurring randomly, for each unique peptide identified.   
To reduce the number of significant hits that were identified, further analysis was 
conducted by myself with the aim of isolating peptides that may be involved in chIFITM-
mediated restriction. To prioritise the proteins that were identified, proteins that are  
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Figure 3.11 Immunoprecipitation of chicken cellular proteins after transient chIFITM-
FLAG overexpression. DF-1 cells were transfected with 1µg chIFITM-FLAG or pFLAG-CMV1 
expression vectors. After 24 hours, cells were lysed, and immunoprecipitations performed 
using FLAG ‘capture’ beads. (A) Eluate samples were separated by SDS-PAGE, transferred 
to a nitrocellulose membrane and a western blot performed using an anti-FLAG antibody. 
(B-D) Eluates were then sent to the University of Liverpool and were analysed by liquid 
chromatography mass spec/mass spec (LC-MS/MS) by Dr Stuart Armstrong. Further 
analysis conducted by myself, isolated peptides that were significant (as determined by a 
two-way ANOVA) and may be involved in chIFITM-mediated restriction as determined by 
prior publications. Results are from three biological replicates.    
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ubiquitous and have many cellular functions were discounted. For example, it is known that 
heat-shock proteins (HSP) are ‘sticky’ and are common in mass spectrometry data 
(Mellacheruvu et al., 2013) and therefore were excluded from any further analysis. 
‘Important’ hits were determined by function and if they had been identified by previous 
publications. The final group of interacting proteins (Figure 3.11B - D) are plotted against 
the difference (x-axis) and Log (P-Value) (y axis). Notably, many proteins were identified 
that have been implicated in huIFITM-mediated restriction via modulating cholesterol/lipid 
biosynthesis: Stearoyl-CoA Desaturase (SCD), Sterol O-Acyltransferase (Acyl-Coenzyme A: 
Cholesterol Acyltransferase) (SOAT1) and Vesicle-Associated Membrane Protein-Associated 
Protein B/C (VAPB). Moreover, Signal Transducer And Activator Of Transcription 3 (STAT3) 
was identified and this acts as a transcription activator after IFN activation. As these 
proteins are involved in processes known to be important for huIFITM-medaited restriction, 
alongside their association with more than one chIFITM peptide, they were deemed 
suitable candidate proteins for further investigation.   
3.10.2 Co-immunoprecipitations of interacting partners identified through mass 
spectrometry  
In order to confirm if these proteins were interacting with chIFITM1, 2 and/or 3, co-
immunoprecipitations were performed in DF-1 cells. Cells were transfected with the 
required constructs depending on whether the interacting protein has been identified by 
mass spectrometry. DF-1 cells were co-transfected with 1µg chIFITM-FLAG and SCD-MYC or 
STAT3-MYC expression vectors and after 24 hours the cells were lysed. In order to identify if 
the proteins of interest had expressed, the crude cell lysates were separated by SDS-PAGE, 
transferred to a nitrocellulose membrane and a western blot performed using an anti-FLAG 
or anti-MYC antibody, alongside a β-actin loading control. The western blots of the cell 
lysates demonstrate that each of the chIFITMs, SCD and STAT3 expressed well and this 
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Table 3.3 Function and localisation of proteins classified as significant interacting partners 
for chIFITM1, 2 and/or 3. 
Protein 
ID 
Protein Name Function Cellular Localisation 
SCD Stearoyl-CoA Desaturase  Enzyme involved in fatty 
acid biosynthesis 
Endoplasmic Reticulum  
SOAT1 Sterol O-Acyltransferase 
(Acyl-Coenzyme A: 
Cholesterol 
Acyltransferase)  
Catalyzes the formation of 
fatty acid-cholesterol 
esters 
Endoplasmic Reticulum  
STAT3 Signal Transducer And 
Activator Of Transcription 
3  
After activation 
translocate to the cell 
nucleus where they act as 
transcription activators 
Cytoplasm/Nucleus 
VAPB Vesicle-Associated 
Membrane Protein-
Associated Protein B/ 
Involved in vesicle 
trafficking 
plasma and intracellular 
vesicle membranes 
 
is evidenced by the strength of the bands present. In contrast, in the negative control there 
was no protein expression in the DF-1 cell lysates and this confirms that the antibodies only 
bind to their specific epitopes and not to cellular proteins. (Figure 3.12). The β-actin loading 
control was present at equitable levels in all of the samples that were assayed.  
In order to blot for interacting proteins, cell lysates underwent immunoprecipitation and 
were incubated with FLAG ‘capture’ beads overnight. These beads were separated, washed 
three times with co-IP wash buffer and protein-antibody complexes eluted from the beads 
using a 3x FLAG peptide via the process of competition elution. The eluate samples were 
separated by SDS-PAGE, transferred to a nitrocellulose membrane and detected with anti-
FLAG and anti-MYC. Bands corresponding to the molecular weights of STAT3 and SCD were 
present in the elutes, which suggests that STAT3 and SCD interact with chIFITM1, 2 and 3. 
This is an interesting observation as SCD-chIFITM1/3 interactions were not identified in the 
initial mass spectrometry results. Moreover, it was not possible to clone SOAT1 or VAPB, 
therefore, it is not possible to draw any conclusions about the interaction of this protein  
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Figure 3.12 Co-Immunoprecipitation of interacting proteins with chIFITM1, 2 or 3. DF-1  
cells were co-transfected with 1µg chIFITM-FLAG and SCD-MYC or STAT3-MYC expression 
vectors. After 24 hours, cells were lysed, and immunoprecipitations performed using FLAG 
‘capture’ beads. (A) Crude cell lysates and eluate samples were separated by SDS-PAGE, 
transferred to a nitrocellulose membrane and a western blot performed using an anti-
FLAG or anti-MYC antibody, alongside a β-actin loading control.  
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with chIFITM1 and 2. This data implies that STAT3 interacts with chIFITM1, 2 and 3 and may 
play a role in chIFITM-mediated restriction, especially considering that its interactions are 
not limited to a specific chIFITM. Moreover, this data may strengthen the mechanism 
postulated by Amini-Bavil-Olyaee et al as it is known that SCD is involved in lipid 
biosynthesis. This may imply that the recruitment of cholesterol may also be important in 
mediating chIFITM viral restriction although further investigation is required.   
3.11 Discussion 
The use of two different next generation sequencing methods, PacBio and MiSeq, 
significantly increased the coverage across the chIFITM locus and resulted in the generation 
of a contiguous sequence across this region. By utilising both PacBio and MiSeq sequencing, 
it was possible to generate a de novo assembly that was an improvement over v4 and v5 of 
the genome that were available at the time of publication (Bassano et al., 2017). In addition 
to sequencing of the IFITM locus for the reference genome (Gallus gallus v5), the locus was 
also sequenced in three chicken cell lines using a novel pull down approach that captures 
and enriches the DNA within the target sequence (Figure 3.7). Using this approach, 
excellent coverage of the IFITM locus was obtained in each cell type, suggesting that the 
DNA pull down probes, developed specifically to target this region, were successful in 
targeting the region in different cell lines that are routinely used in the laboratory. The 
majority of the sequence variation that was observed in the different cell lines was found 
within the NCR or intergenic regions and it is not clear from our findings if this variation will 
have any impact on gene expression or regulation. The coding SNPs within chIFITM1 and 3 
are synonymous mutations, thus it is likely that they would not have an effect on the 
function of the protein. The chicken cell lines were sequenced in order to examine the 
effectiveness of the assays and reagents that were developed to study different aspects of 
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the chIFITM locus. The data presented in this chapter demonstrates that the reagents can 
be used across all of the cell lines that have been sequenced. 
It is important to recognise that the nomenclature used for identifying the different 
chIFITMs is problematic as the sequence identity between chicken and human IFITM 
proteins is low (Table 3.1). However, for consistency, the nomenclature that was first 
described in a study published in 2013 by Smith et al has been used throughout this thesis. 
The genetic divergence of these genes between avian and mammalian species suggest that 
they are undergoing both positive selection and purifying selection due to regions of the 
genes that remain conserved. Smith et al also identified that the direction of transcription 
of chIFITM1 and 2 was opposite when compared to their mammalian counterparts. It is 
unknown if the chIFITM locus has undergone any further modifications including gene 
duplication and inversion with further research necessary. As further characterisation of 
the restrictive profile of each chIFITM continues, the nomenclature used to identify 
members of this family may be redefined. At present, the current system of naming the 
chIFITMs based on synteny with the human locus (on chromosome 11) provides the best 
solution to this problem; rather than re-naming them based on possible functions that have 
yet to be fully elucidated.    
To investigate the basal levels of chIFITM mRNA expression, nineteen tissues from 3 RIR 
chickens at 3 weeks of age, 3 chicken cell lines (DF-1, HD11 and OU-2) and two ex vivo cell 
cultures (CEF and CKC) were evaluated by quantitative RT-PCR (Figures 3.4 and 5). 
Intriguingly the patterns of chIFITM mRNA expression between each tissue analysed were 
broadly similar. The mRNA expression of chIFITM2 and 3 were consistently higher in 
comparison to chIFITM1 and 5. Moreover, there was greater variability in mRNA expression 
levels for chIFITM1 and 5, with higher levels of transcripts observed in the gastro intestinal 
tract and immune tissues such as the caecal tonsil, and lower levels in pancreas, skin and 
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muscle. This pattern of variable mRNA expression was also observed in each of the cell lines 
studied. The differential expression of the chIFITMs may suggest that some of the genes are 
more tightly regulated and this may be important in the context of viral infection and 
innate immunity.  
The cellular localisation of huIFITM1, 2 and 3 has been postulated to have an impact on 
their restrictive profile, although not all studies agree on the exact localisation of these 
proteins (Weston et al., 2014;Narayana et al., 2015). Studies have shown that huIFITM3 
localises to the endosomes and this is important for the restriction of viruses such as IAV, 
which enter through the acidification of late endosomes (Yoshimura et al, 1982). In this part 
of the chapter, the localisation of transiently overexpressed FLAG-tagged chIFITM1, 2 and 3 
in DF-1 and HD11 cells was examined. This study shows that both chIFITM1 and 2 
predominately localise at the plasma membrane, whereas chIFITM3 localises with Rab7, a 
marker for the late endosomes. It has been shown that huIFITM1 localises to the plasma 
membrane, whereas huIFITM2 localise at internal membrane compartments, distinct from 
our observations of chIFITM2 in avian cells (Figure 3.9). This finding is supported by data 
published in 2016 where dIFITM2 localisation was different to huIFITM2 with weak 
localisation within the endosomal compartments (Blyth et al., 2016). This data is also 
consistent with data published by Smith et al where staining of chIFITM2 is predominantly 
at the plasma membrane (Smith et al., 2013). Alignments of human, chicken, duck and 
turkey IFITM2 amino acids sequences reveals that chIFITM2 has an N-terminal truncation, 
lacking the YEML motif (Figure 3.6) which interacts with the μ2 subunit of AP-2 complex 
and targets the protein for internalisation via clathrin-mediated endocytosis (Jia et al, 
2014). This truncation might explain why chIFITM2 resides primarily at the plasma 
membrane and may impact on the restrictive profile of chIFITM2.  
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Trying to identify the mechanism of action for the huIFITM proteins has been difficult and 
there are still many hypothesises that have yet to be definitively proven. In brief, there are 
two main mechanisms that have been proposed, one where the lipid composition affects 
the membrane rigidity of membrane-bound compartments (Amini-Bavil-Olyaee et al., 
2013;Li et al., 2013;Lin et al., 2013) and another where there is a physical interaction with 
the membrane, independent of the lipid composition of the membrane (Desai et al., 2014). 
The data presented in this chapter appears to support the hypothesis of lipid metabolism 
and the role of cholesterol in the restriction of viruses by IFITM-mediated restriction 
(Figures 3.11 and 3.12). Genes encoding enzymes involved in lipid biosynthesis and 
metabolism, such as SCD and SOAT1, have been identified by mass spectrometry and 
interactions between SCD and chIFITM1, 2 and 3 have been confirmed by co-
immunoprecipitation. Moreover, a protein involved in interferon signalling, STAT3, has 
been identified and this may suggest that the mechanisms involved are more complex than 
initially envisaged. In addition, VAPB was identified as interacting with chIFITM1 and 2 and 
this may provide further evidence that these two proteins are localised towards the plasma 
membrane. VAPB is known to dimerise with VAPA and both are involved in vesicular 
trafficking which occurs at the plasma membrane. VAPB was not identified as an interacting 
partner of chIFITM3, a protein found at the endosomes.  
Taken together, the data presented in this chapter demonstrates a much clearer 
understanding of the chIFITM locus and its architecture. Moreover, details regarding 
chIFITM localisation, basal expression, protein topology and interacting partners have also 
been elucidated. This data will help inform concepts surrounding the mechanism of 
chIFITM-mediated restriction. Furthermore, our data demonstrates that despite low 
sequence identity, conserved domains, basal expression and conserved interacting partners 
all suggest that the function of these proteins are similar to their mammalian counterparts.   
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4.1 Introduction 
Viruses are dependent on host cells for a number of critical processes during the course of a 
productive infection. As intracellular parasites they are not capable of independent 
replication, thus they hijack components of the cellular machinery. Cells do not act as idle 
bystanders during this process and initiate an innate antiviral response. Type I and II 
interferons (IFNs) are critical in controlling viral infection by activating a cell-intrinsic anti-
viral state (Schultz et al., 1995a;Schultz et al., 1995b;Sekellick et al., 1998). This is achieved 
by the transcriptional activation and modulation of over 500 genes, collectively known as 
interferon stimulated genes (ISGs) (Schneider et al., 2014). Invading viral pathogens are 
identified by specialised intracellular pattern recognition receptors (PRRs) through the 
detection of pathogen associated molecular patterns (PAMPs) (Mogensen, 2009). Non-host 
cell derived nucleic acids such as dsRNA can elicit a systemic IFN response (Weber et al., 
2006), alongside other structures present on ssRNA viral genomes such as 5’ triphosphate 
groups (Veit Hornung et al., 2006;Pichlmair et al., 2006). Mammalian IFITMs, as ISGs, are 
known to be highly upregulated once viral infection has been initiated (Li et al., 2017). This 
upregulation is a critical step in restricting viral replication, reducing the burden of disease 
in the host.  Numerous studies have shown that human IFITM (huIFITM) and mouse ifitm 
(mifitm) expression can reduce viral replication by several orders of magnitude when 
compared to control samples (Brass et al., 2009;Foster et al., 2016;Lu et al., 2011). 
Currently, little is known about the expression of chIFITMs or how they are regulated. 
Therefore, in this project, chIFITM expression, after treatment with type I and II interferons, 
a synthetic dsRNA mimic poly(I:C) and lipopolysaccharide (LPS) was investigated. The effect 
of viral infection in vitro, in ovo and in vivo with a diverse range of avian viral pathogens on 
chIFITM and Mx, expression was also examined. Mx, a gene that is highly upregulated in 
response to viral infection, has been used as a positive control throughout these studies. 
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4.2 The modulation of chIFITM expression through type I and II 
interferons 
The responsiveness of chicken cells to type I and II interferons has been well documented in 
the literature, but data is often limited to the particular gene of interest. Datasets from 
broad ranging microarrays or RNA sequencing experiments can mask genes with small 
induction profiles, resulting in these genes being overlooked (de Veer et al., 
2001a;Schoggins et al., 2011;Giotis et al., 2016). In addition, microarrays only investigate 
genes present on the array and the chIFITMs were often not included due to their incorrect 
annotation in chicken genome. This has left a gap in the literature regarding the modulation 
of chIFITM expression through treatment with type I and II interferons. Furthermore, little 
has been published about specific chIFITM expression through any mechanism. Two studies 
have examined the response of chicken fibroblast cells to IFNα stimulation, with one of 
these studies also utilising a second type II interferon, IFNγ (Smith et al., 2013;Okuzaki et 
al., 2017). Smith et al examined the responsiveness of DF-1 cells to IFNα and γ and found 
that there was a modest induction in chIFITM3 expression after treatment with IFNα (2.5 
fold higher than mock) and no induction with IFNγ treatment (Smith et al., 2013). The 
second study primarily focused on chIFITM10 induction in CEF cells but found that in the 
presence of IFNα, there was an increase in chIFITM2 expression but no significant 
upregulation in chIFITM10 expression (Okuzaki et al., 2017). Poly(I:C) is a synthetic 
analogue of  dsRNA which is a potent activator of interferon production (Talal, 1971). Many 
viruses produce dsRNA as a replicative intermediate and this product modulates the 
activation of interferon during viral infection (Field et al., 1967;Colby and Duesberg, 
1969;Hilleman, 1970). Poly(I:C) is therefore a useful tool for evaluating gene modulation in 
response to faux viral replication.  
Chapter 4: Characterising chIFITM expression 
160 | P a g e  
 
The effect of poly(I:C) stimulation (a proxy for the effects of viral infection) on chIFITM 
expression was assessed in three chicken cell lines (Figure 4.1). An aliquot of 500ng of HMW 
poly(I:C) was added passively to the cell culture medium and samples were harvested 6 
hours later. The RNA from these samples was extracted, reverse transcribed and RT-PCR 
was performed to calculate the relative fold change, relative to a mock control and 
normalised to three optimized/stable house-keeping genes, β-actin, RPLPO and RPL13. The 
three cell lines induced chIFITM expression differentially, with OU-2 and HD11 cells 
appearing to be more responsive to poly(I:C) stimulation than DF-1 cells.  DF-1 cells treated 
with poly(I:C) resulted in a significant upregulation in chIFITM1 (4.9 fold), 3 (2.3 fold) and 
Mx (9.9 fold) expression (Figure 4.1A). Conversely, chIFITM2, 5 and 10 expression was 
similar to, or below, the levels observed in the mock control. In contrast, much higher levels 
of expression were observed in HD11 and OU-2 cells, with the fold change for all genes 
tested being above the level of basal expression. The relative fold change for chIFITM1 
(11.7 fold), 2 (2.3 fold), 3 (8.1 fold), 10 (2.3 fold) and Mx (40.3 fold) were significantly higher 
than the mock control in HD11 cells (Figure 4.1B). Furthermore, even though chIFITM5 
expression failed to reach statistical significance there was a general trend of upregulation 
following poly(I:C) treatment. Similarly, a significant upregulation in chIFITM1 (2.4 fold), 2 
(5.2 fold) and Mx (11.94 fold) gene expression was observed in OU-2 cells (Figure 4.1C).  
Consistently higher levels of chIFITM gene expression in HD11 cells suggests that these cells 
are more sensitive to poly(I:C) treatment than the other cell lines that were tested and 
would be a suitable cell line to use for further characterisation.  
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Figure 4.1 Determining responsiveness of chicken cell lines to treatment with poly(I:C). 
(A – C) Three chicken cell lines (DF-1, HD11 and OU-2) were treated with 500ng of 
poly(I:C) for 6 hours. These samples were then used in quantitative RT-PCR to assess the 
upregulation of chIFITM and Mx mRNA levels which were normalised to a mock control 
and three house-keeping genes, β-Actin, RPLPO and RPL13. Error bars show standard 
deviations of the means (n =3 biological replicates), * indicates a p-value <0.05, ** 
indicates a p-value <0.01, *** indicates a p-value <0.001, students t-test. 
A B 
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Although poly(I:C) is a good proxy for the replicative intermediates of viral replication, it is  
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Figure 4.2 IFNβ quantification after stimulation of HD11s by IFN agonists. (A) HD11 
cells were treated with IFN agonists and IFNβ promoter activity was quantified by 
relative luminescence from a luciferase reporter normalised to a Renilla and an 
empty vector control. (B) The same samples were then assayed via western blot to 
assess the chIFNα protein levels using an antibody specific to chIFNα as well as 
cellular β-actin. (C) HD11 cells were transfected with pcDNA3.1 or pEGFP-N1 (D) 
and were examined under a fluorescent microscope to assess cell line transfection 
efficiency.  Error bars show standard deviations of the means (n =3 biological replicates), * 
indicates a p-value <0.05, student’s t test. 
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Figure 4.3 IFITM and Mx Induction in HD11s after stimulation with IFN agonists. (A) HD11 
cells were treated with IFN agonists and Mx promoter activity was quantified by relative 
luminescence from a luciferase reporter normalised to Renilla and an empty vector control.  
(B-F) The same samples were then used in quantitative RT-PCR to assess the upregulation of 
chIFITM mRNA levels which where normalised to a mock control and three house-keeping 
genes, TBP, PLA2 and β2M. Error bars show standard deviations of the means (n =3 
biological replicates), * indicates a p-value <0.05, ** indicates a p-value <0.01, *** indicates 
a p-value <0.001, Student’s t test. 
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Although poly(I:C) is a good proxy for the replicative intermediates of viral replication, it is 
not possible to elucidate the type of interferon that is primarily responsible for chIFITM 
induction. To examine the suitability of HD11 cells for promoter reporter assays, they were 
co-transfected with pGL3-P-chIFN-β-luc and a plasmid constitutively expressing Renilla 
(internal control) for 24 hours. After 24 hours the same cells were stimulated by passively 
adding 2000U/ml-1 chicken rIFNα, 50μl of chicken IFNβ/IFNγ cell supernatants from stably-
expressing COS cells or 500ng of HMW poly(I:C) to the cell culture medium. After 24 hours 
the cells were lysed and samples were assayed for firefly and Renilla luciferase activity. 
IFNβ promoter activity was highest with poly(I:C) and IFNγ stimulation and these reached 
statistical significance when compared to an empty vector control (Figure 4.2A). Type I IFN 
expression was confirmed by western blot (α-IFNα) in the poly(I:C) treated sample (Figure 
4.2B). This confirms that promoter activity as well as protein levels are increased. IFNα 
expression was not detected in any of the other samples that were assayed, including the 
vector only background control. The transfection efficiency of HD11 cells was determined 
by transfecting equal concentrations (500ng) of either pcDNA3.1 (Figure 4.2C) or pEGFP-N1 
(Figure 4.2D) and using GFP expression as a read out for total protein expression. The 
transfection efficiency of HD11 cells was approximately 80%, and taken together with the 
IFNβ promoter reporter activity and western blot, suggest that HD11 cells were a suitable 
cell line to continue to elucidate the mechanism of chIFITM upregulation.      
Having confirmed that HD11s can elicit an effective IFNβ response, the effects of IFN 
agonists on ISG expression was assessed using an Mx reporter assay as a positive control. 
Previous studies have shown that Mx is upregulated upon stimulation with a range of 
interferon agonists, primarily poly(I:C) (Li et al., 2012;Harada et al., 2007). Treatment with 
2000U/ml-1 rIFNα, 50μl of IFNβ/IFNγ cell supernatants from stably-expressing COS cells or 
500ng of HMW poly(I:C) resulted in elevated levels of Mx promoter activity, as shown by 
the RLU values, normalised to a Renilla control (Figure 4.3A). The levels of Mx expression 
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varied, with statistically significant inductions observed with the addition of poly (I:C), IFNα 
and IFNγ. There was an increase in promoter activity after stimulation with IFNβ but this 
was not statistically significant. In order to quantify chIFITM and Mx upregulation, the same 
samples were analysed by quantitative RT-PCR, relative to the mock control and normalised 
to three selected house-keeping genes, TBP, PLA2 and β2M (Figure 4.3B – F). The data 
generated from this experiment suggests that there are universal up-regulators of IFITM 
expression, namely IFNα and poly(I:C). These two agonists consistently enhanced the 
expression of all four chIFITMs and the Mx positive control, reaching significance for 
chIFITM3 and chIFITM5. Furthermore, the magnitude of upregulation varied between 
chIFITMs which may be related to their function. Interestingly, IFNα elicited a greater 
induction of chIFITM expression compared with the other type I interferon, IFNβ. Many 
studies have examined the effect of adding exogenous type I interferon to cell cultures and 
in agreement with these findings, have concluded that IFNα is the more potent type I 
interferon (Qu et al., 2013). Previous studies have found that huIFITM5 does not act as an 
ISG, but is involved in bone mineralisation (Moffatt et al., 2008). Notably, this does not 
appear to be the case for chIFITM5 as there is a significant upregulation in chIFITM5 
expression after treatment with IFN and poly(I:C). Mx was significantly upregulated with 
all of the agonists that were tested. Treatment with IFNγ, a type II IFN, resulted in a 
relatively modest induction of chIFITM3 and Mx. This suggests that type II IFNs are able to 
elicit chIFITM induction, but are not the principal activators of chIFITM expression.  
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4.3 Treatment of chicken cells with lipopolysaccharide (LPS) does not 
induce chIFITM expression 
The qPCR data shown in Figure 4.3B-F demonstrates the ability of type I interferons and the 
synthetic dsRNA poly(I:C) to elicit an effective chIFITM response. The data summarising the 
response of human and mouse IFITMs during bacterial infection is unclear. In an ifitm3-/- 
mouse model, they find no statistical difference in the disease phenotype when mice are 
infected with either Salmonella typhimurium, Citrobacter rodentium, or Mycobacterium 
tuberculosis (MTb) when compared to a wildtype control (Everitt et al., 2013). However, 
work published on MTb in human monocytic and alveolar/epithelial cells suggests that not 
only are huIFITM1, 2 and 3 upregulated, but they also play a role in restricting bacterial 
infection (Ranjbar et al., 2015). To date, there is no evidence that bacteria or the endotoxin 
lipopolysaccharide (LPS) induces an effective chIFITM response. The effect of LPS on 
chIFITM expression was tested in two chicken cell lines; HD11 cells that are known to be 
highly sensitive to LPS treatment (Qi et al., 2017) and DF-1 cells where the data is unclear as 
to whether LPS treatment is effective in inducing effector genes such as the 
proinflammatory cytokine interleukin 6 (IL-6). After treatment with 5µg/ ml-1 of LPS for 4 
hours, DF-1 and HD11 cells were then lysed, total RNA was extracted and reverse 
transcribed into cDNA and analysed by quantitative RT-PCR. Treatment of DF-1 cells with 
LPS did not result in the upregulation of any of the genes that were tested, including the 
positive control, IL-6 (Figure 4.4A). In contrast, there was a significant upregulation in IL-6 
mRNA abundance in HD11 cells (Figure 4.4B). It appears that chIFITM and Mx expression in 
HD11 cells is actively downregulated as a result of LPS treatment. Moreover, chIFITM5 
mRNA was not detected in those samples that underwent LPS treatment. 
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Figure 4.4 IFITM, IL-6 and Mx Induction in DF-1 and HD11 cell after LPS treatment. (A) 
DF-1 and (B) HD11 cells were treated with 5µg/ml-1 LPS for 4 hours and were then used in 
quantitative RT-PCR to assess the upregulation of chIFITM, IL-6 and Mx mRNA levels 
which where normalised to a mock control and two house-keeping genes, RPLPO and β-
actin. Error bars show standard deviations of the means (n =3 biological replicates), **** 
indicates a p-value <0.0001, student’s t test. n.d. = not detected. 
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In order to assess the sensitivity of DF-1 cells to a variety of stimuli, an activator of protein 
kinase C (PKC), phorbol 12-myristate 13-acetate (PMA), was added passively to the media 
of DF-1 cells alongside samples treated with either LPS or poly(I:C). The aim of this 
experiment was to assess if DF-1 cells had an intact NF-κB signalling pathway. This was 
visualised by immunofluorescence using an antibody raised against P65 (an essential 
transcription factor complex) which, when activated, should translocate into the nucleus 
(Figure 4.5).  The transcription factor P65 is an essential component of NF-κB signalling and 
has functions that include NF-κB heterodimer formation, nuclear translocation and 
subsequent activation of the complex. In untreated cells, P65 is located both in the 
cytoplasm and nucleus (Figure 4.5A) and several posttranslational modifications are 
required before it becomes active and is translocated into the nucleus. Treatment of DF-1 
cells with PMA and LPS results in the translocalisation of P65 from the cytoplasm to the 
nucleus which indicates that P65 is now active (Figure 4.5B and C). Treatment of DF-1 cells 
with poly(I:C) did not considerably alter the cellular distribution of P65 which was 
predominantly located within the cytoplasm (Figure 4.5D). 
To assess if the abundance of P65 was altered after treatment with either PMA, LPS or 
poly(I:C), DF-1 cells were treated with 1ug/ml-1 of the aforementioned agonists for 4 hours 
(or mock treated). The cells were then lysed, proteins separated by SDS-PAGE and 
transferred onto nitrocellulose membranes. Western blots were performed using a P65 
antibody alongside β-actin. The western blot showed that levels of P65 did not change with 
treatment and were comparable with levels seen in the mock control. This data suggests 
that DF-1 cells have an active NF-κB signalling pathway, with P65 translocating into the 
nucleus after treatment with LPS. ChIFITM, IL-6 and Mx transcript abundance did not 
increase after treatment with LPS in this cell type (Figure 4.4A).  Therefore it is not clear as 
to why treatment of DF-1 cells with LPS did not increase levels of IL-6 mRNA. 
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Figure 4.5 Cellular distribution and protein abundance of P65 when DF-1 cells are 
stimulated with PMA, LPS and poly(I:C).  (A-D) Confocal microscopy of DF-1 cells treated 
with 1ug/ml-1 PMA, 1ug/ml-1 LPS, 1ug/ml-1 poly(I:C) or mock stimulated with PBS for 4 
hours. Panels show nuclei stained with DAPI (4’, 6-diamidino-2-phenylindole [blue]), 
cellular P65 stained with an antibody against P65 (green) and then merged. (E) DF-1 cells 
were treated with 1ug/ml-1 PMA, 1ug/ml-1 LPS, 1ug/ml-1 poly(I:C) or mock treated for 4 
hours. Lysates were separated by SDS-PAGE and proteins were transferred to a 
nitrocellulose membrane and a western blot performed using an antibody specific 
to P65 as well as cellular β-actin.  
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4.4 Differential chIFITM expression when chicken cells are infected 
with a diverse range of avian viruses 
4.4.1 Influenza A Virus (IAV) infection induces chIFITM expression in ex vivo cell 
cultures  
Many studies have investigated the role that human and mouse IFITMs play in the 
restriction of IAV. Extensive investigations in human cell culture models and in vivo, utilising 
ifitm3-/- mice, have conclusively demonstrated that IAV is potently restricted (Everitt et al., 
2012;Bailey et al., 2012;Desai et al., 2014). There is currently limited published data on 
chIFITM expression in IAV infected cells, both in vitro and in vivo. One publication that 
examined chIFITM and duck IFITM (dIFITM) expression in high pathogenicity avian influenza 
(HPAI) (H5N1) infected lung and ilium samples, found that the chIFITMs were only modestly 
upregulated in comparison with the corresponding dIFITMs. Moreover, infection with LPAI 
(H5N2) led to no overall changes in chIFITM expression (Smith et al., 2015). To examine 
what affect IAV infection has on chIFITM expression, ex vivo cell culture models were 
utilised alongside an enzootic strain of IAV (A/chicken/Pakistan/UDL-01/08 [H9N2]) and two 
other representative strains (A/duck/Ukraine/63 [H3N8] and A/duck/sing-Q/119/97 
[H5N3]).     
Chicken embryonic fibroblasts (CEFs) were infected over a 24 hour time course with H9N2 
at a multiplicity of infection (MOI) of 3 and time points were taken at 2, 4, 6, 8, 12 and 24 
hours post infection. The cells were lysed, RNA extracted and reverse transcribed and 
chIFITM expression levels were assessed by quantitative RT-PCR, relative to mock and 
normalised to two house-keeping genes, RPLPO and RPL13. Infection of CEFs with H9N2 
lead to a significant upregulation in chIFITM1 expression at 4 hours post infection and that 
continued until 24 hour post infection (Figure 4.6A). The upregulation of chIFITM2, 3 and 5  
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Figure 4.6 Infection of CEFs with H3N8, H5N3 and H9N2 upregulates the expression of 
the chIFITMs. The expression level and log fold change of chIFITM1, 2, 3, 5 and Mx were 
measured using quantitative RT-PCR after infection with H9N2 (A), H3N8 (B) or H5N3 (C) 
IAV (MOI 3) in CEFs, normalised to house-keeping genes, RPLPO and RPL13. Error bars 
show standard deviations of the means (n =3 biological replicates), * indicates a p-
value <0.05, ** indicates a p-value<0.01, *** indicates a p-value <0.001, 
****indicates a p-value <0.0001, students t test. 
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showed a similar, but lower level of upregulation over the time course, although 
upregulation of chIFITM5 reached significance at 6 and 24 hours post infection. CEFs were 
also infected with two further strains of IAV (H3N8 and H5N3) at the same MOI for 24 
hours. Time points were taken at 2, 6, 12 and 24 hours post infection. The cells were lysed, 
RNA extracted and reverse transcribed and chIFITM and Mx expression levels were 
assessed by quantitative RT-PCR, relative to mock and normalised to two house-keeping 
genes, RPLPO and RPL13. Similar to what was observed for H9N2; there are significant 
increases in chIFITM expression at each time point that was examined. After infection with 
H3N8 there were significant increases in chIFITM expression that began at 6 hours post 
infection for chIFITM2, 3 and Mx (Figure 4.6B). At 12 hours post infection both chIFITM2 
and 3 were significantly upregulated, although there was a decrease in Mx expression 
which resulted in a loss of significance over the mock control. At 24 hours post infection 
chIFITM1, 3, 5 and Mx were significantly upregulated. CEFs were also infected with H5N3 
and quantitative RT-PCR was performed on samples that were taken at the time points 
indicated (Figure 4.6C). Infection with H5N3 lead to a significant upregulation in chIFITM1, 
2, 3, 5 and Mx expression at 6 hours post infection that continued 24 hours post infection. 
Mx is a well-known ISG that is highly upregulated in response to IAV, amongst other viral 
infections (Staeheli et al., 1986). For the purposes of these experiments, Mx was used as a 
positive control except for samples infected with H9N2 due to the constraints of the 
experimental protocol (Figure 4.6A). 
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Figure 4.7 Infection of CEFs with H9N2 upregulates the expression of the chIFITMs. (A) 
CEFs were infected with H9N2 at an MOI 3 for 24 hours. The cells were then fixed and 
immunohistochemistry performed with a monoclonal antibody against NP. (B-D) CEFs 
were mock infected or infected with H9N2. Cells were lysed at 2, 4, 6, 12 and 24 hours 
post infection and lysates were separated by SDS-PAGE. Proteins were transferred to a 
nitrocellulose membrane and a western blot performed using specific mono or polyclonal 
antibodies raised against chIFITM1, 2 and 3 with β-actin as the loading control. 
Densitometry of relative protein expression was performed, normalised to anti-β-actin.  
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Using immunohistochemistry and a monoclonal antibody against the nucleoprotein (NP) of 
IAV (Figure 4.7A), the infection efficiency of H9N2 was determined on CEFs mock infected 
or infected with H9N2 for 24 hours at an MOI - 3. The infection reached 100% of the cells 
within the 24 hour period. No cells in the mock infected group were positive for the NP, nor 
was there any background fluorescence detected. In agreement with the quantitative RT-
PCR data, we observed an increase in chIFITM1, 2 and 3 protein levels, with the greatest 
increase observed at 12 hours post infection (Figure 4.7B-D). chIFITM1, 2 and 3 protein 
levels were elevated at 2 hours post infection but subsequently decreased at 4 and 6 hours 
post infection. In a biphasic manner, protein levels increased again at 12 hours post 
infection before subsiding again at 24 hours post infection. Protein levels at 24 hours post 
infection for chIFITM2 and 3 fell below the level observed for mock infection, while protein 
levels for chIFITM1 remained higher.  This suggests that these IFITMs are not only highly 
upregulated at a transcript level but protein translation is also increased as a result of 
infection with IAV, and appears to be tightly regulated. However, due to ongoing issues 
with antibody production it is not possible to repeat this experiment.  
4.4.2 Infectious bronchitis virus (IBV) infection induces chIFITM expression in ex 
vivo cell cultures  
Several studies have shown that huIFITMs potently restrict coronaviruses such as severe 
acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) (Huang et 
al., 2011;Zhao et al., 2018). Furthermore, as well as demonstrating restriction, studies also 
examine the mode of action of huIFITMs to restrict coronaviruses, concluded to be 
mediated via a cholesterol-independent mechanism (Wrensch et al., 2014). In contrast 
there are no current publications that study chIFITM in the context of coronaviruses that 
infect poultry, namely the prototypic gamma-coronavirus, infectious bronchitis virus (IBV). 
In order to fill this gap in the literature, chIFITM upregulation in the context of IBV infection  
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Figure 4.8 Infection of CK cells with BeauR, M41 and QX upregulates the expression of 
the chIFITMs. (A-E) The expression level and log fold change of chIFITM1, 2, 3 , 5 and Mx 
were measured using quantitative RT-PCR after infection with BeauR, M41 and QX (MOI 1) 
in CK cells, normalised to house-keeping genes, RPLPO and RPL13. Error bars show 
standard deviations of the means (n =3 biological replicates), * indicates a p-value 
<0.05, ** indicates a p-value<0.01, *** indicates a p-value <0.001, ****indicates a 
p-value <0.0001, one-way ANOVA. 
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was studied in a primary ex vivo tissue culture model.  Chick kidney (CK) cells were infected 
over a 24 hour time course with three strains of IBV that have different pathogenicities and 
tissue tropisms. These comprised a tissue culture attenuated strain (BeauR), a pathogenic 
field strain (M41) and a virulent nephropathogenic strain (QX) with time points taken at 2, 
6, 12 and 24 hours post infection. The cells were lysed, RNA extracted, reverse transcribed 
and chIFITM and Mx mRNA expression levels were assessed by quantitative RT-PCR, relative 
to mock and normalised to two house-keeping genes, RPLPO and RPL13. Levels of chIFITM1 
mRNA transcript abundance differed significantly from each other when CK cells were 
infected with these different strains of IBV (Figure 4.8A). At 2 hours post infection there 
was a large, but not significant, increase in the relative fold change in BeauR and QX 
infected samples, but not for cells infected with M41. This affect was lost for BeauR 
infected cells at 6 hours post infection and levels of chIFITM1 expression in BeauR and M41 
infected cells remained similar for all the time points that were assessed after 6 hours post 
infection. In comparison, levels of chIFITM1 transcript abundance were much higher in QX 
infected cells and there was a significant upregulation starting at 6 hours post infection and 
continuing through to 24 hours post infection. chIFITM1 expression was broadly similar for 
all strains at 24 hours post infection. A similar pattern of upregulation was observed across 
all of the chIFITMs, with a stepwise increase in chIFITM and Mx expression over time. In 
agreement with chIFITM1, QX infected cells had a higher level of chIFITM expression at 
earlier time points in comparison with both BeauR and M41 infected cells. Significant 
increases in chIFITM2 and 3 expression were seen at 12 hours post infection when cells 
were infected with the QX strain. A significant upregulation of chIFITM2 and 3 expression 
was observed at 24 hours post infection in all samples, irrespective of the virus used. The 
pattern of chIFITM5 expression was similar to that observed for chIFITM1 (Figure 4.8D). 
chIFITM5 expression was significantly upregulated in QX infected cells, starting at 6 hours 
post infection and continuing throughout the time course. chIFITM5 expression in BeauR 
Chapter 4: Characterising chIFITM expression 
177 | P a g e  
 
and M41 infected samples also reached significance at 24 hours post infection. The 
upregulation of chIFITM2 and 3 in the same samples were broadly similar, with significant 
increases in transcript abundance typically occurring later on during infection (Figure 4.8B 
and C).  In agreement with chIFITM expression, there was also a significant increase in Mx 
expression at 24 hours post infection and this was irrespective of the strain of IBV that was 
tested (Figure 4.8E). Interestingly there was also an increase in Mx expression at 12 hours 
post infection in the samples that had been infected with QX. This suggests that QX 
infection leads to an earlier onset of chIFITM and Mx expression which is significantly 
different to the other two strains that were tested.    
4.4.3 Assessing the effect of temperature and subsequent viral assembly and 
egress in modulating chIFITM expression 
Anecdotal evidence has suggested that BeauR is unable to replicate in vivo which may be 
significant, given the difference in temperature commonly used in cell culture (37°C) and 
the core temperature of birds (41°). Furthermore, research conducted by both the Genetics 
and Genomics and Avian Endemic Virus groups at The Pirbright Institute, have shown that 
live virus cannot be isolated from infected birds or from cells infected in vitro at 41°C. 
Although it has been established that cells at 41°C cannot establish a productive infection, it 
is still unclear as to whether the virus is able to replicate, and indeed, whether either of 
these would have an impact on chIFITM expression. In order to assess the impact 
temperature has on chIFITM expression, DF-1 cells were infected with BeauR and incubated 
at either 37°C or 41°C before downstream analysis was performed.  
DF-1 cells were infected with BeauR at a high MOI (5) for 8 hours after which viral 
supernatants and cell lysates were taken for analysis via plaque assay titration and 
quantitative RT-PCR, respectively. Cell supernatants were harvested and serially diluted (10-
fold) in 1x BES media before infecting CK cells. After 1 hour the inoculum was removed and  
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Figure 4.9 Infection of DF-1 cells with BeauR at 37°C and 41°C upregulates the expression 
of the chIFITMs. DF-1 cells were infected with BeauR (MOI 5). (A) Viral replication was 
measured by plaque assay titration in CK cells of the infected cell supernatant. (B) Viral 
transcription was assessed by absolute quantification of the viral N message by 
quantitative RT-PCR. (C) The expression level and log fold change of chIFITM1, 2, 3, 5 and 
Mx were measured using quantitative RT-PCR normalised to house-keeping genes, RPLPO 
and RPL13. Error bars show standard deviations of the means (n =3 biological 
replicates), * indicates a p-value <0.05, ** indicates a p-value<0.01, *** indicates a 
p-value <0.001, student’s t-test. 
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the cells were overlaid with 2x BES media and 2% agar. Cells were incubated for 3 days until 
plaques in the cell monolayer were visible. The cells were fixed with paraformaldehyde and 
stained using crystal violet. In agreement with previous observations made by the Bickerton 
lab (The Pirbright Institute), plaque assays indicated the viral titre of BeauR when incubated 
at 37°C is 1x103 Pfu/ml at 8 hours post infection. In comparison there were no visible 
plaques observed when DF-1 cells are infected and incubated at 41°C (Figure 4.9A). This 
suggests that a productive infection could not be established in cells placed at the higher 
temperature.  It is still unclear as to whether the virus is unable to replicate at this 
temperature or whether the higher temperature interferes with viral assembly and/or 
egress. To address these questions the cells were lysed, RNA extracted, reverse transcribed 
and quantitative RT-PCR was performed on the N protein sgRNA of BeauR (Figure 4.9B). The 
N protein sgRNA is a product of BeauR replication, thus is a marker for active viral 
replication within the cell (Maier et al., 2013b). The copy number of N sgRNA was 
calculated from a standard curve using plasmids encoding the target sequence. There was 
no significant difference in the copies of N sgRNA detected with cells incubated at both 
temperatures containing ~1x104 copies of N sgRNA/12.5ng RNA.  This data suggests that 
replication of the virus is not affected by temperature; therefore viral assembly or egress of 
the virus is likely to be impacted by the increase in temperature.  
To assess whether temperature has an impact on chIFITM and Mx upregulation, 
quantitative RT-PCR was utilised to examine the relative fold change of the chIFITM and Mx 
genes, relative to a mock infected control and normalised to two house-keeping genes, 
RPLPO and RPL13 (Figure 4.9C). The results show that chIFITM and Mx upregulation are 
unaffected by temperature. The upregulation profiles are very similar, with chIFITM1, 2, 3 
and 5 all displaying equivalent fold changes between temperatures. Although the relative 
fold changes were similar between temperatures, the statistics indicate that there are large 
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standard deviations within samples which accounts for the disparity in assigning statistically 
significant upregulation in gene expression.  
Taken together, this data suggests that temperature does not affect viral genome 
replication; instead it is likely to be implicated in viral assembly, or egress of the virus. 
Moreover, chIFITM expression does not appear to be affected by this change in 
temperature and it is likely that chIFITM mRNA expression is dependent on the early stages 
of a virus life cycle, namely entry and/or replication.      
4.4.4 Herpesvirus of Turkeys (HVT) infection transiently upregulates chIFITM5 and 
Mx mRNA expression 
Herpesvirus of Turkeys is the third serotype within the Marek’s disease virus (MDV) group. 
This group contains viruses that are genetically and antigenically related lymphotropic avian 
herpesviruses (Afonso et al., 2001). MDV1 is the etiologic agent which manifests itself as a 
lymphoma-causing virus in chickens and is important because of its global distribution and 
the large economic effect it has on the poultry industry (Prasad, 1979). In comparison, HVT 
is non-pathogenic in chickens, and because of this, and the associated cross-reactive 
immune response due to viremia, it has been used extensively as a vaccine candidate for 
viruses that infect poultry (Witter, 1972;Witter et al., 1970). Vaccine candidates have been 
produced for protection against: Newcastle disease virus (El Khantour et al., 2017), 
infectious bursal disease virus (Darteil et al., 1995;Perozo et al., 2009), influenza A virus 
(Kapczynski et al., 2016;Rauw et al., 2012) and MDV (Gimeno et al., 2016). HVT contains a 
large dsDNA genome of 159kb encoding 99 functional genes (Afonso et al., 2001). HVT as a 
large dsDNA virus is very different to both IAV and IBV (as RNA viruses) which increases the 
viral diversity being assessed in the context of chIFITM expression. Furthermore, it is known 
that HVT is able to induce a protective immune response when used as a vaccine vector.  
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Figure 4.10 Infection of DF-1 cells with HVT transiently upregulates chIFITM5 and Mx 
expression. (A-E) The expression level and log fold change of chIFITM1, 2, 3, 5 and Mx 
were measured using quantitative RT-PCR after infection with HVT (MOI 0.01) in DF-1 cells, 
normalised to house-keeping genes, RPLPO and RPL13. Error bars show standard 
deviations of the means (n =3 biological replicates), ** indicates a p-value<0.01, *** 
indicates a p-value <0.001, ****indicates a p-value <0.0001, one-way ANOVA. 
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These factors meant that it was unclear if this virus would elicit an innate immune 
response.  
DF-1s were infected over a 48 hour time course with HVT at an MOI 0.01 (CEF:DF-1 ratio) 
and time points were taken at 12, 18, 24, 36 and 48 hours post infection. The cells were 
lysed, RNA extracted, reverse transcribed and chIFITM and Mx mRNA expression levels 
were measured by quantitative RT-PCR, relative to mock samples and normalised to two 
house-keeping genes, RPLPO and RPL13. Infection of DF-1 cells with HVT resulted in a 
downregulation in chIFITM1, 2 and 3 mRNA expression, and reaching levels of significance 
for chIFITM1 mRNA expression from 24 to 48 hours post infection (Figure 4.10A – C). In 
contrast, chIFITM5 mRNA expression was significantly upregulated (>2 fold) at 12 hours 
post infection when compared to a mock infected control. This expression decreased at 18 
hours and then steadily increased again at 24 and 36 hours post infection before plateauing 
at 48 hours post infection with levels remaining similar to those observed in the mock 
infected control (Figure 4.10D). The levels of Mx mRNA expression were also significantly 
upregulated at 12 hours post infection, but again levels decreased at 18 hours post 
infection and continued to decrease in a stepwise manner at 24 and 36 hours post infection 
before reaching levels similar to those observed in the mock samples at 48 hours post 
infection (Figure 4.10E).  
This data is markedly different to that observed for IAV and IBV infected cell cultures where 
a general trend of increased mRNA expression of all four chIFITMs, and the positive control 
Mx, was observed over the course of infection. Infection of DF-1 cells resulted in the 
transient upregulation of chIFITM5 and Mx. This effect was not observed for any other 
chIFITM, at any other time point. This may suggest an active down regulation or 
suppression of chIFITM and Mx expression which may contribute to its efficiency as a 
possible vaccine candidate. 
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4.4.5 In ovo infection with H9N2 upregulates the expression of the chIFITMs 
In addition to assessing the in vitro upregulation of chIFITMs in response to infection with 
IAV, IBV and HVT, the effects of in ovo IAV infection upon chIFITM gene expression was also 
analysed. Infection in ovo allows the examination of the response of the developing chick to 
challenge with H9N2. This has not been explored before in the context of chIFITM 
upregulation. Furthermore, as vaccines for both human and veterinary use are currently 
produced in embryonated hen’s eggs, it will prove useful to assess the impact in ovo 
restriction may have on the vaccine yields that are currently achievable using this model of 
vaccine production. Ten-day old SPF Rhode Island Red embryonated chicken eggs were 
inoculated via injection into the allantoic cavity with 1x103 pfu of H9N2 
(A/chicken/Pakistan/UDL01/08) and tissue samples were taken at 24, 48 and 72 hours post 
infection from the lung, liver and intestine. Samples were also taken from mock (PBS) 
infected embryos.  Samples were homogenised using the TissueLyser, total RNA was 
extracted and reverse transcribed into cDNA. Quantitative RT-PCR was performed, relative 
to three mock controls at each time point and normalised to two house-keeping genes, 
RPLPO and RPL13.  
There was no significant upregulation of chIFITM1 or 5 in the lung, at any time point post 
infection (Fig 4.11A and D) although a general trend of upregulation post infection was 
identified. The upregulation did not reach statistical significance because of the large 
standard deviation between samples. In comparison, a significant upregulation of chIFITM2 
in the lung was detected at all time points post infection, with the most significant 
upregulation occurring at 72 hours post infection (Fig 4.11B). Furthermore, chIFITM3 and 
Mx were significantly upregulated at 48 and 72 and 24 and 72 hours post infection, 
respectively (Fig 11C and E). 
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Figure 4.11 In ovo Infection with H9N2 upregulates the expression of the chIFITMs. (A-O) 
The expression level and log fold change of chIFITM1, 2, 3, 5 and Mx in different tissues 
were measured using quantitative RT-PCR (normalised to RPLPO and RPL13) after infection 
with H9N2 (1000 PFU) IAV in specified-pathogen-free (SPF) embryonated Rhode-Island Red 
hen’s eggs. The presence of IAV in infected tissues was performed using end point PCR of 
the M gene (P) and intensity of the product summarised. Error bars show standard 
deviations of the means (n =3 biological replicates), * indicates a p-value <0.05, ** 
indicates a p-value<0.01, *** indicates a p-value <0.001, ****indicates a p-value <0.0001, 
one-way ANOVA. 
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In the liver there was a significant upregulation of all of the genes that were examined. 
chIFITM1 was significantly upregulated at 48 and 72 hours post infection (Fig 11F), whereas 
chIFITM2, 3, 5 and Mx were significantly upregulated at 24 and 48 hours post infection (Fig 
11G – J). In the liver the most significant upregulation in mRNA expression was detected at 
48 hours post infection for all of the chIFITMs and Mx. The mRNA expression of chIFITM2, 3, 
5 and Mx decreased at 72 hours post infection and this resulted in a loss of significance. The 
greatest level of chIFITM and Mx upregulation was found in the intestine with values 
represented in log10 format for chIFITM1, 5 and Mx. There were significant increases in 
chIFITM2, 3 and Mx mRNA abundance at all time points post infection (Fig 4.11L, M and O). 
chIFITM1 was significantly upregulated at 24 and 48 hours post infection (Fig 4.11K) and 
chIFITM5 was significantly upregulated at only 24 hours post infection (Fig 4.11N), although 
a 10,000 fold increase (in chIFITM5 mRNA) was observed over the mock infected embryos. 
There was a significant upregulation in Mx mRNA abundance in all tissues examined (Fig 
4.11E, J and O). In order to confirm presence of the virus, end point PCR of the M gene of 
IAV was performed for each tissue of each embryo (Fig 4.11P). All but one embryo was 
found to have virus in at least one tissue and the embryo that was IAV negative was 
excluded from further analysis. Taken together, these data demonstrate that chIFITM genes 
are upregulated in ovo following IAV infection, to varying degrees in different tissues. 
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4.4.6 In vivo infection of Rhode-Island Red chicks with H9N2 modulates chIFITM 
expression 
Having demonstrated chIFITM transcript upregulation in vitro and in ovo in response to 
influenza virus infection, it was evaluated if chIFITM transcripts were also upregulated in 
vivo following infection with IAV.  Infections in vivo are complex as there are a multitude of 
factors that are at play simultaneously, such as the induction of an antiviral state which 
modulates the expression of over 500 genes. Moreover, environmental factors, individual 
genetic diversity and the health status of the animal may alter the outcome of infection. In 
vivo models are therefore less controlled in comparison to the highly controlled 
experiments conducted in vitro. Three-week-old Rhode Island Red chickens were inoculated 
with 1x105 pfu of H9N2 (A/chicken/Pakistan/UDL01/08) intra-nasally, and tissue samples 
were taken at day 2 and 5 post infection from the lung, liver and colon. Samples were also 
taken from mock infected birds that were aged matched as controls. Samples were 
homogenised using the TissueLyser, RNA extracted, reverse transcribed and relative 
quantitative RT-PCR was performed. Copies of the M gene (viral), the chIFITMs and Mx 
were calculated from a standard curve using plasmids encoding the target sequence. 
 
RT-PCR of the M gene was used to assess the viral burden in these tissues and relative copy 
numbers were determined against a known standard. Copies of IAV mRNA were detected in 
all of the tissues that were sampled, with IAV mRNA copies increasing in the lung from days 
2 to 5 post challenge (Figure 4.12A). In all the tissues from control birds, chIFITM transcripts 
were detectable at comparable levels at 2 and 5 days post mock infection. In the lungs on 
day 5 post infection all the chIFITM transcripts were detected at lower levels in H9N2 
infected birds with significant down regulation being observed for chIFITM2 and 3 (Fig 
4.12C). 
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4.12 In vivo Infection with H9N2. (A, D and G) Absolute quantification of viral capsid M 
gene in different tissues, at 2 and 5 days post infection using quantitative RT-PCR after 
infection with H9N2 (1 x 105 PFU) IAV in specified-pathogen-free (SPF) RIR birds. (B, C, E, F, 
H, I) The expression level and log fold change of chIFITM1, 2, 3, 5 and Mx in different 
tissues were measured using quantitative RT-PCR. Black bars represent mock infected 
birds; grey bars represent H9N2 infected birds. Error bars show standard deviations of the 
means (n =2 [mock infected] -4 [experimentally infected]), * indicates a p-value <0.05, ** 
indicates a p-value <0.01, ****indicates a p-value <0.0001, one-way ANOVA. 
5 days post 
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There were no significant differences in chIFITM transcript levels between mock infected 
and virus infected birds on day 2 post infection, although there is a general increase in 
transcript abundance in the IAV infected birds compared to the mock, particularly for 
chIFITM1, 5 and Mx (Fig 4.12B). Conversely there was a decrease of M gene mRNA in the 
liver from days 2 to 5 post infection and this suggests that the virus is being cleared from 
this tissue (Fig 4.12D). Although there was a decrease in M gene expression, this did not 
correspond to any change in chIFITM transcripts abundance at 5 days post infection (Fig 
4.12F). There was a significant increase in chIFITM3 mRNA abundance at 2 days post 
infection in the liver (Fig 4.12E), which was not observed for any other chIFITM, at any 
other time point, in any other tissue. Mx expression is significantly upregulated at both 
time points in the liver, even though copies of the viruses decrease from 2 to 5 days post 
infection. There was an increase in M gene mRNA levels in the colon (Fig 4.12G) from 2 to 5 
days post infection and this corresponded with a significant decrease in chIFITM1 transcript 
abundance (Fig 4.12I) at 5 days post infection when compared with the mock control. At 2 
days post infection there were no significant differences in the level of chIFITM transcripts, 
however, chIFITM1 appear to be downregulated, whilst chIFITM2, 3 and 5 are somewhat 
upregulated (Fig 4.12H). At both time points the colon contained significantly more 
transcripts of Mx (Figure 4.12H and I).   
 
The data generated by the in vivo infection of chickens with IAV is more complex and there 
is not a single pattern of upregulation, unlike the in vitro and, to a lesser extent, the in ovo 
infection data. These data show general trends of increasing or decreasing chIFITM 
expression, although there is only a single example of significantly upregulated expression 
of chIFITM3, which is in the liver at 2 days post infection. In contrast, there are examples of 
significant down regulation of chIFITM2 and 3 expression in the lung and of chIFITM1 
expression in the colon, both at 5 days post infection. Mx does not appear to be 
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downregulated at any time, nor in any tissue. This suggests a dynamic process is in 
operation and there may be multiple factors that control and regulate chIFITM expression 
in vivo.    
 
4.5 Discussion 
The results in this chapter examine the ways in which chIFITM expression is modulated by 
molecules that drive innate immune activation and from infection within a diverse range of 
avian pathogens. The initial investigations questioned whether commonly used avian cell 
lines would be a good model for exploring chIFITM upregulation, assessed using the 
synthetic dsRNA mimic poly(I:C). Figure 4.1 demonstrated that there were considerable 
differences in the upregulation of chIFITM transcripts in the three chicken cell lines that 
were examined. Treatment of DF-1 cells, with poly(I:C) gave a muted response, with only 
chIFITM1 and 3 being significantly upregulated. Moreover, chIFITM2, 5 and 10 were not 
upregulated at all; instead levels of transcript abundance were below mock infected levels 
for chIFITM5 and 10. In contrast, treatment of HD11 cells resulted in significant 
upregulation in expression for all chIFITMs except chIFITM5. Treatment of OU-2 cells fell 
somewhere between the other two cell lines, with a general trend of upregulation, but 
again only two chIFITMs, namely chIFITM1 and 2, were significantly upregulated. This led to 
the conclusion that HD11 cells would be the most suitable cell line for studying interferon 
induction and signalling in further detail. 
 Data published by Smith et al. indicated that type I, not type II interferons would lead to 
the activation and upregulation of chIFITM expression. In this study they used DF-1 cells 
stimulated with either IFNα or IFNγ to assess only chIFITM3 upregulation. As is now clear, 
DF-1 cells may not have been the best model for these experiments and this could be 
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attributed to increased levels of constitutive SOCS1 expression in this cell line (Giotis et al., 
2017). Utilising HD11 cells, an IFNβ promoter reporter assay and western blot 
demonstrated that poly(I:C) was able to activate both the IFNβ promoter and drive IFNα 
expression which is evident by the western blot. Analysis of samples treated with the same 
agonists concluded that IFNα and poly(I:C) were predominantly responsible for chIFITM 
upregulation and this appeared to be universal across all four chIFITMs and the positive 
control, Mx. Treatment of cells with IFNγ led to a modest, but insignificant upregulation in 
chIFITM3 expression which suggests that IFNγ is not primarily involved in modulating 
chIFITM expression. These results contribute to what was already known in the literature, 
but also identified a novel ISG, chIFITM5. The role of chIFITM5 had not been examined up 
until now, presumably because huIFITM5 had been implicated in bone mineralisation and 
expression was restricted to the bone marrow. These results demonstrate that the 
chIFITMs act as classical ISGs; they are sensitive to interferon and are upregulated 
universally by IFNα. It has been well established that, in chickens, type I interferons 
differentially activate downstream effector proteins, with α/β activating different proteins 
to a greater or lesser extent. It is an accepted principal that IFNα is a more potent agonist of 
further IFNα and β activation which may contribute to an enhanced level of chIFITM 
expression (Qu et al., 2013).   
The currently available evidence does not irrefutably demonstrate that bacteria are 
efficiently restricted by human or mouse IFITMs. Although the data in the mammalian field 
may be controversial, no work has currently been published elucidating the relationship 
between bacteria and the chIFITMs. In this part of the chapter, lipopolysaccharide (LPS) was 
used to examine this relationship in two cell lines, DF-1 and HD11 cells. LPS treatment in 
DF-1 cells did not lead to an upregulation of the positive control, IL-6. In order to further 
investigate whether DF-1 cells had an intact NF-κB signalling pathway, P65 translocation 
was used as a marker of NF-κB transcriptional activation. This work found that DF-1 cells 
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have an intact NF-κB signalling pathway and this was evidenced by the fact that P65 
translocated from the cytoplasm into the nucleus which is a marker of P65 activation. As 
the positive control in DF-1 cells failed, no further conclusions could be confidently drawn 
from this data. In comparison HD11 cells responded well to LPS treatment and IL-6 was 
significantly upregulated, which confirmed what was already published in the literature 
(Setta et al., 2012). Under the same LPS treatment chIFITMs were not upregulated, on the 
contrary, expression levels of chIFITM2 and 5 dropped below those seen in mock treated 
cells. This suggests that LPS does not activate chIFITM expression. Moreover, chIFITM 
expression may be actively downregulated as the cell may have a preference for 
upregulating proinflammatory cytokines instead of ISGs, as if often the case during bacterial 
infection.  
Understanding the molecules that are involved in ISG modulation can help to elucidate 
roles that the chIFITMs undertake in the context of cellular infection. In order to further 
understand the interplay between host cell restriction factors and invading viral pathogens, 
the next set of experiments examined whole avian viruses in avian cell culture and 
measured chIFITM upregulation over a time course. In Figure 4.6, primary ex vivo cell 
cultures were utilised alongside a current enzootic strain of IAV (H9N2) and two further 
representative strains (H3N8, H5N3). Infection with H9N2 led to a significant upregulation 
in chIFITM1 and 5 expression, with chIFITM1 being most significantly upregulated over the 
course of infection (Figure 4.6A). The upregulation in chIFITM1 mRNA levels corresponds 
with an increase in chIFITM1 protein abundance (Figure 4.7B). Cells infected with H3N8 
displayed a different and more complex expression profile (Figure 4.6B). During the course 
of infection chIFITM1 displayed a biphasic regulation, initially increasing from 2 to 6 hour 
post infection, decreasing to mock levels at 12 hours post infection and then increasing 
significantly at 24 hours post infection. In contrast, chIFITM2 was significantly upregulated 
at 6 and 12 hours post infection, but levels of mRNA transcript abundance were lower at 2 
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and 24 hours post infection. The expression of chIFITM3 followed a similar profile to that of 
chIFITM2, although chIFITM3 was still significantly upregulated at 24 hours post infection. 
chIFITM5 was upregulated at 2 to 12 hours post infection, showing significant upregulation 
at 24 hours post infection. Infection with H5N3 resulted in a significant upregulation in all 
chIFITMs at 6 hours post infection and this continued throughout the time course. The only 
exception being chIFITM2 which was not significantly upregulated at 24 hours post 
infection. These data demonstrates the complex modulation of ISGs in the context of viral 
infection. The differences in upregulation may reflect the virus’s ability to antagonise 
interferon signalling, thus ISG expression. In a study examining two H1N1 viruses, the 
pandemic A/California/4/2009 and seasonal A/New Caledonia/20/1999, the authors report 
significant differences in gene expression through the Jak/Stat signalling pathway and the 
subsequent expression of ISGs (Fribourg et al., 2014). This study highlights the differences 
in interferon antagonism that are predominantly, but not solely, modulated through the 
activity of NS1 (Killip et al., 2017).      
To investigate whether chIFITM expression could be upregulated by positive sense RNA 
viruses, the prototypic gamma coronavirus IBV was used to infect an ex vivo cell culture 
comprising chick kidney cells. Three strains of IBV were used to compare strains with 
different pathogenicities and tissue tropisms. These comprised a tissue culture attenuated 
strain (BeauR), a pathogenic field strain (M41) and a virulent nephropathogenic strain (QX). 
The data demonstrates that infection with QX results in earlier upregulation of chIFITM 
expression than the other two strains. Infection with QX results in a significant upregulation 
in chIFITM1 and chIFITM5 expression at 6 hours post infection, which continues to 24 hours 
post infection. In addition, chIFITM2 and 3 were upregulated at 12 hours post infection and 
this continues throughout the duration of the time course. Conversely, infection with 
BeauR or M41 leads to chIFITM upregulation, but only at 24 hours post infection. This may 
suggest that tissue tropism is a factor that influences chIFITM expression as QX is 
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nephropathogenic and this strain elicits an earlier response in the CK cells. Moreover, the 
apathogenic strain elicits a similar level of chIFITM expression to the pathogenic strain. This 
suggests that pathogenicity does not play a significant role in chIFITM induction during the 
course of infection.  
Anecdotal evidence, which is still under investigation by the avian endemic viruses group, 
reveals that infectious BeauR virions are not detected when DF-1 cells are incubated at 
41°C. This implies that either the virus cannot replicate at this temperature or the virus is 
being disrupted during virus assembly or egress. In order to evaluate what step is inhibited 
and whether this has an impact on chIFITM expression, DF-1 cells were infected and then 
incubated at either 37°C or 41°C. Infectious virions were not detected by plaque assay 
titration when cells were incubated at 41°C. In comparison, replicating virus was detected 
by quantitative RT-PCR in both samples which suggests that viral replication is not inhibited 
by the increase in temperature. Quantitative RT-PCR was used to assess chIFITM 
expression. There was very little difference in the induction profiles of the chIFITMs and any 
differences in significance are likely to be attributed to the standard deviations between 
biological replicates. Taken together, this data suggests that temperature does not affect 
viral replication of IBV. Moreover, disruption of viral assembly and/or egress is not a factor 
that influences chIFITM expression during infection.  
Whilst IAV and IBV represent two distinct species of viruses, their relatively small genomes 
(13.5kb and 27kb respectively) are similarly comprised of RNA. In contrast HVT has an 
expanded dsDNA genome (159kb) and utilises different mechanisms for replication, gene 
regulation and innate immune invasion alongside a unique method of viral entry. 
Investigating this viral diversity allows for a more complete characterisation of chIFITM 
expression during viral infection. Unlike infection with IAV and IBV, infection with HVT is 
mediated through cell to cell spread and the viral contents are released into the cell 
Chapter 4: Characterising chIFITM expression 
199 | P a g e  
 
cytoplasm in an endosomal-independent manner which may negate chIFITM-mediated 
restriction (Akhtar and Shukla, 2009). During the course of infection, there was a notable 
lack of chIFITM expression with the exception of chIFITM5 and Mx which are significantly 
upregulated at 12 hours post infection. This appears to be transient and significance is lost 
later on during infection. Moreover, chIFITM1 expression is significantly downregulated 
from 24 to 48 hours post infection. This is unique insomuch that this pattern of chIFITM 
modulation has not been observed for any other virus that has been studied in vitro thus 
far. The inability of the cell to upregulate chIFITM expression during HVT infection might be 
a consequence of viral entry or the mechanisms the virus exploits during gene expression 
and replication. It is worth noting that the MOI calculation and the method of viral entry 
and spread is very different to that of both IAV and IBV. 
It has been known since the early 1960’s that embryos are able to mount a protective 
interferon response from 8 days of fertilisation (Baron and Isaacs, 1961). This early 
interferon response is able to protect the developing chick from challenge in ovo. Even 
though an interferon response is initiated, there is still very little data available that details 
the magnitude of the response or the genes that are upregulated in ovo. The use of CEFs 
acts a proxy for in ovo responses but these models do not isolate single organs or tissues 
and thus it remains unclear if individual organs respond differentially to infection. In this 
section of the chapter, SPF RIR embryonated hen’s eggs were inoculated with 1x103pfu and 
tissues were harvested at 24, 48 and 72 hours post infection. Quantitative RT-PCR was used 
to examine the response of these tissues to infection with LPAI. There was a striking pattern 
of chIFITM upregulation in these tissues (Figure 4.11). The chIFITMs were most significantly 
upregulated in the lung at 72 hours post infection, in the liver at 48 hours post infection and 
in the intestine at 24 hours post infection. Although upregulation is most significant at the 
time points mentioned, there is still significant upregulation in chIFITM expression at other 
time points which appear to be in a chIFITM and tissue specific pattern. End point PCR of 
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the M gene was performed to assess the level of infection in each tissue. The results of this 
PCR did not correlate with chIFITM expression which indicates that chIFITM expression is 
not dependent on high levels of viremia. Indeed, it is still unclear if certain tissues are able 
to induce chIFITM expression to a greater or lesser extent and whether this is temporally 
regulated as the embryo develops. Another possible explanation is that infection leads to a 
systemic interferon response whereby tissues with a low viral load are primed for infection 
by the initiation of interferon signalling. What is clear, however, is that embryos are able to 
upregulate the expression of the chIFITMs from 11 days post infection in response to 
infection with H9N2.  
The effect of H9N2 infection in vivo was used to assess chIFITM modulation in the host 
species. So far, only one study examines chIFITM expression in vivo and this was with the 
HPAI, H5N1 and LPAI H5N2 (Smith et al., 2015). In this study the authors noted a muted 
chIFITM response in the lungs and ilium, which was much lower in magnitude to the 
expression of dIFITMs in the same tissue. Similarly, in our experiments, the response to 
infection with H9N2, chIFITMs were not expressed to very high levels in any of the tissues 
that were examined. Moreover, there was only a single significant upregulation and this 
was in the liver at 2 days post infection with chIFITM3 (Figure 4.12E). There was a general 
trend of upregulation in chIFITM expression in each of the tissues at 2 days post infection, 
notably, chIFITM1 and 5 in the lung and chIFITM3 and 5 in the colon, although these failed 
to reach statistical significance. In contrast, there was a significant downregulation of 
chIFITM2 and 3 in the lung and chIFITM1 in the colon at 5 days post infection. This may 
suggest that the virus is able to modulate expression of the chIFITMs later on during 
infection and this corresponds with an increase in virus in these tissues from 2 to 5 days 
post infection as detected by quantitative RT-PCR against the M gene. This implies that the 
virus is able to control the expression of chIFITM expression in vivo, likely through the 
actions of a global interferon antagonist. 
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In conclusion, the data presented in this chapter shows the dynamic regulation of the 
chIFITMs in vitro, ex vivo, in ovo and in vivo. It appears that chIFITM expression is a highly 
regulated process and may suggest a complex interplay between viruses and the host cell 
which in turn regulates the expression of this family of ISGs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5: ChIFITM-mediated viral restriction of avian viral pathogens 
202 | P a g e  
 
 
 
Chapter 5 
ChIFITM-mediated restriction 
of avian viral pathogens   
 
 
 
 
 
 
 
 
 
Chapter 5: ChIFITM-mediated viral restriction of avian viral pathogens 
203 | P a g e  
 
5.1 Introduction 
The discovery of the human IFITM proteins occurred many decades ago in 1984, making 
them some of the first proteins to be classed as ISGs (Friedman et al., 1984). The IFITMs 
were initially termed 9–27(IFITM1), 1-8D (IFITM2), and 1-8U (IFITM3), a nomenclature that 
is very different to the one used currently.  The ability to restrict viruses by the IFITM 
proteins was described much later on, first being reported in 1996 with the partial 
restriction of  Vesicular stomatitis virus (VSV) by huIFITM1 (Alber and Staeheli, 1996). A 
further study examined the relationship between hepatitis C virus (HCV), IL-1 and 1-8U 
(IFITM3) and found that increased expression of 1-8U was associated with a decrease in 
HCV mRNA, although no specific conclusions regarding antiviral activity were made from 
this study (Zhu and Liu, 2003). It was not until 2009 that IAV-targeting RNA interference 
studies started to identify IFITM1, 2 and 3 as potential restriction factors against IAV (Brass 
et al., 2009;Shapira et al., 2009). Since this time, many studies have investigated the role of 
IFITM-mediated restriction of a diverse range of pathogens, both bacterial and viral, in a 
wide array of host organisms. 
Human IFITM (huIFITM) proteins have been proposed to restrict the entry and replication 
of several highly pathogenic human viruses, although the exact mechanisms involved 
remain unclear. The viruses restricted by huIFITMs include: IAVs, flaviviruses (Dengue 
virus), filoviruses (Ebola virus and Marburg virus), coronaviruses (SARS and MERS) and HIV-
1 (Brass et al., 2009;Foster et al., 2016;Lu et al., 2011;Huang et al., 2011). Murine models 
utilising knockout technologies have found that ifitm3-/- mice are more susceptible to IAV 
(Bailey et al., 2012;Everitt et al., 2012), respiratory syncytial virus (RSV) (Everitt et al., 2013) 
and West Nile virus (WNV) (Gorman et al., 2016) infection. Thus far, very little evidence is 
available detailing the restriction of avian viruses in avian cell culture. The chIFITMs were 
first characterised in 2013 by Smith et al. In this study they utilised a human cell line (A549) 
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stably expressing chIFITM2 or 3 alongside DF-1 cells either transiently overexpressing 
chIFITM3 or treated with a siRNA against chIFITM3 (which ablated endogenous expression). 
Using lentiviral vectors pseudotyped with the Lagos bat virus (LBV), rabies virus (RABV) or 
influenza (H1 [human], H5 [human], H7 [bird], or H10 [bird]) glycoproteins, they assessed 
percentage infection by FACS or virus replication by plaque assay titration (Smith et al., 
2013).  
This chapter expands on previous studies and examines whether chIFITM-mediated 
restriction can be achieved with whole avian virus infection, rather than with pseudotyped 
lentiviral vectors. Furthermore, Smith et al focused only on chIFITM2 and 3 and did not test 
to see if chIFITM1 or 5 restrict viral pathogens. Therefore the scope of the investigation will 
be broadened to include the whole chIFITM family, alongside a diverse range of avian viral 
pathogens.      
5.2 Transfection reagents are differentially toxic to cells 
Transfection is an important process that allows for the introduction of foreign nucleic acid 
into cells. Transient transfection has a wide range of applications and is a commonly used 
laboratory technique employed for the overexpression or silencing (via siRNAs) of a gene in 
a concentration dependent and temporally regulated manner (Sharifi Tabar et al., 2015). 
During this process nucleic acids are not incorporated into the genome, thus the effect is 
short lived. The duration of transfection can be modulated by environmental factors such 
as media composition or cellular factors such as cell division (Gu et al., 2016). The purpose 
of transfection is to study the function or regulation of a gene or gene product in the 
context of whole cell expression. This may identify possible interactions that modulate the 
expression or function of the protein of interest (Kim and Eberwine, 2010). The most 
common form of transfection in mammalian tissue culture is chemical transfection with a 
cationic lipid. This method has relatively low levels of cytotoxicity, has an acceptable 
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transfection efficiency and is possible to perform in a standard laboratory (Maurisse et al., 
2010;Kim and Eberwine, 2010). In this part of the chapter, the cytotoxicity’s of different 
chemical transfection reagents were assessed in DF-1 cells. For the purpose of subsequent 
experiments, low cellular toxicity was required as the DF-1 cells were going to be 
transfected and then infected. High levels of cytotoxicity would impede the efficient 
infection of the transfected cells and the results would be less robust.  
DF-1 cells were transfected with either 1µg of pcDNA3.1 or 20nM of scrambled siRNA 
according to the manufacturer’s protocol for the individual transfection reagent being 
evaluated. Twenty four hours after transfection, the supernatant was removed, cells were 
trypsinised and stained with trypan blue. The ratio of living to dead cells was measured by 
the TC20 automated cell counter. There was a significant difference in the viability of cells 
transfected with siRNA using lipofectamine 2000 and HiPerfect (Figure 5.1). The lower cell 
viability obtained using lipofectamine 2000 suggests that this transfection reagent would 
not be suitable for the subsequent experiments that require viral infection. For the delivery 
of plasmid DNA there was no significant difference between lipofectamine 2000 and 
FuGene which suggests that the use of either would make little difference to cell survival. 
These results highlight the adverse impact that transfection can have on cell viability. The 
consequences of these impacts on experimental results are not fully understood.  
5.3 Transient overexpression results in chIFITM-mediated restriction 
of avian viruses 
5.3.1 Transient overexpression of chIFITM1, 2, 3 and 5 in CEFs restricts H9N2   
Previous studies have demonstrated the potent restriction of IAV by huIFITM1, 2 and 3 in 
vivo and in vitro (Brass et al., 2009;Everitt et al., 2012;Mills et al., 2014;Williams et al., 
2014;Sun et al., 2016). Similar work has shown that the murine Ifitm3  
Chapter 5: ChIFITM-mediated viral restriction of avian viral pathogens 
206 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Determining the toxicity of transfection reagents in DF-1 cells. DF-1 cells were 
transfected with 1ug of pcDNA3.1 or 20nM of scrambled siRNA according to the 
manufacturer’s protocol. After 24 hours cells were trypinised and stained with trypan blue. 
The ratio of living to dead cells was calculated by the TC20 automated cell counter (Bio 
Rad). Error bars show standard deviations of the means (n =3 biological replicates), * 
indicates a p-value <0.05, students t-test. 
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(Bailey et al., 2012;Everitt et al., 2013) and duck IFITM3 (Blyth et al., 2016) are capable of 
restricting the infectivity of IAV. At present, there is a lack of published data examining the 
expression of chIFITMs in the context of viral restriction of avian viruses that have not been 
pseudotyped onto lentiviral vectors. Furthermore, it is not clear if chIFITM5 has a role in 
restricting viral pathogens. In order to investigate this, chicken embryonic fibroblasts (CEFs) 
or DF-1 cells were transiently transfected for 24 hours and infected with IAV or IBV. 
Restriction was determined by a reduction in viral titres, as quantified by plaque assay 
titration, at 24 hours post infection. One of the major problems in avian viral research is the 
relatively limited host tropism that is observed affecting the ability of avian viruses to infect 
cells either in vitro or ex vivo. Therefore, it is not possible to perform all in vitro 
experiments in the same cells because of the limited tropism exhibited. Many viruses used 
in the laboratory are unable to infect commonly used chicken cell lines, and ex vivo cells are 
often used as a model of infection. This presents a problem when assessing viral restriction 
as these cells are often of mixed cell type, difficult to transfect and require high 
concentrations of DNA in order to overcome this barrier. To fully characterise the 
restriction of avian influenza A virus in the natural host, CEFs were transfected with 5µg of 
plasmids encoding either chIFITM1, 2, 3 or 5 for 24 hours or were mock transfected with 
lipofectamine 2000 only. These cells were infected with a chicken H9N2 influenza virus at a 
high multiplicity of infection (MOI - 3) for 24 hours, and the supernatants were assayed for 
the presence of infectious virions by plaque assay. The supernatants were serially diluted in 
serum-free DMEM and used to infect MDCK cells in 12-well plates. After 1 hour of 
incubation, the inoculum was removed, and the cells were overlaid with DMEM containing 
0.2% BSA, 2% agar and 1μg trypsin ml−1. After 3 days, the overlay was removed, and the 
cells were stained with crystal violet to determine the pfu/ml. Overexpression of chIFITM1, 
2, 3 and 5 (or a mix of all 1, 2, 3 and 5 chIFITM plasmids) significantly restricts the 
replication of H9N2 by 0.88, 0.6, 0.8, 0.45 and 0.75 logs respectively (Figure 5.2A). To assess  
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Figure 5.2 Transient overexpression of chIFITM1, 2, 3 and 5 in CEFs significantly reduces 
IAV viral titres. (A) Chicken embryonic fibroblasts were transfected with 5μg of plasmid 
encoding chIFITM1, 2, 3 or 5 for 24 hours. These cells were then infected with H9N2 (MOI 
3) for 24 hours and the supernatants harvested. Viral replication of the infected cell 
supernatant was measured by plaque assay titration relative to the control (cells treated 
with lipofectamine 2000). (B) Cells were lysed at 24 hours post infection and lysates were 
separated by SDS-PAGE. Proteins were transferred to a nitrocellulose membrane and a 
western blot performed using specific antibodies raised against a distinct epitope of each 
individual chIFITM protein with β-actin as the loading control. Error bars show standard 
deviations of the means (n =3 biological replicates), * indicates a p-value <0.05, students t 
test. (-, untransfected; +, transfected) 
A 
B 
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the level of endogenous chIFITM expression and overexpression by plasmid transfection in 
CEFs, cells were lysed at 24 hours post infection and lysates were separated by SDS-PAGE. 
Proteins were transferred to a nitrocellulose membrane and a western blot performed 
using mono- or polyclonal antibodies raised against distinct epitopes of the chIFITM 
proteins (Figure 5.2B). All four chIFITM exogenous proteins were separately expressed in 
CEFs and were readily identified. Untransfected cells showed low or absent basal 
endogenous chIFITM expression. 
5.3.2 Transient overexpression of chIFITM1, 2, 3 and 5 in DF-1 cells differentially 
restricts H3N8, H5N3 or H9N2   
The transient transfection of ex vivo cell cultures is problematic and requires the use of a 
high concentration of plasmid DNA in order to successfully blot for chIFITM protein (Figure 
5.2B) in CEFs. This difficulty is not unique to CEFs and has been observed for other ex vivo 
cell culture preparations as well as in vivo (Kim and Eberwine, 2010). This may be due to ex 
vivo cell cultures containing a mixed cell population which change with each preparation. 
Continuous cell lines are easier to transfect, often requiring less DNA and transfection 
reagent to achieve the same result. DF-1 cells are a common chicken cell line used in many 
studies to assess the effects of overexpression. In order to expand the scope of this 
investigation, two additional strains of IAV (H3N8 and H5N3) were used.  
 
It is known that diverse strains of IAV show different sensitivities to host cell antiviral 
responses, but It is currently unknown if this extends to chIFITM mediated-restriction. In 
order to investigate differential restriction, the chIFITM genes were transiently 
overexpressed and restriction measured by plaque assay titration. To confirm the 
restriction observed in CEFs Figure 5.2A, DF-1 cells were transfected with 1μg of plasmid 
encoding chIFITM1, 2, 3 or 5. These cells were infected with a chicken H3N8, H5N3 or H9N2  
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Figure 5.3 Transient overexpression of chIFITM1, 2, 3 and 5 in DF-1 cells significantly 
reduces IAV viral titres. (A-C) DF-1 cells were transfected with 1μg of plasmid encoding 
chIFITM1, 2, 3 or 5 for 24 hours. These cells were then infected with H3N8, H5N3 or H9N2 
(MOI 1) for 24 hours and the supernatants harvested. Viral replication of the infected cell 
supernatant was measured by plaque assay titration relative to the control (cells 
transfected with an empty vector). (D) Cells were lysed at 24 hours post infection and 
lysates were separated by SDS-PAGE. Proteins were transferred to a nitrocellulose 
membrane and a western blot performed using an anti-FLAG antibody against a C-terminal 
FLAG tag with β-actin as the loading control. Error bars show standard deviations of the 
means (n =3 biological replicates), ** indicates a p-value<0.01, *** indicates a p-value 
<0.001, ****indicates a p-value <0.0001, one-way ANOVA. 
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influenza virus (MOI - 1) for 24 hours, and the supernatants assayed for the presence of 
infectious virions. Material to be assayed was serially diluted in serum-free DMEM and used 
to infect MDCK cells in 12-well plates. After 1 hour of incubation, the inoculum was 
removed, and the cells were overlaid with DMEM containing 0.2% BSA, 2% agar and 1μg 
trypsin ml−1. After 3 days, the overlay was removed, and the cells were stained with crystal 
violet to determine the pfu/ml. Transient overexpression of chIFITM1, 2, 3 and 5 restricted 
the replication of H3N8 by 0.70, 0.61, 0.62, 0.58 log10, respectively (Figure 5.3A), and all of 
these were significant when compared to the vector only control. Additionally, transient 
overexpression of chIFITM1, 2, 3 and 5 restricted the replication of H5N3 by 0.70, 0.21, 
0.61, -0.19 log10, respectively (Figure 5.3B). Overexpression of chIFITM1 and 3 resulted in a 
significant decrease in viral titre when compared to the vector only control. There was no 
significant difference in viral titre when cells overexpressing chIFITM2 were challenged. In 
contrast there was a significant increase in viral titre with cells transiently overexpressing 
chIFITM5. This implies a much more complex virus-host interactome and may suggest that 
the chIFITMs are able to restrict viral pathogens differentially and this may be virus and/or 
chIFITM dependent.  Transient overexpression of chIFITM1, 2, 3 and 5 followed by infection 
with H9N2 resulted in a decrease of 0.56, 0.42, 0.43 and 0.36 log10 in viral titres, 
respectively (Figure 5.3C). This suggests that H3N8 and H9N2 have similar restrictive 
profiles, whereas H5N3 is sensitive only to chIFITM1 and 3 overexpression under these 
experimental conditions.  
 
Cells were lysed at 24 hours post infection and lysates were separated by SDS-PAGE. 
Proteins were transferred to a nitrocellulose membrane and a western blot performed 
using an anti-FLAG antibody against C-terminal FLAG tag or an antibody that was produced 
against a distinct epitope of chIFITM5 in DF-1 cells (Figure 5.3D). The expression of all four 
chIFITM proteins was detected in transfected DF-1 cells. The presence of a double band for  
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chIFITM3 has also been observed for FLAG-tagged mammalian IFITM3, for which there is no 
explanation (Yount et al., 2012;Chesarino et al., 2014a). The other chIFITMs have only a 
single band at the expected size.  
5.3.3 Transient overexpression of chIFITM2 in DF-1 cells restricts IBV   
Alongside influenza A, coronaviruses such as IBV also present a threat to the poultry 
industry. IBV is an infectious disease in countries which have an intensive poultry industry 
with rates of infection reaching almost 100% in many instances (Ignjatovic and Sapats, 
2000). The rates of mortality associated with IBV are variable and depends on the strain of 
the circulating virus, with estimates ranging between 20-30%, although co- infections likely 
exacerbate the clinical outcome of IBV infection (Meulemans et al., 1987;Cumming, 
1969b;Cumming, 1969a). There is significant morbidity associated with IBV infection, which 
has a costly impact on the poultry industry through loss of productivity and a reduction in 
the quality of meat and eggs. This loss is estimated to be between $3567.4 - $4210.8 per 
1000 birds (Colvero et al., 2015). 
Human coronaviruses are potently restricted by huIFITM proteins. There have been 
extensive studies conducted with SARS and MERS due to their pandemic potential. In 2011, 
a study observed preferential restriction of SARS by huIFITM1. This was assessed by 
analysing the effects from both the overexpression and ablated expression of huIFITM1 
(Huang et al., 2011). In contrast, a more recent study focussing on SARS, MERS and two 
lesser known coronaviruses, NL63 and 229E (Zhao et al., 2018) found that there was no 
clear evidence of one huIFITM being more restrictive than another. Moreover, this study 
found that there was a difference in restriction between cell lines, although it is not clear if 
it was the cell line or the vector construct that resulted in the observed differences.  At 
present  
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Figure 5.4 Transient overexpression of chIFITM2 in DF-1 cells significantly reduces IBV 
viral titres. (A) DF-1 cells were transfected with 1μg of plasmid encoding chIFITM1, 2, 3 or 
3MUT for 24 hours. These cells were then infected with BeauR (MOI 1) for 24 hours and the 
supernatants harvested. Viral replication of the infected cell supernatant was measured by 
plaque assay titration relative to the control (cells transfected with an empty vector). (B) 
Cells were lysed at 24 hours post infection and lysates were separated by SDS-PAGE. 
Proteins were transferred to a nitrocellulose membrane and a western blot performed 
using an anti-FLAG antibody against a C-terminal FLAG tag with β-actin as the loading 
control. Error bars show standard deviations of the means (n =3 biological replicates), *** 
indicates a p-value <0.001, one-way ANOVA. 
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there is a lack of published data demonstrating whether the chIFITMs are able to restrict 
avian coronaviruses, namely the prototypic gammacoronavirus, IBV.   
Studies have suggested that the cysteine residues at positions 71 and 72 are also important 
for viral restriction in human and murine IFITM3 (Yount et al., 2012;Chesarino et al., 
2014b). It has been found that S-palmitoylation of cysteine residues 71, 72 and 105 of 
IFITM3 by the palmitoyltransferase ZDHHC20, is important for protein accumulation in cell 
membranes in addition to the anti-viral activity of IFITM3 against IAV (Compton et al., 
2016;Yount et al., 2010;McMichael et al., 2017). It has been found that chIFITM3 contains 
two palmitoylated cysteine residues at position 71 and 72 (Yount et al., 2010;Yount et al., 
2012) but contains a leucine residue at position 105. In all chIFITM genes, the palmitoylated 
cysteine residue found at position 105 in huIFITM genes, has been replaced with a leucine 
residue. It is unknown if the loss of a post-translationally modified amino acid at this 
position will have a detrimental impact on the restrictive ability of the chIFITMs. To assess 
the importance of the conserved residues at positions 71 and 72, both were mutated by 
site-directed mutagenesis (SDM) to alanine residues, thus removing two key post-
translational modifications, in addition to assessing the restriction of IBV with wild-type 
chIFITM proteins. 
To address this current lack of data, DF-1 cells were transiently transfected with 1μg of 
plasmid encoding chIFITM1, 2, 3 or 3MUT for 24 hours. These cells were infected with BeauR 
(MOI - 1) for 24 hours, and the supernatants were assayed for the presence of infectious 
virions. Briefly, material to be assayed was serially diluted in 1x BES and used to infect CK 
cells in 12-well plates. After 1 hour of incubation, the inoculum was removed, and the cells 
were overlaid with 2x BES and 2% agar. After 3 days the cells were fixed with 10% 
paraformaldehyde (PFA) in PBS which was overlaid onto the agar and incubated for 15 
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minutes. Agar was removed from each well and cells stained with 0.1% crystal violet (w/v) 
for 10 minutes and plaques counted to determine the pfu/ml.  
 
Transient overexpression of chIFITM2 significantly restricted the replication of BeauR by 
0.45 log10 (Figure 5.4A) when compared to the vector only control. There was also a 
decrease in the viral titres harvested from cells that were overexpressing chIFITM1, 
although this was not statistically significant. Cells overexpressing either chIFITM3 or 3MUT 
had levels of viral titres that were comparable to each other as well as to the mock control, 
therefore no statistical difference was observed. The restriction of IBV is different to that of 
IAV (Figure 5.2A and 5.3A-C). IAV is potently restricted by chIFITM1, 2, 3 and 5 expression 
while only the overexpression of chIFITM2 restricts IBV. This may suggest that viral entry, 
and the processes that mediate this essential part of the viral lifecycle, may play a role in 
determining viral susceptibility to chIFITM-mediated restriction. Moreover, it is likely that 
chIFITM localisation plays an essential role in restricting viral infection hence further work is 
required in order to elucidate this relationship in more detail. It was not possible to assess 
the role that cysteine residues at positions 71 and 72 have in the restriction of IBV as 
neither the wildtype nor the mutant were able to competently restrict IBV. Therefore, it is 
still unclear if these residues play a critical role in the restriction of avian viruses and this 
will have to be assessed in the context of IAV infection. 
 
 
 
 
Chapter 5: ChIFITM-mediated viral restriction of avian viral pathogens 
217 | P a g e  
 
5.4 Transient knockdown of chIFITM expression results in increased 
viral titres 
5.4.1 Transient knockdown of chIFITM1 renders CEFs more susceptible to IAV 
infection 
Using siRNA as a tool to validate the role of a gene is common and was used in the study 
that initially found that huIFITM3 was a potent restriction factor of IAV (Brass et al., 2009) 
and that chIFITM3 is a restriction factor of pseudotyped lentiviral vectors (Smith et al., 
2013). Synthesising and delivering siRNAs into the cell is a straightforward process that 
results in a good knockdown of host gene expression when the siRNAs have been designed 
correctly. It is more difficult to achieve a good knockdown of host innate immune genes 
due to their relative abundance and their subsequent reactivation upon viral infection 
(Malathi et al., 2007;Meng et al., 2013). These studies have shown that the innate immune 
system is activated by the detection of aberrant or foreign RNA, such as the introduction of 
siRNA, via the cytosolic receptors RIG-1, MDA-5 and LGP2 (Takeuchi and Akira, 2010). This 
suggests that achieving a prolonged knockdown of chIFITM gene expression may be difficult 
due to the subsequent reactivation of gene expression. In order to test this hypothesis, four 
individual siRNAs were designed against each chIFITM transcript alongside a single siRNA 
targeting chIFITM3 and a scrambled siRNA (negative control) that were originally used in 
the 2013 study published by Smith et al. To confirm the anti-viral effect observed with 
transient overexpression, transient knockdown of endogenously expressed chIFITM 
transcripts was undertaken in CEFs 24 hours prior to IAV infection. 5nM of each siRNA 
(20nM in total) was transfected into CEF cells using HiPerfect as per the manufacturer’s 
protocol. After 24 hours the same cells were infected with H9N2 IAV (MOI – 3) for 24 hours 
after which the supernatants were harvested and viral replication was quantified by plaque 
assay titration. Material to be assayed was serially diluted in serum-free DMEM and used to  
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Figure 5.5 Transient knockdown of chIFITM1 renders CEFs more susceptible to IAV 
infection. (A) The effect of knocking down endogenous chIFITM1, 2 or 3 expression in CEF 
cells infected with H9N2. Viral replication of the infected cell supernatant was measured 
by plaque assay titration relative to the control (cells transfected with a scrambled siRNA).   
(B) The expression level and log fold change of chIFITM1, 2 and 3 were measured using 
quantitative RT-PCR after pre-incubation with a non-targeting siRNA or ones specific to 
chIFITM1, 2 or 3, relative to mock and normalised by two house-keeping genes, RPLPO and 
RPL13. Error bars show standard deviations of the means (n =3 biological replicates), * 
indicates a p-value <0.05, *** indicates a p-value <0.001, one-way ANOVA. 
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infect MDCK cells in 12-well plates. After 1 hour of incubation, the inoculum was removed, 
and the cells were overlaid with DMEM containing 0.2% BSA, 2% agar and 1μg trypsin ml−1. 
After 3 days, the overlay was removed, and the cells were stained with crystal violet to 
determine the pfu/ml. A statistically significant increase in viral supernatant titre (0.71 
log10) was observed with knockdown of chIFITM1, followed by infection with IAV (Fig 5.5A), 
but no statistical difference in virus titres was observed for any other chIFITM knockdown 
(Fig 5.5A). A combination of all of the siRNAs (5nM of each individual siRNA) at a final 
concentration of 20nM (siRNA mix) did not increase viral titres and this is likely to be 
because the most effective siRNAs, likely targeting chIFITM1, were further diluted in this 
pool when compared to targeting chIFITM1 alone. The cells transfected with the negative 
scramble had similar titres to those cells that were untransfected and this was confirmed by 
a lack of a statistical difference between the two groups.  Using the same individually 
designed siRNAs in unstimulated CEFs, chIFITM transcript levels were assessed by 
quantitative RT-PCR. CEFs were transfected with siRNAs targeting chIFITM1, 2, 3 or a 
scrambled siRNA for 24 hours. Cells were harvested 24 hours post transfection, cells were 
lysed, RNA extracted and reverse transcribed and chIFITM expression levels were assessed 
by quantitative RT-PCR, relative to mock control and normalised to two house-keeping 
genes, RPLPO and RPL13. Although all knockdowns were significant when compared to 
chIFITM transcript abundance in the mock control, there are variances in the knockdown 
efficiency.  Scrambled siRNA did not alter chIFITM transcript abundance when assessed 
against chIFITM3. Knockdown of chIFITM1 and 2 was greater than 70% but chIFITM3 
knockdown only achieved 30% (Figure 5.5B) when compared to chIFITM levels in the mock 
control.Interrogating this effect in a heterogeneous cell line may allow for further analysis 
as transfection and infection efficiencies are different between cell lines and ex vivo tissue 
culture models.  
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5.4.2 Transient knockdown of chIFITM1 and 3 renders DF-1 cells more susceptible 
to IAV infection 
To fully characterise the effect of chIFITM gene knockdown and the impact that this has on 
the restriction of avian IAV, DF-1 cells were transfected with the same siRNAs as mentioned 
in section 5.3.1, although a higher total concentration of 80nM (20nM of each individual 
siRNA in a pool of four targeting each gene) was used to assess gene knockdown in this 
continuous cell line. Moreover, in order to expand the study and to further characterise 
strains we have already investigated, three strains of IAV (H3N8, H5N3 and H9N2) were 
used, whereas only the enzootic strain (H9N2) was used in section 5.3.1.  
20nM of each siRNA (80nM in total) was transfected into DF-1 cells using HiPerfect as per 
the manufacturer’s protocol. After 24 hours the same cells were infected with H3N8, H5N3 
or H9N2 IAV (MOI – 1) for 8 and 24 hours after which the supernatants were harvested and 
the quantification of viral particles was performed using plaque assay titration. Material to 
be assayed was serially diluted in serum-free DMEM and used to infect MDCK cells in 12-
well plates. After 1 hour of incubation, the inoculum was removed, and the cells were 
overlaid with DMEM containing 0.2% BSA, 2% agar and 1μg trypsin ml−1. After 3 days, the 
overlay was removed, and the cells were stained with crystal violet to determine the 
pfu/ml.  A statistically significant increase in viral supernatant titre (0.71 log10) was 
observed with knockdown of chIFITM3, followed by infection with H3N8 (8 hours post 
infection), but no other significant increases in viral titres were observed for the other 
chIFITM knockdowns after infection with H3N8, including the samples assayed at 24 hours 
post infection (Figure 5.6A). Knockdown of chIFITM3 led to an increase in viral titres of 1.3 
log10 and 0.9 log10 at 8 and 24 hours post infection respectively when DF-1s were infected 
with H5N3 (Figure 5.6B). Although a significant knockdown using siRNAs against chIFITM1 
could not be detected by quantitative RT-PCR, there was a significant increase in viral titres  
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Figure 5.6 Transient knockdown of chIFITM1 and 3 renders DF-1s more susceptible to IAV 
infection. (A - C) The effect of knocking down endogenous chIFITM1, 2, 3 or 5 expression in 
DF-1 cells infected with H3N8, H5N3 or H9N2 (MOI 1, 8 and 24 hours) was measured by 
plaque assay titration in MDCK cells. (D) The expression level and log fold change of 
chIFITM1, 2, 3 and 5 were measured using quantitative RT-PCR (relative to mock, 
normalised to RPLPO and RPL13) after pre-incubation with a non-targeting (scrambled) 
siRNA or siRNAs specific to chIFITM1, 2, 3 or 5. (E) The effect of infection on knockdown 
was assessed by the expression level and log fold change of chIFITM1, 2, 3 and 5 measured 
using quantitative RT-PCR (relative to mock, normalised to RPLPO and RPL13) 48 hours 
after transfection and 24 hours after infection (MOI 1). (F) The expression level and log 
fold change of chIFITM1, 2, 3 and 5 were measured using quantitative RT-PCR (relative to 
mock, normalised to RPLPO and RPL13) after infection with H9N2 in DF-1 cells (MOI 1, 24 
hours). Error bars show standard deviations of the means (n =3 biological replicates), * 
indicates a p-value <0.05, ** indicates a p-value<0.01, *** indicates a p-value <0.001, 
****indicates a p-value <0.0001 one-way ANOVA. 
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(0.9 log10) at 24 hours post infection when chIFITM1-depleted cells were infected with 
H5N3 (Figure 5.6B). There were no significant differences in viral titres for chIFITM-depleted 
cells that were infected with H9N2 (Figure 5.6C).   
Transient knockdown of endogenously expressed chIFITM transcripts in a continuous 
chicken cell line was evaluated 24 hours post transfection and before IAV infection. Using 
the same method as previously described, samples were harvested at 24 hours post 
transfection. The cells were lysed, RNA extracted and reverse transcribed and chIFITM 
expression levels were assessed by quantitative RT-PCR, relative to mock and normalised to 
two house-keeping genes, RPLPO and RPL13.  Scrambled siRNA did not significantly alter 
chIFITM transcript abundance when assessed against an average of all four chIFITMs under 
mock conditions (Fig 5.6D). A statistically significant knockdown of chIFITM 2 (35%), 3 (32%) 
and 5 (75%) was achieved in this cell line. A reliable knockdown of chIFITM1 expression 
could not be achieved and consequently this did not reach significance in comparison to the 
negative scramble. The siRNA knockdown of chIFITM expression was variable across all 
chIFITMs that were quantified (Figure 5.6D). The absence of a significant increase in viral 
titres for cells depleted of chIFITM1 and infected with H9N2 may be explained by the poor, 
non-significant knockdown of chIFITM1 in this cell type. It is not yet understood why 
chIFITM1 knockdown was better in CEFs when compared to DF-1 cells, although the 
increase in H5N3 viral titres at 24 hours post infection suggest that variability may be a 
factor in determining which cells are susceptible to infection. 
To evaluate the impact that transfection and infection has on chIFITM expression, the 
native upregulation of the chIFITMs were measured using samples without transfection of 
the negative scramble (80nM).  Samples were taken 24 and 48 hours post infection with 
H9N2 (MOI – 1) and were analysed using quantitative RT-PCR. The cells were lysed, RNA 
extracted and reverse transcribed and chIFITM expression levels were assessed by 
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quantitative RT-PCR, relative to mock and normalised to two house-keeping genes, RPLPO 
and RPL13. Transfection of the negative scramble, followed by infection with H9N2 led to 
significant upregulation in both chIFITM1 and chIFITM5 mRNA expression, when compared 
to the mock control. The transcript abundance of chIFITM2 was upregulated 2 fold, whilst 
chIFITM3 was not upregulated and levels of mRNA were comparable to those of the mock-
infected control. In contrast, in the untransfected cells, only chIFITM5 was significantly 
upregulated upon infection with H9N2. Moreover, although levels of chIFITM1 and 2 were 
scarcely upregulated, these failed to reach the levels observed in the pre-transfected 
sample and were not significant. As described previously, levels of chIFITM3 remained 
comparable to mock-infected levels. This data suggests that siRNA treatment may increase 
chIFITM transcript abundance which may be a result of further innate immune activation 
driven by siRNA transfection. This implies that siRNA treatment for the purposes of 
knocking down ISG expression may not be the most preferable method of choice as the 
knockdown appears to be inefficient. In order to reduce cellular stress, the activation of 
innate immune pathways and the subsequent induction of ISG expression, other methods 
of gene silencing, such as CRISPR/CAS9 may allow for better silencing without reactivation. 
5.4.3 Transient knockdown of chIFITM2 renders DF-1s more susceptible to IBV 
infection 
As has previously been mentioned in chapter 4, the cellular tropism of both M41 and QX is 
constrained and they are only able to infect primary chick kidney cultures which are not 
suitable for transfection experiments. Due to these constraints, BeauR is utilised as a model 
strain of IBV as it can infect DF-1 cells, a cell line that can also be transfected. The data has 
demonstrated that the chIFITMs are transcriptionally upregulated in response to viral 
challenge (Figure 4.7) and this was investigated using quantitative RT-PCR and this was 
significant for all four chIFITM genes at 24 hours post infection. Furthermore, DF-1 cells 
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transiently transfected with the chIFITM expression constructs resulted in a significant 
decrease in viral titres for chIFITM2 overexpressing cells. The data implies that the chIFITMs 
play a functional role in the restriction of IBV, although there is currently a lack of data 
demonstrating if knockdown of chIFITM expression results in increased viral titres.  
 
In order to address these challenges and gaps in our current understanding, DF-1 cells were 
transiently transfected with 20nM of each siRNA (80nM in total) using HiPerfect as per the 
manufacturer’s protocol. These cells were infected with BeauR (MOI - 1) for 24 hours, and 
the supernatants assayed for the presence of infectious virions. Briefly, material to be 
assayed was serially diluted in 1x BES and used to infect CK cells in 12-well plates. After 1 
hour of incubation, the inoculum was removed, and the cells were overlaid with 2x BES and 
2% agar. After 3 days the cells were fixed with 10% paraformaldehyde (PFA) in PBS which 
was overlaid onto to the agar and incubated for 15 minutes. Agar was removed from each 
well and cells stained with 0.1% crystal violet (w/v) for 10 minutes and plaques counted to 
determine the pfu/ml. A statistically significant increase in viral supernatant titre (1.1 log10) 
was observed with knockdown of chIFITM2, followed by infection with BeauR (24 hours 
post infection, MOI – 1), but no other significant increases in viral titres were observed for 
any of the other chIFITMs that were targeted (Figure 5.7A). The viral titres between 
infected cells and cells that were treated with scrambled siRNA before infection are not 
significantly different. Transient knockdown of endogenously expressed chIFITM transcripts 
was assessed by quantitative RT-PCR with samples that were harvested at 24 hours post 
transfection. The cells were lysed, RNA extracted and reverse transcribed and chIFITM 
expression levels were assessed by quantitative RT-PCR, relative to mock and normalised to 
two house-keeping genes, RPLPO and RPL13.  Scrambled siRNA did not significantly alter 
chIFITM transcript abundance when assessed against an average of all four chIFITMs at 
basal levels (Figure 5.7B). The knockdown of all four chIFITM genes was significant when  
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Figure 5.7 Transient knockdown of chIFITM2 renders DF-1s more susceptible to IBV 
infection. (A) The effect of knocking down endogenous chIFITM1, 2, 3 or 5 expression in 
DF-1 cells infected with BeauR (MOI 1, 24 hours) was measured by plaque assay titration in 
CK cells. (B) The expression level and log fold change of chIFITM1, 2, 3 and 5 were 
measured using quantitative RT-PCR (relative to mock, normalised to RPLPO and RPL13) 
after pre-incubation with a non-targeting (scrambled) siRNA or siRNAs specific to 
chIFITM1, 2, 3 or 5. (C) The effect of infection on knockdown was assessed by the 
expression level and log fold change of chIFITM1, 2, 3 and 5 measured using quantitative 
RT-PCR (relative to mock, normalised to RPLPO and RPL13) 48 hours after transfection and 
24 hours after infection (MOI 1). (D) The expression level and log fold change of chIFITM1, 
2, 3 and 5 were measured using quantitative RT-PCR (relative to mock, normalised to 
RPLPO and RPL13) after infection with BeauR in DF-1 cells (MOI 1, 24 hours). Error bars 
show standard deviations of the means (n =3 biological replicates), * indicates a p-value 
<0.05, ** indicates a p-value<0.01, *** indicates a p-value <0.001, ****indicates a p-value 
<0.0001 one-way ANOVA. 
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compared to the scrambled siRNA control, similar to what was observed in the IAV study 
(Figure 5.6D). In agreement with data shown earlier in this chapter, transfection with siRNA 
prior to infection appears to prime the cell for an enhanced response as the chIFITMs are 
transcriptionally upregulated when compared to the infection only control and normalised 
to the mock infection control. There is a significant increase in the mRNA expression for all 
four chIFITMs, and only chIFITM1 has a less significant increase in gene expression 
compared to the infection only control (Figure 5.7C and D). Furthermore, the pattern of 
chIFITM gene expression is similar between the two conditions, with chIFITM5 having the 
greatest increase in mRNA expression followed by chIFITM2. Although the Y axis on both 
figures is in a log2 format, it is important to note that the scales are different. For example 
the Y axis is significantly higher for the samples treated with scrambled siRNA prior to 
infection than for the samples that were only infected with BeauR.  
Taken together with the transient overexpression data (Figure 5.4), these observations 
suggest that chIFITM2 is the primary restriction factor of IBV in DF-1 cells. The other 
chIFITMs, either when ablated or overexpressed, do not appear to play a significant role in 
the restriction of IBV. This may imply that viral entry and/or replication is a determining 
factor in restriction, although the mechanisms underpinning this are unclear. The specific 
antiviral activities of chIFITM-mediated restriction may be important in the context of viral 
infection as chIFITMs differentially restrict viral pathogens and this may be dependent on 
the cell line used.  
 
 
 
Chapter 5: ChIFITM-mediated viral restriction of avian viral pathogens 
232 | P a g e  
 
5.5 DF-1 cells stably-expressing chIFITM1, 2, 3 or 3MUT result in the 
restriction of avian viruses 
5.5.1 DF-1 cells stably-expressing chIFITM1, 2, 3 or 3MUT differentially restrict 
H3N8, H5N3 or H9N2   
Stable transfection allows for the expansion of cells that are stably expressing a gene of 
interest under the selection of a reporter gene or antibiotic. Stably transfected nucleic acid 
can either be delivered into the cells for incorporation into the host genome or it can be 
transfected into the target cell where it remains as an expression vector without 
incorporation.  
Transient transfection delivers nucleic acid, such as dsDNA plasmids, into cells in a copy 
number independent manner.  Cells will therefore express one or more copies of the 
exogenous gene, resulting in differential expression levels of the gene of interest. After 
stable transfection, it is possible to select clonal populations that can be expanded so that 
the expression profile of each cell is comparable.  In this study, DF-1 cells were transfected 
with expression vectors that had the chIFITM gene sequences cloned into them with a FLAG 
tag on the C-terminus immediately following the chIFITM protein. Synthetic copies of 
chIFITM1, 2, 3 and 3MUT gene strings were cloned into the BamHI and NotI sites of the 
vector pcDNA4myc/HIS B and sequences and junctions confirmed by Sanger sequencing. 
Stably transfected cells were generated by transfecting DF-1 cells with 1μg of plasmid and 
4μl of Lipofectamine 2000 in one well of a 12 well plate, as per the manufacturers protocol. 
After 24 hours the medium was removed from the cells and replaced with DMEM 
containing 10% fetal bovine serum (FBS) and 100μg/ml zeocin. To determine the 
incorporation of the pcDNA4 plasmids into the target cells, untransfected DF-1 cells were 
treated with the same concentration of zeocin and cell death was used as a marker for  
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Figure 5.8 DF-1 cells stably-overexpressing chIFITM1, 2, 3 and 3MUT restrict IAV infection. 
(A – C) DF-1 cells stably-expressing chIFITM1, 2, 3 or 3MUT were infected with IAV (H3N8, 
H5N3 or H9N2, respectively, MOI 0.1) for 12, 24 or 48 hours. Viral replication was 
measured by plaque assay titration in MDCK cells of the infected cell supernatant relative 
to the control (empty vector). (D) Lysates were separated by SDS-PAGE and proteins 
were transferred to a nitrocellulose membrane and a western blot performed using 
a monoclonal antibody against the FLAG tag. Error bars show standard deviations of the 
means (n =3 biological replicates), * indicates a p-value <0.05, ** indicates a p-value<0.01, 
*** indicates a p-value <0.001 ****indicates a p-value <0.0001, one-way ANOVA. 
H9N2 
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vector incorporation. To verify the observations achieved with either transient knockdown 
or transient overexpression, DF-1 cells that stably express chIFITM1, 2, 3 or 3MUT were 
generated. The chIFITM3MUT cell line was been engineered so that the cysteine residues at 
positions 71 and 72 were mutated to alanine residues, which we hypothesise would alter 
the antiviral properties of chIFITM3.  
The stably-expressing DF-1 cells, alongside a vector only control and untransfected DF-1 
cells, were infected with the aforementioned strains of IAV (H3N8, H5N3 or H9N2) at an 
MOI of 0.1 for 12, 24 or 48 hours. The supernatants from infected cells were harvested and 
the quantification of viral particles was performed using plaque assay titration. Material to 
be assayed was serially diluted in serum-free DMEM and used to infect MDCK cells in 12-
well plates. After 1 hour of incubation, the inoculum was removed, and the cells were 
overlaid with DMEM containing 0.2% BSA, 2% agar and 1μg trypsin ml−1. After 3 days, the 
overlay was removed, and the cells were stained with crystal violet to determine the 
pfu/ml. Under these experimental conditions a statistically significant difference in the 
restriction of these viruses by the chIFITMs was observed. H3N8 and H5N3 were restricted 
by all of the chIFITMs that were tested (Figure 5.8A and B). The only significant difference 
between these two strains was observed at 12 hours post infection (Figure 5.8A). In these 
samples chIFITM2 and chIFITM3MUT were not able to restrict H3N8, although this effect was 
not observed at the later time points. A 1 log10 reduction in viral titres was consistently 
observed in those cells that were stable-expressing chIFITM1, 3 and 3MUT. Smaller but still 
significant reductions in viral titres were observed with cells stably-overexpressing 
chIFITM2. Infection with H9N2 led to a smaller, but still significant, decrease in viral titres 
with chIFITM3 and 3MUT at 12 hours post infection and with chIFITM1, 3 and 3MUT at 48 
hours post infection. No significant differences in viral titres were observed at 24 hours post 
infection when these cells were challenged with H9N2. Moreover, there was no significant 
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decrease in viral titres for cells stably-expressing chIFITM2 and infected with H9N2. This 
may suggest preferential restriction of IAV by chIFITM1 and 3.                             
The level of chIFITM protein expression was assessed using western blot against the C-
terminal FLAG tag (Figure 5.8D). Samples of stably expressing cell lysate were taken at 0 
hours post infection to assess protein expression at the start of infection. The cells were 
lysed, the proteins were separated by SDS-PAGE and transferred onto a nitrocellulose 
membrane. Western blots were performed using a FLAG antibody alongside β-actin loading 
control. All of the chIFITM proteins were expressed when compared to the vector only 
control. Levels of β-actin were relatively stable across all of the samples, with the exception 
of the chIFITM2 overexpressing cell lysate where the level of β-actin was lower than the 
corresponding control.  
These data suggest that chIFITMs are potent restriction factors of IAV. In particular, H3N8 
and H5N3 viral titres are significantly reduced by chIFITM1, 2, 3 and 3MUT overexpression, 
although nuances in the data suggest that not all chIFITMs are equally as potent in 
restricting IAV. Moreover, the data suggests that chIFITM2 is less able to restrict IAV as the 
differences in viral titres, although significant, are lower than those observed with chIFITM1 
and 3 overexpression. This implies that chIFITM1 and 3 preferentially restrict IAV in vitro. In 
addition, this study aimed to determine the importance of the cysteine residues at 
positions 71 and 72 in chIFITM-mediated restriction. It appears that there is little difference 
in the restrictive profile between the native and the mutated chIFITM3 proteins. There was 
a greater degree of variation in the chIFITM3MUT viral titres early on post infection, but 
these effects were transient and viral titres were comparable at later time points, across all 
three strains of IAV that were tested. It is therefore proposed that mutations at these 
positions have little impact on restriction, which is in contrast to data published in the 
mammalian field.   
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5.5.2 Stably-expressing DF-1 cells differentially restrict IAV when infected at a high 
MOI  
The ability of a virus to colonise a host is critical in ensuring its maintenance in the viral 
population (Caron et al., 2017). Viral infections are able to propagate with relatively few 
virions. This makes seasonal cases of influenza prevalent in the community as well as other 
viral infections. In section 5.4.2 a relatively low MOI was used to assess chIFITM mediated 
restriction and this simulates a more realistic model of infection, especially when 
transmission is mediated through liquid droplets produced from coughing and/or sneezing. 
These data demonstrate that three strains of IAV are potently restricted by chIFITM 
overexpression, although differences between both viral restriction and the chIFITMs 
mediating this effect suggest that restriction is not universal. Moreover, chIFITM1 and 3 
may preferentially restrict influenza. In agreement with other data presented in this 
chapter, H9N2 appears to be less sensitive to chIFITM-mediated restriction than the other 
two avian influenza A viruses that have been examined. Although the mechanism 
underlying this is currently unknown, it is possible that one of the viral interferon agonists, 
NS1 or PB1-F2, is mediating this effect.  
Stably-expressing DF-1 cells were infected with chicken H3N8, H5N3 or H9N2 influenza 
virus (MOI - 5) for 12 or 24 hours, and the supernatants were assayed for the presence of 
infectious virions. Material to be assayed was serially diluted in serum-free DMEM and used 
to infect MDCK cells in 12-well plates. After 1 hour of incubation, the inoculum was 
removed, and the cells were overlaid with DMEM containing 0.2% BSA, 2% agar and 1μg 
trypsin ml−1. After 3 days, the overlay was removed, and the cells were stained with crystal 
violet to determine the pfu/ml.  Cells overexpressing any of the chIFITMs at 12 hours post 
infection and infected with H3N8 were not able to restrict viral infection as evidenced by 
non-significant differences in viral titres (Figure 5.9A). At 24 hours post infection there was  
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Figure 5.9 DF-1 cells stably-overexpressing chIFITM1, 2, 3 and 3MUT restrict IAV infection. 
(A – C) DF-1 cells stably-expressing chIFITM1, 2, 3 or 3MUT were infected with IAV (MOI 5) 
for 24 or 48 hours. Viral replication was measured by plaque assay titration in MDCK cells 
of the infected cell supernatant relative to the control (empty vector). Error bars show 
standard deviations of the means (n =3 biological replicates), * indicates a p-value <0.05, 
****indicates a p-value <0.0001, one-way ANOVA. 
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a significant decrease in viral titres in cells overexpressing chIFITM1, 2, 3 or 3MUT. The most 
significant decrease in viral titres was observed with chIFITM2 and 3MUT which is in contrast 
with the data presented in figure 5.8A. It is unknown whether an increase in the number of 
viral particles added during infection alters the restrictive nature of the chIFITM proteins 
but these data highlights a difference under these experimental conditions. Infection with 
H5N3 resulted in a significant decrease in viral titres at both 12 and 24 hours post infection. 
The viral titres of both the infection and vector only controls increased over time unlike the 
chIFITM stably-expressing samples that remained at comparable levels between time 
points (Figure 5.9B). In agreement with data shown in figure 5.8B, chIFITM1 and 3/3MUT 
appear to restrict IAV preferentially, with cells overexpressing chIFITM2 having higher viral 
titres in comparison to either chIFITM1 or 3/3MUT. These data presented in figure 5.9C is 
similar to the data in figure 5.8C in regards to the difference in viral titres, although smaller 
in magnitude and restriction occurring later during infection. Overexpression of all the 
chIFITM proteins enables restriction of H9N2, although chIFITM3 appears to preferentially 
restrict this virus at a high MOI. The differences in the restrictive capabilities of chIFITM3 
and 3MUT appear to be small and this data does not suggest a loss of function when the 
cysteine residues are mutated to alanine residues. Moreover, it could be suggested that the 
alanine substitutions confer an advantage to chIFITM3 when these cells are challenged at a 
high MOI. There appears to be a further reduction in viral titres in comparison to the wild-
type chIFITM3 after cells are challenged with either H3N8 and or H5N3.   
Taken together, these data suggests that the chIFITM proteins are able to potently restrict a 
current enzootic strain of avian influenza virus (H9N2) alongside two further strains (H3N8, 
H5N3) of IAV at a low and a high MOI. This suggests a functional role for the chIFITM 
proteins in the restriction of viral infections with strains of low pathogenicity avian 
influenza virus.  
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5.5.3 DF-1 cells stably-expressing chIFITM2 restrict IBV when cells are challenged 
at a high MOI  
Data presented in this chapter demonstrates that the overexpression of chIFITM2 renders 
the cells more refractory to infection with IBV. Conversely, knocking down chIFITM2 
expression makes cells more susceptible to infection with BeauR. Although the exact 
mechanism for this remains unclear, it may be because of the relocalisation of IFITM2 from 
intracellular compartments in mammalian cells to the plasma membrane in chicken cells. In 
order to examine this in further detail, the stably-expressing DF-1 cells were used to 
characterise the restriction of IBV when these cells are challenged with a high MOI as 
opposed to the lower MOI (1) that was used in both the transient overexpression (figure 
5.4) and knockdown (figure 5.7) experiments.    
Stably-expressing DF-1 cells were infected with BeauR (MOI - 5) for 8 hours, and the 
supernatants assayed for the presence of infectious virions. Briefly, material to be assayed 
was serially diluted in 1x BES and used to infect CK cells in 12-well plates. After 1 hour of 
incubation, the inoculum was removed, and the cells were overlaid with 2x BES and 2% 
agar. After 3 days the cells were fixed with 10% paraformaldehyde (PFA) in PBS which was 
overlaid onto to the agar and incubated for 15 minutes. Agar was removed from each well 
and cells stained with 0.1% crystal violet (w/v) for 10 minutes and plaques counted to 
determine the pfu/ml. In agreement with the previous data presented in this chapter, the 
only significant decrease in virus titre was observed in cells overexpressing chIFITM2. There 
was no statistical difference between the virus titres of any of the other overexpressing cell 
lines when compared to the vector only control. This suggests that chIFITM2 is the only 
restriction factor of the non-pathogenic strain of IBV, BeauR in vitro, although it is unclear if 
chIFITM2 is a restriction factor of other strains within the IBV viral family. As previously  
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Figure 5.10 DF-1 cells stably-overexpressing chIFITM2 restrict IBV infection. DF-1 cells 
stably-expressing chIFITM1, 2, 3 or 3MUT were infected with IBV (MOI 5) for 8 hours. Viral 
replication was measured by plaque assay titration in CKC cells of the infected cell 
supernatant relative to the control (empty vector). Error bars show standard deviations of 
the means (n =3 biological replicates), * indicates a p-value <0.05, one-way ANOVA. 
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described, the other strains are not able to infect continuous cell lines as their cellular 
tropism is restricted. 
5.6 Mutational analysis of chIFITM3 suggests that conserved domains 
may be important in determining antiviral activity against IAV 
It has been determined that the IFITM proteins are post-translationally modified and that 
these modifications have an impact on viral restriction if mutated (Chesarino et al., 
2014a;Chesarino et al., 2014b;Compton et al., 2016). These modifications include: 
palmitoylation (Cys71, 72 and 105), phosphorylation (Tyr20 and 99), ubiquitination (Lys24, 
83, 88, 104) and methylation (Lys88). In 2014, Jia et al. described a motif that is critical for 
endosomal localisation (YEML motif) which is important for the cellular distribution and 
restriction of IFITM3 (Jia et al., 2014). It has been hypothesised that two specific residues 
(F75 and 78) may be important for dimerization which in turn may be essential for the 
correct structure required for restriction (John et al., 2013). This study examined the 
importance of these residues in mammalian IFITM3 and described how these residues 
facilitate a physical association between IFITM proteins. It has been found that the 
palmitoylation of cysteine residues is necessary for the restrictive activity of IFITM3 
(Chesarino et al., 2014b;Yount et al., 2012;Yount et al., 2010). Moreover, the palmitoylation 
of Cys72 may play a critical part in modulating IFITM3 antiviral activity. The three palmitoyl 
groups found on huIFITM3 have been shown to confer stability, are necessary for the 
correct cellular localisation and for their association with lipid rafts (Yount et al., 
2012;Yount et al., 2010). It has been hypothesised that the ubiquitination of the IFITM 
proteins regulates their expression and stabilises the protein in vitro, with ubiquitinated 
IFITM3 localising to the endosomes compared to IFITM3 which mislocalises when 
ubiquitination is perturbed (Chesarino et al., 2014a). Although it has been found that 
ubiquitination of these residues in essential for a multitude of functions, mutating these 
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residues to alanine residues does not significantly alter the restriction of enveloped viruses 
(Shan et al., 2013). A study published in 2013 showed that the methylation of huIFITM3 is 
increased through IAV infection and decreased with IFNα treatment. This may suggest that 
IAV actively promotes IFITM3 methylation as this perturbs the antiviral function and may 
act as a strategy for innate immune evasion (Shan et al., 2013). Phosphorylation of the 
Tyr20 residue has been shown to regulate subcellular localization and restriction activity of 
IFITM3 (Chesarino et al., 2014a). In addition, mutating Tyr99 to Ala99 differentially reduces 
the restrictive capabilities of IFITM3 in regards to IAV infection, but not for DENV (Jia et al., 
2012;John et al., 2013). 
In this study we aimed to assess whether the residues identified as being important or 
essential for the restrictive capabilities of huIFITM3 are necessary for chIFITM-mediated 
restriction, and whether the loss of these residues through mutation would alter the 
restrictive profile of chIFITM3. In order to investigate this, wildtype amino acids were 
sequentially mutated to alanine residues in blocks of ten. Starting from the second residue 
immediately after the start methionine, ten alanine residues were incorporated into the 
backbone of chIFITM3 with sequential mutagenesis across the whole protein, ending at the 
stop codon which was not mutated (Figure 5.11A). It was hypothesised that if residues 
within the alanine scanning mutant were important, then the restriction of IAV would be 
detrimentally affected and that this would be assessed through increased viral titres 
compared to the wildtype chIFITM3 positive control. Restoration of IAV viral titres would be 
assessed as a comparison to an empty vector control.      
It has already been established that the mutation of two palmitoylated cysteine residues at 
position 71 and 72 does not appear to have any detrimental impact on chIFITM3 viral 
restriction (Figures 5, 6, 7 and 8). It is not clear if this is due to them being non-essential in 
the avian host or whether there are compensatory residues which are differentially post-
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translationally modified and assume a similar role of those missing residues in chickens. To 
confirm whether the aforementioned residues/motifs are essential, DF-1 cells were 
transfected with 1μg of plasmid encoding the wildtype chIFITM3 or an alanine scanning 
mutant (Figure 5.11A). These cells were then infected with H9N2 influenza virus (MOI - 1) 
for 24 hours, and the supernatants assayed for the presence of infectious virions.  
Material to be assayed was serially diluted in serum-free DMEM and used to infect MDCK 
cells in 12-well plates. After 1 hour of incubation, the inoculum was removed, and the cells 
were overlaid with DMEM containing 0.2% BSA, 2% agar and 1μg trypsin ml−1. The virus 
only and vector only controls showed comparable titres at 24 hours post infection (Figure 
5.11B). Transfection of any of the alanine scanning constructs prior to infection with IAV 
resulted in a significant decrease in viral titre compared to the vector only control (Figure 
5.11B and C). The average decrease in viral titre across all 14 alanine scanning mutants and 
the wildtype chIFITM3 control was 0.63 log10. However, variations in viral titres were 
observed with the lowest level of restriction seen with IFITM3.11 (0.4 log10) and the 
greatest level of restriction with IFITM3.2 (0.81 log10), which was superior to the restriction 
observed with wildtype chIFITM3. The large variation within the alanine scanning mutants 
suggests that specific regions of the chIFITM3 protein are important in mediating 
restriction. Mutant 3.11, located within the C-terminus, appears to be significantly less able 
to restrict IAV and these reductions in viral restriction are significant when compared to 
wildtype chIFITM3. In particular, mutants 3.11, 3.12 and 3.13 have viral titres that are, on 
average, 0.2 log10 more than the average of the mutants across the entire protein. This 
suggests that this region is important in mediating restriction, although they do not restore 
viral titres to the levels seen in the vector only control, implying partial but not complete 
ablation of function. The level of chIFITM3 protein expression was assessed using western 
blot against the C-terminal FLAG tag (Figure 5.11D). Samples of transiently transfected cell 
lysates were taken at 24 hours post transfection to assess protein expression at the start of 
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infection. The cells were lysed, proteins separated by SDS-PAGE and transferred onto 
nitrocellulose membranes. Western blots were performed using a FLAG antibody alongside 
a β-actin loading control. All of the chIFITM3 mutants were expressed when compared to 
the wildtype chIFITM3 protein levels. A decrease in protein abundance when compared to 
wild type chIFITM3 protein levels was detected in mutants 3.9, 3.12 and 3.14 although 
bands were detected in the corresponding lanes. Levels of β-actin were detected in all 
samples at equitable levels, even in those samples where chIFITM3 expression was lower 
than expected.  
The impact of mutating residues that are post-translationally modified on the restrictive 
capabilities of human IFITMs has been well studied, focussing particularly on huIFITM3. The 
data presented in those studies has suggested that altering certain essential residues, such 
as Cys72, has a profound impact on restriction, whereas other residues (Lys88) can be 
readily mutated without a loss of function (Yount et al., 2012). The data presented in this 
section sought to address whether any residues or regions within chIFITM3 were essential 
for restriction. It appears that no specific region of chIFITM3 is absolutely essential for 
restriction. There are notable and significant differences in the viral titres obtained from 
cells that have been transfected with alanine scanning mutants, but all of these proteins 
were able to restrict IAV when compared to a vector only control. This may imply that the 
C-terminus is important in mediating restriction, as there are significant increases in viral 
titres in cells expressing constructs 3.11 – 3.14, but the increases observed are not large 
enough to suggest that these regions are critical. A study published in 2013 suggested that 
the N-terminus is essential in huIFITM3 for the restriction of IAV, but no such evidence 
presented here suggests that this is the case with chIFITM3 (Bailey et al., 2013). Moreover, 
Bailey et al. suggest that the C-terminus does not play a significant role is huIFITM3 
restriction of IAV, whereas the data presented here appears to suggest that this region may 
play a minor role in determining restriction of IAV by chIFITM3. It was already known that 
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Construct ID Viral titre (log10) Difference (log10) 
Vector control 5.912045007 
 
IFITM3 5.148704431 0.76 
IFITM3.1 5.176091259 0.74 
IFITM3.2 5.105510185 0.81 
IFITM3.3 5.108338347 0.8 
IFITM3.4 5.206375163 0.71 
IFITM3.5 5.213073939 0.7 
IFITM3.6 5.304634838 0.61 
IFITM3.7 5.312107508 0.6 
IFITM3.8 5.240965871 0.67 
IFITM3.9 5.253258022 0.66 
IFITM3.10 5.278753601 0.63 
IFITM3.11 5.511883361 0.4 
IFITM3.12 5.424608892 0.49 
IFITM3.13 5.457377702 0.45 
IFITM3.14 5.369525692 0.54 
B 
C 
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Figure 5.11 Mutational analysis of chIFITM3 suggests that certain domains may be important in determining antiviral activity against IAV. (A) A schematic 
representation of the alanine scanning substitutions that have been made within each construct. Sequentially ten wild-type residues were mutated to 
alanine residues in order to assess the impact these substitutions have on restriction of IAV. (B) DF-1 cells were transfected with 1μg of plasmid encoding 
chIFITM3 or an alanine scanning mutant for 24 hours. These cells were then infected with H9N2 (MOI 1) for 24 hours and the supernatants harvested. Viral 
replication of the infected cell supernatant was measured by plaque assay titration relative to the control (cells transfected with an empty vector). (C) A table 
of H9N2 viral titres and the differences in viral titres in comparison to the vector only control. (D) Cells were lysed at 24 hours post infection and lysates were 
separated by SDS-PAGE. Proteins were transferred to a nitrocellulose membrane and a western blot performed using an anti-FLAG antibody against a C-
terminal FLAG tag with β-actin as the loading control. Error bars show standard deviations of the means (n =3 biological replicates), ** indicates a p-
value<0.01, ****indicates a p-value <0.0001, one-way ANOVA. 
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the amino acid sequence homology between human and chicken IFITM3 was low at 36%. 
However, data published thus far had not been established if these conserved residues 
were important in mediating chIFITM antiviral activity. This data suggest that this is not the 
case. Mutations incorporated into the protein do not appear to be detrimental to 
restriction, even if viral titres are increased when mutations are introduced near to or 
incorporating the C-terminus.     
5.7 Discussion  
It has been established that mammalian IFITM proteins act as potent restriction factors, 
specifically of IAV and other enveloped viruses that enter the cell through the acidification 
of the endosomes (Desai et al., 2014). To complement the early characterisation of these 
proteins, there have been a tremendous number of studies that have sought to uncover the 
mechanisms underpinning this activity (Desai et al., 2014;Li et al., 2013). Current evidence 
is still unclear and in some instances conflicted, although several hypothesise has been 
suggested. The most favoured current hypothesis is that the IFITMs are able to recruit 
cholesterol which modifies the rigidity of the membranes surrounding the endosomal 
compartment. This process traps the virus which is then degraded through the lysosomal 
pathway (Amini-Bavil-Olyaee et al., 2013). Studies utilising mass spectroscopy have 
identified a number of interacting partners that are involved in cholesterol biosynthesis and 
the recruitment of cholesterol. Additionally, the membrane topology of the huIFITMs is also 
unclear with the most robust evidence coming from studies using NMR and EPR to suggest 
a type 2 membrane topology (Ling et al., 2016). Further research is required in order to 
make more detailed claims into their antiviral activity and the mechanisms that modulate 
this. 
In contrast, very little is currently known about the antiviral role that the chIFITMs play in 
restricting avian viruses in the avian host. Initial work was undertaken in 2013 which 
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suggested that chIFITMs were restriction factors, however, this work was fragmented as 
each study focussed only on a particular member of the chIFITM gene family and chIFITM1 
was not investigated at all (Smith et al., 2013). In addition, the authors did not use whole 
avian viruses, instead using pseudo-typed lentiviral vectors, making it difficult to draw 
accurate conclusions. This results in a gap in our understanding of the restrictive ability of 
chIFITMs as a whole. When one considers that the amino acid homology between human 
and chicken IFITM3 is only 36%, it is not surprising that certain residues and motifs, such as 
the cysteine residues at position 71, 72 and 105 are absent in some chIFITM protein 
sequences. It is unclear if compensatory residues assume the role of those missing residues 
or whether they are dispensable for their antiviral activity in chickens. To investigate the 
restrictive profile of the chIFITMs in further detail, siRNA knockdown, transient 
overexpression and stable overexpression was used in continuous avian cells alongside 
strains of pathogenic IAV and non-pathogenic, lab attenuated IBV.    
To investigate the role that the chIFITMs play in restricting viral replication, the chIFITMs 
were transiently overexpressed in both primary ex vivo tissue cultures and in a continuous 
avian cell line that is routinely used in the laboratory. Whilst these are useful tools for 
studying gene function, it is important to consider that transfection and the reagents used 
can place the cell under extreme stress. This in turn can lead to the activation of an antiviral 
state or, under extreme circumstances, can culminate to the cell undergoing apoptosis 
(Wenzel et al., 2012;Li et al., 1999). In experiments where the cells are to be transfected as 
well as infected, it is important that the cells remain viable for the duration of the 
experiment. Experimental and anecdotal evidence suggest that different chemical 
transfection reagents place the cells under different amounts of stress. Furthermore, the 
transfection of different nucleic acids also exert differential adverse effects on the cell. The 
results in Figure 5.1 demonstrate that different transfection reagents are differentially 
cytotoxic to the cell, demonstrating the importance of using the most optimal transfection 
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reagents as a high proportion of dead cells after transfection may adversely affect the 
outcome of the infection experiment. Also, it is clear that different nucleic acids, such as 
siRNA and dsDNA plasmids, can impact on cellular health and maintenance (Li et al., 1999). 
As previously discussed, primary cells are more difficult to transfect and this often results in 
using a higher concentration of plasmid and transfection reagent in order to achieve 
comparable results. In this specific example, 5µg of DNA was required in CEFs in 
comparison to 1µg in DF-1 cells in order to demonstrate a good level of chIFITM protein 
expression. When CEFs were challenged with H9N2 after transfection there was a 
significant decrease in viral titres for all the chIFITM expressing cells, which suggests that 
they all have an antiviral function when overexpressed in avian cells. When DF-1 cells are 
transfected with the same chIFITM gene sequences and infected at a lower MOI (1) with 
different strains of influenza there is a more nuanced outcome. DF-1 cells transfected with 
plasmids encoding the chIFITM sequences and then infected with H3N8 and H9N2 resulted 
in a significant decrease in viral titres, similar to that observed with CEFs. Interestingly, 
infection with H5N3 does not show a uniform pattern of restriction. The pan restriction 
observed with both H3N8 and H9N2 does not appear to be the case for cells infected with 
H5N3. In these samples only cells overexpressing chIFITM1 and chIFITM3 were able to 
restrict H5N3, although the magnitude of restriction was larger than that observed for both 
H3N8 and H9N2. The viral titres for cells overexpressing chIFITM2 and infected with H5N3 
was not significantly different to the empty vector control. Moreover, cells overexpressing 
chIFITM5 had significantly higher viral titres than the vector only control, thus this implies 
that chIFITM5 is pro-viral and results in more progeny virus being made over the 24 hour 
time course. When DF-1 cells were transfected with chIFITM1, 2, 3 and 3MUT and then 
infected with BeauR (IBV), only those cells expressing chIFITM2 had reduced viral titres 
compared to a vector only control as measured by plaque assay titration. This suggests that 
only chIFITM2 is able to restrict BeauR which is in contrast to infection with IAV. IAV is able 
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to be restricted by more than one of the chIFITM proteins and this may imply a dual level of 
control in IAV infected cells.  
Having established that the chIFITMs are able to restrict viral replication when 
overexpressed in both primary ex vivo and in vitro cell cultures, we then sought to test 
whether reduced chIFITM expression would result in increased viral titres. Four siRNAs 
were designed against each chIFITM transcripts (except chIFITM3 where a single published 
siRNA was used) and these were transfected into CEFs and DF-1s. Knockdown of chIFITM 
expression was variable (Figures 5.5B, 5.6D and 5.7B) and this could be attributed to innate 
immune activation due to the transfection protocol. The knockdown of chIFITM1 in CEFs 
resulted in a significant increase in viral titres at 24 hours post infection when these cells 
were infected with H9N2. Similarly, studies conducted in DF-1 cells, increases viral titres 
were observed in cells with diminished chIFITM3 expression at 8 hours post infection when 
infected with H3N8 (Figure 5.6A) and H5N3 (Figure 5.6B). In addition, cells with reduced 
chIFITM1 and 3 expression had increased viral titres at 24 hours post infection when 
infected with H5N3 (Figure 5.6B). There were no significant differences with cells that 
underwent the same knockdown protocol and were then infected with H9N2. This may 
suggest that different viruses display different sensitivities to chIFITM restriction and of 
those cells that are sensitive; chIFITM1 and 3 may preferentially restrict IAV. In contrast, 
DF-1 cells with diminished chIFITM2 expression had increased BeauR viral titres when 
assessed against cells that had been transfected with a scrambled siRNA control. Taken 
together with the overexpression data, this implies that BeauR is preferentially restricted by 
chIFITM2, although the mechanisms behind this remain unclear. Quantitative RT-PCR data 
suggests that knockdown by siRNAs followed by infection with either H9N2 or BeauR 
resulted in more significant chIFITM upregulation when compared to the virus only, no 
transfection control (Figures 5.6E and F, 5.7C and D). This may suggest that knockdown 
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prior to infection activates an innate immune response thus increasing chIFITM expression 
above levels observed with infection alone.  
To remove the need for prior transfection, stably-expressing DF-1 cells were created that 
each express chIFITM1, 2, 3 or 3MUT. It has been known that chemically transfecting cells 
prior to infection can perturb cell membranes and this may have consequences for 
downstream analysis including assessing virus replication by plaque assay titration. These 
cells were challenged with the aforementioned strains of IAV at two MOIs (0.1 and 5) in 
order to assess whether these cells could competently restrict IAV under two different 
conditions. In agreement with data previously described, when stably-expressing cells are 
infected at a low MOI, chIFITM1 and 3 were able to restrict infection by H3N8, H5N3 and 
H9N2, although the magnitude of restriction was different between the strains of IAV used. 
Overexpression of chIFITM2 was also able to restrict infection with H3N8 and H5N3, 
although the viral titres were higher than those cells expressing either chIFITM1 or 3. When 
the same cells were infected at a high MOI a similar pattern of restriction was observed. 
One notable difference was an increase in restriction by chIFITM2. When challenged at a 
high MOI the same cells appear to be more refractory to infection in comparison to cells 
that were infected with a lower MOI (Figure 5.8A, B and C). Moreover, reductions in viral 
titres are observed later on in infection at 24 hours when these cells are challenged with 
H3N8 and H9N2. Significant reductions in viral titres are observed at 12 hours post infection 
for cells infected with H5N3. In contrast to what is known in the mammalian IFITM 
literature (Yount et al., 2012;Yount et al., 2010), mutation of both Cys71 and 72 did not lead 
to any detrimental impacts on chIFITM-mediated restriction. At earlier time points there 
was a greater degree of variation in the chIFITM3MUT viral titres but these effects were 
transient and viral titres were comparable at later time points, across all three strains of IAV 
tested. The differences in the restrictive capabilities between chIFITM3 and 3MUT appear to 
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be small, and this data does not suggest a loss of function when these ‘critical’ cysteine 
residues are mutated to alanine residues.        
The stably-expressing DF-1 cells were also infected at a high MOI (5) for 8 hours with 
BeauR. Consistent with data already presented in this chapter, chIFITM2 expressing DF-1 
cells were able to significantly restrict BeauR. Viral tires for the other chIFITM-
overexpressing cells were comparable to the vector only control. This suggests that under 
the conditions tested, only chIFITM2 is able to restrict infection with BeauR, although only 
one strain of IBV was used due to the restricted cellular tropism of the more pathogenic 
strains.  
Many studies have identified important residues in huIFITM3 that modulate its antiviral 
activities. Studies have described the many ways in which residues are post-translationally 
modified, and studies utilising mutagenesis have demonstrated that antiviral activity can be 
lost if these residues are substituted with alanine residues. Particular emphasis has been 
placed on three palmitoylated cysteine residues at positions 71, 72 and 105 which are 
important for protein stability, cellular localisation and association of chIFITM3 with lipid 
rafts (Narayana et al., 2015). Other residues undergo phosphorylation (Tyr20 and 99), 
ubiquitination (Lys24, 83, 88, 104) (Yount et al., 2012) and methylation (Lys88) (Shan et al., 
2013) although not all of these residues are essential for restriction and can be mutated to 
alanine residues without a loss of function. In the data presented here, sequential 
mutations were made across the whole chIFITM3 protein except for the start methionine 
and stop codon. The viral titres obtained from this experiment suggest that the cysteine 
residues at position 71 and 72 are not essential for restriction, which is in agreement with 
the data generated utilising the stably-expressing cell lines. There were increases in viral 
titres when cells were expressing chIFITM3.11 – 3.14 which suggests that the C-terminus 
has a role in determining antiviral activity. Although viral titres were increased when 
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mutations were made in this region, there was not a complete ablation of function, with 
levels below that observed with the vector only control. It remains unclear if this is virus 
specific and whether there are specific residues that modulate this effect specifically.   
To conclude, it has been demonstrated that chIFITMs are potent restriction factors and are 
able to restrict a diverse range of strains of IAV and the laboratory attenuated strain of IBV, 
BeauR. Taken together this data demonstrates that chIFITM1 and 3 preferentially restrict 
IAV, although at high MOIs it appears that chIFITM2 is able to restrict IAV to levels which 
are not seen at low MOIs. In contrast, only chIFITM2 is able to restrict IBV and this has been 
investigated through transient overexpression, knockdown and stable overexpression. It is 
unclear what mechanism is driving restriction, although it could be hypothesised that the 
cellular relocalisation of chIFITM2 may be partially responsible for this phenotype. Further 
research is required to examine this relationship in more detail and it would be useful to 
investigate whether pathogenic strains of IBV are also restricted by chIFITM2. The data 
presented in Figure 5.11A-D also suggests that specific regions of chIFITM3 are not 
absolutely essential for restriction. When blocks of 10 amino acids were mutated to alanine 
residues there was not a complete loss of restriction and all chIFITM3 variants were able to 
restrict IAV, when compared to a vector only control. This work suggests that the C-
terminus may influence restriction, although the individual residues involved are yet to be 
identified.  
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6.1 Concluding remarks 
The main aims of this project were to investigate the architecture of the chIFITM locus, 
determine the expression of the chIFITM genes and to elucidate which viruses are 
restricted by chIFITM expression.  
The chIFITM locus is present in the genome of the ancestor (Gallus gallus) as well as in 
avian cell lines used in research. Re-sequencing this locus now means that a high quality, 
contiguous sequence is available and will aid further research. It also allows for greater 
interrogation of this locus by comparative genomics, something that has not been possible 
up until now. Moreover, it has now been shown that these genes are constitutively 
expressed in all tissues and cell lines.  
It is now clear that the chIFITMs are robustly upregulated in response to either IAV and IBV 
viral challenge, stimulation with the dsRNA analogue poly(I:C) or after treatment with 
exogenous type I interferon. Notably, infection with HVT does not induce chIFITM 
expression although the reasons for this remain unclear. Moreover, the data presented in 
this thesis using pull-down assays provides evidence that the chIFITMs are able to restrict 
enveloped viral pathogens via the possible modulation of lipid biosynthesis which may 
prevent viral entry into the cytoplasm. Targeted mutations of the cysteine residues at 
positions 71 and 72 do not appear to abolish or diminish the restrictive ability of the 
chIFITMs, unlike mammalian IFITMs. Mutagenesis across the entire polypeptide of 
chIFITM3 has failed to identify any regions of the protein that are essential for chIFITM-
mediated restriction. 
 Taken together, this demonstrates that chIFITMs are part of the wider ISG family and 
suggests that they have a functional role in restricting enveloped viral pathogens. In 
addition, the findings of this thesis establish that chIFITM5 is a novel ISG as it is potently 
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upregulated upon viral infection and its expression is found in every cell line, ex vivo cell 
culture and tissue that was investigated.  
6.1 Future work and directions 
The work outlined in this thesis advances our knowledge of chIFITMs and their restriction of 
avian viral pathogens. However, there are still a number of areas where further research 
would enhance our knowledge of these genes and may broaden our insights into chIFITM-
mediated viral restriction. The sequence diversity within the chIFITM locus has not been 
extensively examined in outbred chicken populations. There are a diverse range of chickens 
that occupy distinct geographical niches which may have a greater degree of variation 
within the chIFITM locus. Chickens in these environments are often unvaccinated and 
encounter a wide range of viral pathogens. This places additional selection pressures on the 
animals, which may result in chIFITM genes that have more potent antiviral activity. To do 
this, it would be possible to use the DNA sequencing technology outlined in chapter 3 to 
assess the chIFITM locus from a variety of different chickens, worldwide. This would allow 
for further investigations into SNPs that confer a protective advantage against emerging 
avian viral pathogens. Moreover, any SNPs identified could be used in commercial breeding 
programmes, ensuring the welfare of chickens and enhancing the resistant of commercial 
poultry to viruses. 
Although potential protein-chIFITM interactions have been identified in this study by mass 
spectrometry, and preliminary research undertaken to confirm these interactions, it has not 
been possible to investigate any possible mechanisms of action. Further investigations 
could be undertaken utilising yeast-2-hybrid screens and high resolution microscopy. In 
order to examine the functional relevance of these interactions, molecular techniques such 
as CRISPR/Cas9 could be used, as it may be possible to perturb these interactions, therefore 
reducing the functional activity of the chIFITM proteins. This would provide useful insights 
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into the mechanism mediating viral restriction and it may be possible to elucidate how 
viruses are able to evade chIFITM-mediated restriction. Furthermore, many studies have 
shown that the IFITM proteins are found within the plasma and intracellular membranes 
and this has been hypothesised to be necessary for restriction. However, it is still not clear 
if the IFITM proteins reside in only one location or whether they are trafficked around the 
cell in response to viral infection. These studies have been frustrated by a lack of reagents, 
namely antibodies that cross-react and detect more than one IFITM protein simultaneously. 
To examine this in further detail it may be necessary to design and make further sets of 
custom antibodies or it may be possible to genetically alter a cell line in such a way that the 
chIFITM/IFITM genes are tagged within the germline. This would somewhat alleviate the 
problems associated with transient overexpression as the wildtype gene could be 
stimulated and the localisation examined without the need for prior transfection.   
Data presented in this thesis has demonstrated that in vivo modulation of chIFITM 
expression is complex. Only one example of chIFITM upregulation was found at 2 days post 
infection, whereas there were multiple examples of downregulation of chIFITM expression 
at day 5 post infection. Currently, there are very few studies that have examined the in vivo 
regulation of chIFITM expression in response to viral infection. Upregulation of chIFITM 
expression occurs very quickly after the virus has established infection in the host cell. 
Therefore, it would be beneficial if tissues were harvested earlier during infection to ensure 
a more robust assessment of chIFITM expression can be made. Although only a single 
significant increase in chIFITM expression was found in the IAV study (chapter 4), it may be 
that tissues were harvested too late in infection. In addition, there are currently no data 
that examines the in vivo effects of infection with a diverse range of avian viruses. 
Conducting a larger scale experiment with a number of different viruses would be 
expensive and time consuming, so it may be more practical to combine studies with groups 
already undertaking in vivo experimentation.  
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Although the findings in this thesis demonstrate that enveloped viruses can be restricted by 
one or more chIFITM in vitro, it is still unclear if there are avian viruses that are insensitive 
to restriction. With stably expressing cell lines it would be possible to investigate this, using 
both plaque assay titrations and FACs to determine viral entry and replication. With new 
advances in CRISPR/Cas9 technology it may also be possible to generate a number of avian 
cell lines that have one or more of the chIFITM genes knocked out from the genome. Using 
these cells, it may be possible to determine which chIFITMs are essential for viral restriction 
and could provide further insights into viral specificity. 
The chIFITM gene family is known to encode five genes, although this project has primarily 
focused on chIFITM1, 2, 3 and 5 and only preliminary investigations into chIFITM10 have 
been undertaken. The function(s) of huIFITM10 are currently unknown, although it has not 
been implicated in viral restriction to date. It is clear by data produced by others in the 
Genetics and Genomics groop and by (Okuzaki et al., 2017), that chIFITM10 has some 
antiviral function and it is upregulated in response to treatment with poly(I:C). Additional 
investigations would further elucidate its function, although it appears that chickens have 
five antiviral IFITM genes, in comparison to humans who appears to have only have three 
(clade I). 
Finally, vaccines are the main tool used to counter endemic and emerging viral pathogens, 
both in humans and domesticated livestock. Vaccines are predominantly produced in cell 
culture or embryonated chicken eggs and it has been proposed that host immune 
responses are a significant bottleneck in production, thereby reducing viral yields. It may be 
possible to employ CRISPR/Cas9 gene editing technology to stably knock-out individual 
chIFITM genes, or the entire chIFITM locus. Enabling the vaccine virus to replicate more 
efficiently, thus increasing vaccine yields. An increase in vaccine yields would mean that the 
same number of embryonated hens eggs would produce more vaccine antigen, therefore, 
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the price per vaccine would decrease and the availability of the vaccine would increase. 
This technology would be instrumental for enhancing availability of vaccines for a wide 
range of human and livestock diseases, particularly for countries where these viruses are 
currently endemic.    
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Table 7.1: Cellular proteins identified through LC-MS/MS that have a significant 
interaction with chIFITM1-FLAG 
Protein ID Unique peptides Confidence p Value (-log10) 
Fold change (Log2) 
chIFITM-
FLAG/FLAG 
HSP25 13 323.31 4.305603414 6.834736506 
DYNC1H1 68 323.31 2.835969155 5.421052933 
CCT8 3 99.631 5.141197079 5.26325798 
EIF3A 6 323.31 2.585348053 5.074971517 
NCAPG2 11 49.391 4.270305368 4.937030792 
LDHA 19 323.31 2.518098041 4.813216527 
SQSTM1 15 323.31 1.470419201 4.731942495 
CCT3 24 305.37 1.880163207 4.702330271 
CANX 20 157.95 1.257145499 4.494015376 
IPO7 10 232 3.280602704 4.39438502 
CDK1 8 35.88 1.223571466 4.281110764 
ATP1A1 15 139.5 2.62818604 4.224599202 
Gga.29531 6 47.091 2.147919477 4.162239075 
CCT2 20 145.55 2.068429602 4.157755534 
TCP1 22 323.31 2.265824833 4.130930583 
SF3B1 13 225.89 2.108254562 4.118561427 
TLN1 34 174.23 2.523705007 4.078789393 
PHB2 6 96.297 2.572913722 3.913258235 
SCD 4 37.377 3.254485621 3.893405914 
PSMC2 15 144.7 1.501915552 3.8703626 
ITGAV 8 46.996 5.122413932 3.79074351 
PSMC6 13 144.67 1.759887094 3.787675858 
ASNS 10 33.647 1.533082583 3.73182869 
THBS1 13 66.292 1.819960634 3.726994832 
VDAC2 8 74.109 1.606765662 3.725519816 
IMMT 11 41.53 3.039864163 3.722098668 
LOC422993 3 23.29 2.819725271 3.715384165 
HSPD1 32 323.31 2.041430986 3.693489075 
ATP5A1 22 237.25 2.169944784 3.68871816 
FASN 19 134.74 1.557370524 3.664454778 
CCT5 31 323.31 2.032462167 3.660306295 
PHB 12 113.93 1.581966882 3.650803884 
CKAP5 14 43.292 3.589406719 3.638519923 
CCT7 24 317.94 2.431943039 3.637254715 
EPRS 42 323.31 1.668972189 3.581262589 
ACTG1 3 153.56 1.267821947 3.551416397 
P4HA1 9 26.705 2.795478247 3.533287684 
PSMC3 19 206.76 1.447710318 3.527540207 
CCT6A 8 76.084 1.933596484 3.527329127 
SLC25A6 8 323.31 2.46148202 3.487776438 
HADHA 12 61.348 3.520863473 3.457870483 
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SEC16A 6 52.355 2.352883693 3.450616837 
STIM1 9 70.254 2.745501458 3.42634201 
TUBA4B 5 66.675 1.99495939 3.382062276 
RARS 16 70.115 2.192744878 3.373652776 
ATP2B4 8 34.53 3.658400427 3.363090515 
USP10 6 23.566 2.614748908 3.362263362 
USP5 17 220.37 5.016576333 3.348976771 
GNAI2 8 66.375 3.25124411 3.307685852 
CDC5L 5 12.866 4.785674639 3.267774582 
ATP2A2 10 37.284 2.652855517 3.255442301 
CSPG4 19 250.35 2.119175017 3.218390783 
FDPS 9 94.391 2.129536124 3.19761912 
CDC42 9 98.625 1.425154204 3.19547526 
EIF3J 4 31.952 2.42980925 3.150187174 
MYO1C 5 17.606 2.375271122 3.142530441 
IARS 31 221.35 1.142744362 3.133894602 
FARSA 7 98.578 3.12503711 3.133508046 
SDR16C5 6 105.5 2.103298843 3.127801895 
PSMD11 7 17.25 2.401419822 3.093861262 
FAP 7 28.318 3.772544743 3.088174184 
DNAJA2 8 87.09 1.439065443 3.087294896 
PPFIBP1 11 150.82 2.307074908 3.060188929 
CMPK 5 13.041 1.558977479 3.056732178 
CCT4 17 269.31 1.274252171 3.050540924 
PSMC5 9 98.398 1.429098755 3.016515732 
FUBP3 3 12.631 3.343757074 2.982807795 
IDH1 7 20.494 3.003159615 2.915957133 
RPN1 15 113.75 0.894955971 2.914335251 
PFKP 12 103.4 1.208276847 2.894284566 
CLTC 15 55.967 2.420110117 2.893357595 
ERLIN2 4 25.402 2.773810015 2.886475881 
DCTN1 19 177.17 4.124129402 2.884970983 
PDCD6IP 7 35.052 2.833244977 2.863434474 
ASPH 9 32.303 1.745605023 2.837875366 
CSE1L 13 148.96 1.456381008 2.824026108 
THBD 6 78.016 1.733421265 2.807112376 
SPARC 2 5.6287 2.314068436 2.803776423 
HSP90AB1 17 189.11 1.774212827 2.803049723 
ANO5 7 64.922 3.467850015 2.788849513 
CCDC47 10 30.393 1.844698043 2.787649155 
PEBP1 2 16.19 1.459741425 2.786532084 
RACK1 9 89.626 0.918557514 2.781419754 
AIMP2 6 51.175 1.508468518 2.777436574 
STAT3 15 211.23 2.64815975 2.776613235 
PSMD3 6 118.71 2.024544988 2.760412852 
AACS 5 12.064 1.741834717 2.739242554 
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GLG1 9 33.482 1.551758626 2.716735204 
TMX3 6 48.607 2.623314275 2.704293569 
LOC426023 2 157.16 0.961344933 2.703414917 
PSMD2 13 153.17 1.501737941 2.698867798 
ENDOD1 6 22.892 3.529420587 2.683257421 
RPS19 9 46.62 1.084119756 2.673265457 
U2AF1 7 49.804 1.853636133 2.673015594 
RPN2 7 19.119 3.397314714 2.63639768 
FAM129A 7 61.942 2.356880002 2.630837123 
NDUFA13 2 5.8809 1.060605641 2.628943761 
GAPDH 23 323.31 2.929298554 2.624592463 
EHD3 6 14.311 2.07677479 2.620141347 
chPKCI 3 8.3655 1.944439407 2.608301163 
RPS27 3 6.4858 3.495934757 2.594365438 
AARS 12 66.434 1.67803325 2.59357516 
SNRPA1 7 37.593 2.014927908 2.587144852 
TUBA3E 8 161.67 2.294180078 2.586465836 
SFXN1 5 21.707 2.676637603 2.586369832 
PITPNB 7 91.343 1.121468219 2.575382868 
ACAT1 14 170.81 3.058768422 2.568665187 
HMGCS1 13 232.38 0.944311687 2.566100438 
YWHAQ 8 323.31 0.967804325 2.560787837 
Gga.8044 6 35.601 2.760698487 2.559461594 
PSMD1 3 13.45 2.333457727 2.557753881 
HMOX1 4 76.834 1.479380276 2.54686292 
VAPB 5 14.111 1.553510606 2.543721517 
DDX1 10 53.472 1.593217418 2.542738597 
CNN2 7 54.582 1.233704488 2.536920547 
CTSB 8 100.36 1.281013919 2.521387736 
ACTC1 2 323.31 2.196103426 2.510709763 
FKBP10 11 63.753 1.183137794 2.508864085 
RPRD2 26 175.01 1.304629494 2.498984019 
CAPZA2 3 34.656 1.146767094 2.497057597 
GCN1 8 18.537 2.097475145 2.495181402 
UTRN 13 41.284 2.823791563 2.470219294 
EIF4A2 16 323.31 2.756572828 2.468886693 
ACTR2 4 67.241 1.468417717 2.46795845 
AHCY 12 48.978 0.913343492 2.46537145 
NSF 7 38.856 1.920549436 2.459726969 
C8H1ORF27 4 48.942 0.891287095 2.452457428 
TMEM43 6 17.45 3.145093585 2.43120575 
SNRNP200 5 24.904 4.304018846 2.429847717 
LSS 5 9.7567 2.086062129 2.420662562 
ITGB1 10 123.8 1.697889508 2.400142034 
RAN 8 39.098 2.91438789 2.399489085 
PGK1 25 323.31 3.439503246 2.388788859 
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TMED10 3 8.393 2.011539633 2.384888331 
YWHAH 2 6.4754 0.907783324 2.384681702 
DDOST 6 25.592 2.102387326 2.37872378 
PSME3 5 17.173 2.203478537 2.377358119 
SSR1 4 36.772 0.951832008 2.37128067 
ACTR3 9 99.696 1.924622382 2.356495539 
rbf 3 9.5799 2.022676364 2.346045812 
VAC14 4 62.707 2.173292958 2.338926315 
MAP2K1 4 59.022 2.875290313 2.32945315 
SOD1 3 75.467 0.950012703 2.313290278 
PSMD7 5 19.446 1.427790875 2.291647593 
Gga.6352 7 21.881 2.349628297 2.289354324 
PYCR2 7 25.084 2.96821938 2.285896937 
LRPPRC 8 31.999 1.709519104 2.284812291 
NOP58 6 26.616 1.854223541 2.278680801 
Gga.13539 4 13.612 2.129574379 2.272961299 
NOTCH2 8 59.641 1.177802415 2.265687943 
TNPO2 5 13.978 2.19825106 2.264511744 
RAB1A 5 51.725 1.444960092 2.263924917 
LOC107050681 2 7.833 1.194780348 2.24335289 
COPA 22 98.863 2.079152769 2.213364919 
ITGA4 5 19.631 2.085949564 2.196920395 
ATP6V1A 5 31.195 1.498944796 2.188772202 
ATAD3A 3 26.098 2.12806293 2.175035477 
PLXNB2 4 27.007 2.573939939 2.167338689 
NAP1L1 14 289.48 2.293023899 2.14788119 
BTF3 3 64.365 3.572391935 2.143585841 
RHOA 4 20.506 2.203238275 2.126673381 
EIF3I 10 51.11 1.815638114 2.120548884 
API5 3 59.919 2.969269337 2.114971797 
IDH2 10 57.949 4.298106925 2.114658356 
CTNNB1 6 25.752 1.577592526 2.112138112 
DHRS7 4 15.398 2.533973309 2.100897471 
MOCS3 5 17.321 2.331300359 2.084353765 
PSMC1 9 69.023 2.317540965 2.076733271 
NUP93 7 25.174 3.086492511 2.068166097 
UQCRC2 7 22.2 1.242487267 2.065335592 
SDPR 4 36.328 2.045241942 2.063906988 
ATOX1 2 4.999 1.780900457 2.05995814 
ALG14 2 22.474 1.431153376 2.040431341 
EIF1AY 3 10.252 2.321634934 2.030502955 
COPB1 6 20.925 2.116842505 2.026149114 
HSP90B1 23 323.31 1.058872729 2.025220871 
GBF1 4 14.251 4.164874977 2.010924021 
LDHB 8 37.561 1.56694683 2.009641647 
CTNNA1 5 29.523 2.016348127 2.009197871 
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SLK 3 16.265 2.231857144 2.006470362 
RPL36A 2 8.4456 1.411720515 1.986380259 
ALDH18A1 11 25.153 2.006606749 1.973993937 
COX4I1 2 5.2368 2.299689399 1.970929464 
PDLIM5 10 137.62 2.44801124 1.915373484 
UBAP2L 5 17.46 2.486885322 1.89474233 
MCM3 7 45.438 1.227478824 1.892674128 
HP1BP3 4 24.102 2.793816016 1.88903745 
PSPC1 5 69.157 2.556588234 1.884175618 
SLC25A3 6 35.115 1.903750275 1.881043116 
SERPINH1 18 194.12 1.187668326 1.877236048 
SEC24D 2 28.262 2.77314512 1.873903275 
XPO5 4 50.792 1.302642628 1.870145798 
MCM5 6 29.08 1.435611573 1.866726557 
TM9SF2 4 20.586 2.620409504 1.850023905 
PPP4R1 3 46.071 1.702153525 1.837327957 
DARS 15 89.271 2.648201797 1.8364652 
cRac1A 4 8.3718 2.584680817 1.827336629 
PFDN5 2 15.575 3.119213542 1.825728734 
IQGAP1 36 323.31 1.625705284 1.81727155 
MMP2 4 41.839 2.262808234 1.779094696 
ATP5B 13 216.4 2.689281965 1.767122269 
ACAD9 3 17.126 1.307210951 1.736946742 
ITGA3 8 43.677 1.572075141 1.686815262 
GARS 14 76.71 3.093960841 1.646132787 
HSPA4L 15 108.95 1.438531838 1.640161514 
ST13 4 9.9389 1.505745967 1.599136988 
KTN1 4 111.4 2.261345946 1.590699514 
RAB5C 4 18.734 1.803799774 1.58764712 
EIF4G1 21 184.79 2.308550044 1.585198085 
SEPT2 2 5.2564 1.721428045 1.545096715 
RLI 4 11.786 1.66293744 1.544646581 
CHMP4B 2 7.9591 3.46332992 1.540771484 
NDUFA5 3 17.596 2.326935183 1.536884308 
RPS7 13 84.611 1.643951874 1.53361702 
LOC107049501 4 72.957 1.804135718 1.518319448 
C1H21ORF33 3 12.642 2.367531411 1.478792826 
ALG12 2 5.528 1.773801761 1.464152018 
HEATR1 5 28.313 2.405157671 1.453435262 
EEF1A 24 323.31 1.843960831 1.435681025 
TUFM 8 23.213 2.047409639 1.377058029 
DYNC1LI1 5 233.81 2.304305619 1.330360413 
ABCF2 3 6.4771 2.662077272 1.306410472 
HSPA8 43 323.31 2.225863201 -1.542245229 
PPM1B 24 323.31 2.505344328 -1.570994695 
NT5C2 8 41.665 1.671545303 -1.576644262 
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YBX1 4 62.589 1.95898217 -1.607637405 
BOD1L1 49 323.31 3.022677205 -1.748095194 
NCL 32 323.31 1.470378971 -1.761480967 
SPATA2L 2 8.6975 1.333498196 -1.933946609 
HSPA5 60 323.31 2.565852157 -1.957557678 
NDUFAF7 12 101.58 2.452812561 -1.966108958 
S100A6 5 15.419 2.982895828 -1.986438115 
HSPH1 89 323.31 2.629169436 -2.089324951 
ROCK1 8 48.623 1.151578878 -2.095235189 
SPTBN1 110 323.31 2.21435941 -2.103445689 
IMPDH2 4 323.31 2.387622173 -2.1088473 
SPINW 9 33.674 2.292014507 -2.213559469 
SPTAN1 5 323.31 2.16577041 -2.222287496 
HNRNPH3 8 130.99 2.11451382 -2.334253311 
ATXN3 6 77.165 2.508016568 -2.389877955 
vcp 2 323.31 1.586693911 -2.619759242 
TRA2A 4 13.521 1.535457001 -2.692606608 
SPTAN1 2 14.628 1.718737045 -2.902865092 
TRA2B 4 20.807 1.966623003 -4.002351761 
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Table 7.2: Cellular proteins identified through LC-MS/MS that have a significant 
interaction with chIFITM2-FLAG 
Protein ID 
Unique 
peptides 
Confidence 
p Value (-
log10) 
Fold change (Log2) chIFITM-
FLAG/FLAG 
chIFITM2 8 49.593 2.445076959 7.469003677 
HSP25 13 323.31 4.326174743 7.363372167 
DYNC1H1 68 323.31 3.087061802 6.315587997 
EIF3A 6 323.31 2.877993257 5.918581645 
CCT3 24 305.37 2.202832132 5.674060186 
CCT8 3 99.631 5.646946062 5.670385361 
SDR16C5 6 105.5 3.115409114 5.200796127 
SF3B1 13 225.89 2.427561743 4.876956304 
SQSTM1 15 323.31 1.481708979 4.710184097 
IPO7 10 232 3.724051702 4.545094808 
IARS 31 221.35 1.69521349 4.48835055 
LDHA 19 323.31 2.369464322 4.442468643 
CDK1 8 35.88 1.22976687 4.332385381 
NCAPG2 11 49.391 2.653844397 4.252642949 
EPRS 42 323.31 1.915573275 4.242449443 
CSE1L 13 148.96 3.033449365 4.212331136 
CANX 20 157.95 1.182678703 4.207326253 
ATP1A1 15 139.5 2.673207375 4.180628459 
CCT7 24 317.94 2.788449422 4.156349182 
Gga.29531 6 47.091 2.302121127 4.137016932 
STIM1 9 70.254 3.15435794 4.014463425 
STAG2 16 177.78 3.438425849 3.996290207 
FAM129A 7 61.942 2.599629678 3.930781047 
TCP1 22 323.31 2.173285664 3.9271698 
CCT2 20 145.55 1.921301166 3.896890004 
ASNS 10 33.647 1.592795141 3.876338323 
TLN1 34 174.23 2.124380342 3.844771067 
PSMC6 13 144.67 1.753329829 3.778470993 
CCT5 31 323.31 2.071155924 3.768192291 
PSMC2 15 144.7 1.464661699 3.750332514 
AIMP2 6 51.175 1.959364534 3.742291133 
FASN 19 134.74 1.569717909 3.738395055 
TNPO1 6 20.847 2.773956048 3.705701828 
RARS 16 70.115 2.310301802 3.673597972 
IMMT 11 41.53 3.042550972 3.670180003 
SCD 4 37.377 3.184947219 3.603063583 
DCTN1 19 177.17 3.527874568 3.530180613 
HADHA 12 61.348 3.589676138 3.502772649 
ATP5A1 22 237.25 2.079727631 3.477888743 
HSPD1 32 323.31 2.03957805 3.402423223 
TMX4 3 11.002 3.560774855 3.38886706 
FARSA 7 98.578 2.178199862 3.385704676 
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PHB 12 113.93 1.430900091 3.373878479 
RPS27 3 6.4858 2.848336909 3.3373305 
CCT8 2 7.5913 2.568147928 3.328855515 
VDAC2 8 74.109 1.65354084 3.327263514 
PHB2 6 96.297 2.182346833 3.305337906 
EIF3J 4 31.952 2.068944969 3.275941849 
CCT6A 8 76.084 1.701558527 3.274384181 
THBS1 13 66.292 1.874612898 3.261089325 
SLC25A6 8 323.31 2.425711778 3.236560822 
VAC14 4 62.707 2.207904651 3.20622317 
GNAI2 8 66.375 3.334751828 3.193691254 
POLR2B 9 19.278 3.15837681 3.174894969 
MYO1C 5 17.606 2.078571365 3.172915141 
U2AF1 7 49.804 1.669443595 3.157801946 
FDPS 9 94.391 2.336276036 3.152849833 
CKAP5 14 43.292 2.782566784 3.146830877 
TNPO2 5 13.978 2.75640114 3.142286936 
RPS19 9 46.62 1.39274428 3.140827815 
RPN2 7 19.119 1.559585966 3.138600032 
STAT3 15 211.23 3.253114784 3.137093226 
P4HA1 9 26.705 2.597993725 3.119019826 
CCDC47 10 30.393 2.187215393 3.119002024 
PSMC3 19 206.76 1.29274579 3.101836522 
EHD3 6 14.311 2.075124468 3.100144068 
XPO1 11 92.471 2.21486258 3.095006307 
TUBA4B 5 66.675 1.704561631 3.082262675 
CLTC 15 55.967 3.295478158 3.046436946 
EIF3K 8 63.536 1.162587029 3.018058141 
PSMD3 6 118.71 2.11284867 3.013111115 
NDUFA13 2 5.8809 1.188381765 2.9940389 
PSMC5 9 98.398 1.442907793 2.909222921 
CCT4 17 269.31 1.202932268 2.902838389 
CMPK 5 13.041 1.500558835 2.89503479 
CSPG4 19 250.35 1.839671256 2.892531077 
ACTG1 3 153.56 1.021841036 2.863100052 
YWHAQ 8 323.31 1.166970481 2.846311569 
SDPR 4 36.328 2.091962443 2.845929464 
CDC42 9 98.625 1.2677994 2.824139913 
chPKCI 3 8.3655 2.035773364 2.816921234 
ACAT1 14 170.81 3.343049678 2.806132634 
USP10 6 23.566 1.964289597 2.7915109 
PSMD2 13 153.17 1.549901919 2.769669851 
PFKP 12 103.4 1.138503569 2.749342601 
IDH1 7 20.494 3.095953473 2.743671417 
TMEM43 6 17.45 2.856196409 2.738091151 
DDX1 10 53.472 1.580641185 2.736730576 
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GCN1 8 18.537 2.419450625 2.716710409 
MOCS3 5 17.321 2.590021774 2.709089915 
RHOA 4 20.506 2.647159908 2.707740148 
HSP90AB1 17 189.11 1.733848243 2.702168783 
CTSB 8 100.36 1.376642342 2.696722031 
ATP2A2 10 37.284 2.790578061 2.683575312 
NSF 7 38.856 1.923326078 2.67626826 
ATP2B4 8 34.53 1.087421815 2.67515564 
PPFIBP1 11 150.82 1.849545044 2.674128215 
UTRN 13 41.284 2.003754865 2.651385625 
COPG1 6 66.787 1.945678963 2.649789174 
USP5 17 220.37 4.88746192 2.649095535 
ENDOD1 6 22.892 3.40595702 2.634342194 
AHCY 12 48.978 0.991467659 2.630637487 
ALDH18A1 11 25.153 2.192563401 2.607969284 
Gga.8044 6 35.601 2.035424533 2.58783404 
PLXNB2 4 27.007 2.930530676 2.545332591 
EIF3I 10 51.11 1.929255832 2.540725072 
EDC4 4 13.804 1.440294548 2.539190292 
GBF1 4 14.251 4.242959724 2.522668839 
RAN 8 39.098 2.291259128 2.517677307 
GAPDH 23 323.31 2.517200415 2.505799611 
ATAD3A 3 26.098 2.054974092 2.479478836 
RPRD2 26 175.01 1.262749462 2.466138204 
SOAT1 2 18.005 1.929849629 2.453660329 
SFXN1 5 21.707 3.995052514 2.450597763 
ITGB1 10 123.8 1.568793014 2.438363393 
NOTCH2 8 59.641 1.257267175 2.434970856 
PITPNB 7 91.343 1.075769867 2.434462229 
SPARC 2 5.6287 2.499294348 2.432851156 
GLG1 9 33.482 1.134580148 2.415925344 
DNAJC1 4 10.751 1.327652289 2.390054703 
ACTC1 2 323.31 1.917813454 2.379570643 
CNN2 7 54.582 1.375774375 2.378480911 
NUP93 7 25.174 2.738056578 2.377450307 
EEF1E1 3 17.328 1.636046975 2.375113805 
PSMD1 3 13.45 1.916109624 2.36824735 
ITGAV 8 46.996 1.511563258 2.353199641 
COPB1 6 20.925 2.248721538 2.337599436 
PPP2R5E 2 2.1576 1.169149278 2.336082458 
RAB1A 5 51.725 1.304254284 2.332671483 
XPO5 4 50.792 1.752807287 2.317404429 
EIF3B 10 78.999 1.074088508 2.312555313 
ERLIN2 4 25.402 3.761337636 2.31069692 
TMX3 6 48.607 4.468018685 2.28552564 
PSME3 5 17.173 2.862764768 2.281152725 
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HEATR1 5 28.313 2.725178487 2.273145676 
PSMD11 7 17.25 1.998459688 2.272556941 
TPD52L2 4 55.373 1.936268512 2.266269684 
TUBA3E 8 161.67 1.99339852 2.257233938 
PGK1 25 323.31 4.012831993 2.246002197 
DCTN3 5 38.743 1.609935437 2.20492808 
COPA 22 98.863 2.101759404 2.195163091 
DARS 15 89.271 3.163852173 2.167094549 
ASPH 9 32.303 1.329528784 2.165141424 
HMOX1 4 76.834 1.831881513 2.156843185 
API5 3 59.919 1.336446884 2.150719961 
KTN1 4 111.4 2.430243023 2.150167465 
VCL 7 119.78 1.106810367 2.144846598 
EIF4A2 16 323.31 2.517714032 2.14086469 
DYNC1LI1 5 233.81 2.828902861 2.138638179 
RPL15 7 29.814 1.631813014 2.132679621 
SLC25A3 6 35.115 2.053256381 2.118378321 
ALG14 2 22.474 1.410899491 2.113187154 
ANO5 7 64.922 3.111842095 2.088412603 
OTUB1 13 173.11 1.819916747 2.087624232 
VIM 24 184.76 1.77520025 2.086383184 
NOP58 6 26.616 1.468047372 2.05809466 
PYCR2 7 25.084 3.299878345 2.055835724 
DNM1 2 20.948 1.359274639 2.037164052 
BTF3 3 64.365 3.776356396 2.035149256 
ACTR3 9 99.696 1.676200702 2.030383428 
HECTD1 5 13.916 1.452998213 2.019544601 
cRac1A 4 8.3718 2.371487155 2.009869893 
PSMC1 9 69.023 2.187439075 1.999320984 
ITGA4 5 19.631 1.741431953 1.986832937 
SNRNP200 5 24.904 4.203478592 1.979991277 
LRPPRC 8 31.999 1.54016619 1.977901459 
MAP2K1 4 59.022 2.589000326 1.972227732 
CTNNB1 6 25.752 1.313219265 1.954692841 
VAPB 5 14.111 1.241655034 1.95451355 
IDH2 10 57.949 2.055378598 1.940518061 
rbf 3 9.5799 2.205205921 1.847288132 
HP1BP3 4 24.102 2.925596402 1.809938431 
NAA25 12 56.679 2.206889853 1.799413045 
NAP1L1 14 289.48 1.935406173 1.79881986 
HEATR3 2 23.072 1.707934755 1.792274475 
EIF4G1 21 184.79 2.451553611 1.792161306 
DHRS7 4 15.398 2.524164254 1.768868764 
IQGAP1 36 323.31 1.54661529 1.729729335 
UQCRH 2 15.468 1.863087647 1.703221003 
UBAP2L 5 17.46 3.075062166 1.687862396 
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PSPC1 5 69.157 1.757423804 1.678568522 
PAK1 2 8.0648 1.822117097 1.654495875 
ATP6V1B2 5 14.039 1.958081339 1.623662949 
AIMP1 10 98.839 2.104155018 1.616096497 
LARS 5 20.747 1.905938539 1.507425308 
PLXNA1 2 2.4045 3.1704939 1.384658178 
RPS3 19 192.75 2.517771255 1.368536631 
HDX 5 14.986 2.30542369 -1.480677923 
BOD1L1 49 323.31 1.994677676 -1.652287165 
CTGF 12 109.18 1.773437219 -1.726145426 
NCL 32 323.31 1.468261448 -1.734089533 
LOC107049323 2 128.52 1.589549929 -1.851186117 
SPTBN1 110 323.31 1.974706753 -1.892238617 
DEK 2 1.7474 1.917386635 -1.984127045 
TRA2A 4 13.521 1.42866799 -2.014672597 
SPTAN1 5 323.31 1.851981086 -2.079819361 
HSPA5 60 323.31 2.875608695 -2.081845601 
NDUFAF7 12 101.58 2.514862995 -2.089780807 
NT5C2 8 41.665 1.952556557 -2.119684855 
ATXN3 6 77.165 2.249910735 -2.282540003 
IMPDH2 4 323.31 2.785973109 -2.284492493 
HNRNPH3 8 130.99 2.242230366 -2.294961929 
HSPH1 89 323.31 3.382627134 -2.300445557 
vcp 2 323.31 1.460722495 -2.396660487 
ERH 6 88.804 2.464682059 -2.59946696 
SPINW 9 33.674 3.383617848 -2.784644445 
S100A6 5 15.419 2.142808292 -2.987522125 
TRA2B 4 20.807 1.776776852 -3.08575503 
SPTAN1 2 14.628 1.75086118 -3.134355545 
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Table 7.3: Cellular proteins identified through LC-MS/MS that have a significant 
interaction with chIFITM3-FLAG 
Protein ID 
Unique 
peptides 
Confidence p Value (-log10) 
Fold change (Log2) 
chIFITM-FLAG/FLAG 
LOC770612 7 104.65 3.630419145 10.29512533 
HSP25 13 323.31 4.363101183 7.070083618 
CANX 20 157.95 1.580599825 5.756710052 
SQSTM1 15 323.31 1.667569334 5.47755305 
DYNC1H1 68 323.31 2.818217715 5.227775574 
NCAPG2 11 49.391 3.856420356 5.020467122 
CCT8 3 99.631 5.253041713 4.807755152 
EIF3A 6 323.31 2.447108438 4.704882304 
ATP1A1 15 139.5 2.838708768 4.623772939 
THBS1 13 66.292 2.406049554 4.605814616 
ITGAV 8 46.996 4.826042316 4.600322088 
CDK1 8 35.88 1.276132774 4.48836263 
CCT3 24 305.37 1.716308328 4.130586624 
ATP2A2 10 37.284 2.570121093 4.088137309 
CCT2 20 145.55 2.003683254 4.085613887 
SCD 4 37.377 3.359428192 4.081071854 
FARSA 7 98.578 2.304696861 4.08078448 
IMMT 11 41.53 3.036923864 4.011659622 
PSMC2 15 144.7 1.537516983 3.980131149 
ACTG1 3 153.56 1.251361668 3.947575251 
IPO7 10 232 3.085629834 3.775609334 
STIM1 9 70.254 3.03844791 3.77339681 
CYR61 2 14.44 2.999902365 3.764981588 
PHB 12 113.93 1.615315907 3.750914256 
LDHA 19 323.31 1.859074064 3.738895416 
PHB2 6 96.297 2.360877934 3.710563024 
TMEM43 6 17.45 2.700800181 3.691612244 
ATP5A1 22 237.25 2.130403853 3.688059489 
PSMC6 13 144.67 1.704122697 3.687732061 
TCP1 22 323.31 2.055135774 3.626918157 
NOTCH2 8 59.641 2.191827677 3.611919403 
HADHA 12 61.348 3.168827339 3.599042257 
SLC25A6 8 323.31 2.524756661 3.582530975 
PSMC3 19 206.76 1.448062762 3.576231003 
CKAP5 14 43.292 3.191180412 3.495733897 
VDAC2 8 74.109 1.72076105 3.486772537 
P4HA1 9 26.705 2.838202836 3.463476817 
SF3B1 13 225.89 1.909343675 3.457794825 
DNAJA2 8 87.09 1.662178633 3.451449712 
CSE1L 13 148.96 2.397118543 3.371655782 
SDR16C5 6 105.5 2.015931289 3.371075312 
CCT5 31 323.31 1.824752823 3.362906138 
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GNAI2 8 66.375 2.946411855 3.331900279 
RPN2 7 19.119 2.616228518 3.277194341 
MYO1C 5 17.606 2.499839688 3.275560379 
RARS 16 70.115 2.155700426 3.267416636 
FASN 19 134.74 1.390022188 3.236302694 
U2AF1 7 49.804 2.718207812 3.223299026 
POLR2B 9 19.278 2.52044985 3.212713242 
TUBA4B 5 66.675 1.825230428 3.171902339 
PSMC5 9 98.398 1.535975837 3.140721003 
TLN1 34 174.23 2.202330253 3.130899429 
SSR1 4 36.772 2.567321682 3.121081034 
EPRS 42 323.31 1.443976356 3.116552989 
ERLIN2 4 25.402 2.447678652 3.082304637 
GLG1 9 33.482 1.538048547 3.023597717 
Gga.29531 6 47.091 1.710323425 3.014978409 
CCT6A 8 76.084 1.585401196 3.007674535 
HSPD1 32 323.31 1.867353318 2.995848974 
HMOX1 4 76.834 2.958081115 2.958384832 
SFXN1 5 21.707 3.117408207 2.910378774 
TUBA3E 8 161.67 2.301732918 2.899048487 
PSMD2 13 153.17 1.61735499 2.889470418 
FAP 7 28.318 3.343122045 2.879177729 
DCTN1 19 177.17 3.296528472 2.870218913 
PSMD3 6 118.71 2.03873117 2.854577382 
ATP2B4 8 34.53 1.077305789 2.834074656 
USP10 6 23.566 2.233138151 2.830677032 
DDOST 6 25.592 2.047615449 2.821216583 
AP2M1 6 38.937 1.913654624 2.818874359 
CSPG4 19 250.35 1.852461453 2.770407995 
RPS27 3 6.4858 1.876748494 2.758853277 
ACTC1 2 323.31 2.163619022 2.734042486 
CCDC47 10 30.393 1.982588088 2.697664261 
CLTC 15 55.967 2.600831902 2.679939906 
SLC25A3 6 35.115 2.294947555 2.672269185 
SLC25A13 3 8.3486 1.854762227 2.62946256 
ACAT1 14 170.81 3.445964044 2.624891917 
CTSB 8 100.36 1.409661889 2.59772555 
KTN1 4 111.4 2.139658459 2.593623479 
CCT7 24 317.94 1.880483298 2.588375092 
ATP5C1 8 44.925 1.926817115 2.586951574 
RAN 8 39.098 2.443365293 2.585869471 
PPFIBP1 11 150.82 2.050195045 2.58391126 
ANO5 7 64.922 3.624847559 2.57084465 
Gga.13539 4 13.612 2.417575186 2.526112874 
APLP2 5 24.719 1.500355612 2.517800013 
RPRD2 26 175.01 1.20259298 2.516488393 
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STAT3 15 211.23 2.208806802 2.508850098 
FUBP3 3 12.631 2.534501024 2.504039764 
ITGA4 5 19.631 2.213135992 2.494370778 
EHD3 6 14.311 2.006874987 2.492059072 
ASPH 9 32.303 1.387204197 2.4868927 
EIF3J 4 31.952 2.034913949 2.446747462 
GCN1 8 18.537 2.235974076 2.417862574 
PSMC1 9 69.023 2.310755002 2.36905543 
VAC14 4 62.707 2.408947437 2.355473836 
TMX3 6 48.607 3.400009938 2.345234553 
SNRNP200 5 24.904 3.342706877 2.326904933 
THBD 6 78.016 1.325099924 2.304016113 
NSF 7 38.856 1.874121466 2.278828303 
MMP2 4 41.839 2.479936824 2.258871714 
NUP93 7 25.174 2.722212028 2.25872167 
MAP2K1 4 59.022 2.901282265 2.208045959 
PSMD11 7 17.25 1.769480054 2.205809275 
RAB5C 4 18.734 1.407370142 2.189044317 
LSS 5 9.7567 2.174658748 2.154309591 
SPARC 2 5.6287 1.816069601 2.153369268 
CTNNA1 5 29.523 1.566157168 2.139104843 
UTRN 13 41.284 2.551315918 2.136250178 
EIF3I 10 51.11 1.594381025 2.11662674 
GAPDH 23 323.31 2.610707212 2.079033534 
Gga.6352 7 21.881 2.235736161 2.070884069 
PSMD1 3 13.45 2.105053158 2.056708654 
FAM129A 7 61.942 3.412036058 2.053544998 
MCM5 6 29.08 1.646871779 2.025832494 
RPL15 7 29.814 1.574807581 2.014740626 
PLXNB2 4 27.007 2.972082723 2.012008667 
COPA 22 98.863 1.989875709 2.011975606 
PSME3 5 17.173 2.686152341 2.000639598 
COPB1 6 20.925 1.997127405 1.892422358 
RUVBL1 7 29.977 2.25725563 1.874531428 
ATP6V1B2 5 14.039 1.824879551 1.865509669 
TM9SF2 4 20.586 1.823669904 1.83956782 
UBAP2L 5 17.46 2.445918997 1.801150004 
USP5 17 220.37 2.950680161 1.788431168 
SLK 3 16.265 1.955582593 1.773825328 
GBF1 4 14.251 2.346721719 1.732352575 
RPS3 19 192.75 3.10433856 1.727890015 
SOAT1 2 18.005 2.10342566 1.699886322 
EIF4G1 21 184.79 2.468801552 1.628341675 
CNDP2 5 9.4043 1.833866252 -2.038715998 
FUS 3 29.89 1.77693538 -2.194421132 
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